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INTRODUCTION 
Siddha system of medicine is one of the ancient system contemporaneous with those 
of the submerged lands, Egyptian, Mesopotamian, Chinese, and Grecian medicines. The 
ancient Siddhars knew the scientific truth by meditation and worked wonders through their 
mental force. 
The Siddha system is based on a combination of ancient medicinal practices and 
spiritual disciplines as well as alchemy and mysticism. As herbs, metals, minerals, animals 
and its derivatives are the sources of Siddha medicines. 
 This system endorses safest medical care. Siddha is the only system comprising 64 
varieties of medicines i.e. 32 classifications of internal medicines and 32 classifications of 
external medicines. 
Á¡ÚÀ¡Î þøÄ¡¾ ¯ñÊ ÁÚòÐñ½¢ý 
°ÚÀ¡Î þø¨Ä ¯Â¢÷ìÌ.     
                                        -¾¢ÕìÌÈû 
According to Siddha, “changes in diet and life style, Environmental factors and 
congenital or genetically inherited” are the key factors predisposed for the instigation of each 
disease via disturbing the equilibrium status of the vital forces termed Vali, Azhal, Iyam. 
 
Á¢¸¢Ûõ Ì¨ÈÂ¢Ûõ §¿¡ö¦ºöÔõ á§Ä¡÷ 
ÅÇ¢Ó¾Ä¡ ±ñ½¢Â ãýÚ. 
                                     -¾¢ÕìÌÈû 
 
Noi naadal ( to diagnose the affected disease) and Noi mudhal nadal ( to find out the 
root cause of the disease) are the crucial approaches employed in Siddha in the process of 
diagnosis therefore permanent remedy is also achievable since the treatment is focused to 
cure the disease and root cause of the disease.  
“Envagai thervu” is the diagnostic tool followed in Siddha for arriving right 
diagnosis.While treating the patient, special concern will be paid in Yakkai (Body 
constitution), Thinai (sort of land where the patient living) and Paruvakaalam (Season) for 
the effectiveness of the treatment. 
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Since the disease occurs due to the derangement of three life factor Siddhars have 
classified the disease accordingly .They classified as vatha disease 80, pitha disease 40, kapha 
disease 21. Swasakasam is one among the kapha disease. 
According to Siddha system of medicine, cause of any disease is attributed to the 
derangement of humours. Likewise, in the case of asthma, the disease is attributed to the 
derangement of kabam humour. The amplified kabam humour alone or otherwise associated 
with other deranged humours, either vatham or pitham affects the throat, nose, respiratory 
airways and lungs.  
Bronchial asthma is a heterogeneous pulmonary disorder characterized by recurrent 
episodes of cough, breathlessness and wheezing, which may resolve spontaneously or after 
the use of bronchodilator medication. 
The global prevalence of asthma is anticipated to be approximately 4.5 per cent. 
There are about 334 million patients with asthma affecting all age groups, across the world. 
In the Indian study on Epidemiology of asthma, respiratory symptoms and chronic bronchitis 
in adults (INSEARCH) a survey conducted in two phases across 16 centers in India, the 
prevalence of asthma in adults was 2.05 per cent, with an estimated burden of 17.23 million.  
In Siddha literature, various herbal drugs either single or compound and herbo-
mineral drugs are mentioned for the management of bronchial asthma. 
  In the text, Agathiyar vaithiya kaviyam-1500 “Mantharakasa lehiyum” a Siddha 
formulation has been specifically indicated for SWASAKASAM (Bronchial asthma). The 
main ingredients of the above said are well known for its Expectorant, Anti spasmodic, 
Carminative, Stimulant, Tonic, Bronchodilator, Anti-oxidant, Anti-inflammatory and 
Digestive activities.  
 The preparation is simple, easily available and cost effective. The above said drug 
formulation, has not undergone any clinical trial. So, it is proposed to carry an open clinical 
trial to find out its efficacy in Swasa kasam.  
 
 
 
  
 
 
AIM AND OBJECTIVES 
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AIM AND OBJECTIVES 
  AIM                                                                  
Clinical study on “SWASAKASAM” (Bronchial asthma) and the drug of choice is 
MANTHARAKASA LEHIYUM (Internal). 
OBJECTIVES 
1) Primary Objective 
To study the Siddha formulation MANTHARAKASA LEHIYUM (Internal) in the 
management of “SWASAKASAM (Bronchial Asthma). 
2) Secondary objective 
1. To study other cofactors related to the disease like age, occupation, socioeconomic 
status. 
2. To study the comorbid factors related to the disease such as gastroesophageal  reflux 
disease (GERD), rhinosinusitis, apnea and anxiety etc. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
REVIEW OF LITERATURE 
  
  
 
 
SIDDHA ASPECT 
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SIDDHA ASPECT 
As per Yuki Vaidhya Chinthamani,   
Veru Peyargal (Synonyms)  
Izhuppu Irumal 
Swasa Irumal 
Isivu Irumal 
Eyal (Definition): 
 Severe cough with or without expectoration, Expiration is like a hiss of a serpent, 
Sense of heat in both nostrils, Frequent hemming, Indigestion and Flatulence, Hoarseness of 
voice. 
Noi Varum Vazhi   (Etiology) 
Yugi Vaidhya Chinthamani Says, 
“     
                   ”     (690) 
 
”     
    
    
    
    
   
    
   ”. (691) 
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Diet and habits: 
 Exposed to excessive smoke 
 Increased acidity 
 Intake of allergy inducing food 
 Starving on hunger 
 Lack of Exercise 
 Excessive intake of cold water, food items 
 Excessive intake of non-vegetarian diet 
 Excessive Mental Stress 
 Taking improperly cooked food 
 
“                  
        
§¾¡   ¦º¡ýÉ ¾¡Öõ 
                         
 ஒÕ     
    ¦¸¡Î¨Á¸¼¡ý  §Å¡÷ìÌõ 
  ¦º¡ýÉ §ÀîÍ 
   À¢Ãñ§¼¡÷ìÌí   ” (692) 
Mental stress due to: 
 Stealing foods which were offered to GOD 
 Cursing life partner 
 Persons who don‟t keep his words 
 Ingratitude 
Madhava Nidhanam @ Roga Vrichayam say‟s 
 Excessive Smoke  
 Controlling reflexes like sneezing and Cough. 
 Food enters into the larynx while swallowing 
 Taking improperly cooked food 
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Siddha Maruthuvam [Pothu] Says, 
 Exposure to cold weather 
 Over strain in hot climate 
 Intaking of cold and hot foods 
 Singing/speaking in high pitched voice 
 Inhalation of pleasant / irritable odor. 
Anubava Vaitheya Deva Ragaseyam Says, 
 Elevation of vital humours such as Vatham and Kabam 
 Persistence fever  
 Excessive Cold 
 Anemia due to toxicity  
 Air pollution of dust, husk etc…  
 Trauma on vital organs. 
Murkurigal (Preliminary Signs) 
 Sore throat 
 Redness of throat 
 Pricking sensation in the throat 
 Low pitched voice  
 Running nose 
 Aspiration of hot foods 
§¿¡ö ±ñ: Noi Enn (Classification) 
Yugi Vadihya Chindamani says, 
¾¡É¡É ¸¡ºÁÐ ÀýÉ¢¦Ãñ ¼¡Ìó  
   ¾¡ì¸¡É Áó¾¡Ã ¸¡ºò §¾¡Î 
À¡É¡É Àì¸Áó ¾¡Ã ¸¡ºõ 
   À¡í¸¡É Í¼÷ ¸¡ºõ Å¡¾ ¸¡ºõ 
§ÀÉ¡É À¢ò¾Á¡í ¸¡ºò §¾¡Î 
   §À÷¦À¡¢Â ÍÅ¡º¸¡ ºò§¾¡ ¦¼¡ì¸ 
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²É¡É இÃò¾Á¡í ¸¡ºò §¾¡Î 
   இ¨ÃôÀ¡É º¢§ÄòÁ¸¡ ºó¾¡ É¡§Á.       (689) 
 
  ¬¸¢ýÈ À£É¢ºò¾¢ý ÍÅ¡º ¸¡ºõ 
   «Æ¢Å¡¾ À¢ò¾ò¾¢ý ¸¡º Á¡Ìõ 
  §À¡¸¢ýÈ À¢ò¾º¢§ÄðÁ ¸¡ºó ¾¡§É 
   Ò¸ú¦À¡¢Â ¦º¡ó¾Á¡í ¸¡ºò §¾¡Î 
§¾¸¢ýÈ ¸¡ºÁÐ ÀÉ¢¦Ãñ ¼¡Ìó 
   ¦¾Ç¢Å¡¸ þ¾Û¨¼Â ¦ºÂ¨Äì §¸§Ç. (690) 
 
Swasa kasam is one among the twelve types of Kasam. 
The Twelve types are,       
1. Mandhara Kasam     7. Ratha Kasam 
2. Pakka Mandhara Kasam    8. Silethuma Kasam                      
3. Sudar Kasam     9. Peenisa Kasam 
4. Vatha Kasam              10. Vathapitha Kasam 
5. Pitha Kasam              11. Pitha silethuma Kasam 
6. Swasa Kasam               12. Thontha Kasam 
T.V.Sambasivam Pillai Dictionary says 
There are twenty types of kasam 
1. Swasa kasam                11. Eelai kasam 
2. Manthara kasam                12. Sudar kasam 
3. Ratha kasam     13. Pakka kasam 
4. Vadha kasam     14. Pakka manthara kasam 
5. Pitha kasam     15. Pennisa kasam 
6. Vali kasam     16. Naadha kasam 
7. Silethuma kasam     17. Virana kasam 
8. Thontha kasam     18. Karppa kasam 
9. Neela kasam     19. Adaippu kasam 
10. Bala kasam     20. Gunma kasam 
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Tamilaga Siddha Vaitheya Gurugulam Says, 
There are twelve types. Those are, 
1. Vatha Kasam         7. Swasa Kasam 
2. Pitha Kasam       8. Mandhara Kasam 
3. Kaba Kasam       9. Patcha Mandhara Kasam 
4. Vatha Kaba Kasam              10. Ratha Kasam 
5. Pitha Kaba Kasam              11. Peenisa Kasam 
6. Thontha Kasam      `        12. Sudar Kasam 
Vaidya sara sangraham classifies as 
1. Manthara eraippu 
2. Swasa kasam  
3. Pachai udambi ledutha swasakasam 
 
SWASA KASAM 
Kuri Gunangal (Signs and Symptoms) 
Siddha literatures described the signs and symptoms of Swasa kasam as follows, 
Yugi Vaidhya Chinthamani Says, 
“  §¸¡     
 §À¡    
    
      
           §À¡  
      
              
                 ¦É¡ .” 
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Characteristic of swasa kasam According to Yugi Vaidhya Chinthamani severe cough 
with or without expectoration, Expiration is like a hiss of a serpent, frequent hemming, sense 
of heat in both nostrils, emaciation, Hoarseness of voice, indigestion and flatulence. 
Uyir Kakkum Siddha Maruthuvam @ Athma Ratchamirtham Says, 
Characteristics of Swasa kasam as per Uyir kakkum siddha maruthuvam as follows 
Dryness of the skin, fatigue, vomiting due to indigestion,  headache, constipation with 
sweating, cough, fever, chillness and pedal edema. 
Tamilaga Siddha Vaitheya Gurugulam Says, 
Breath sound like hissing of snake, cough with expectoration of excess amount of 
sputum, indigestion, emaciation, low pitched voice, viscous secretion in uvula, flatulence, 
dryness and heat sensation in the nose, dyspnoea, wheezing and hysteria. 
Mukkura Verupadugal (Pathology)  
The disease occurs due to the derangement of three life factor (Vatham, Pitham, 
Kabam). Siddhars have classified as Vatha disease 80, Pitha disease 40, and Kaba disease 21. 
Likewise, in the case of asthma, the disease is attributed to the derangement of kabam 
humour.  
The amplified kabam humour alone or otherwise associated with other deranged 
humours, either vatham or pitham affects the throat, nose, respiratory airways and lungs. 
This is clearly indicated by Theraiyar as,  
 “     ”    -  
1.    Excess of Kaba in the respiratory organs affects the Melnooku kal and uyir kal and so the 
vayu is not able to reach the terminal points of respiration which producing gasping and 
labored breathing. 
 2.  Some authors said that the disease is caused by deranged Vatha. This thought is also 
acceptable because the destruction of Vayu in the respiratory tract is abnormally present. 
3.   Excessive intake of Pitha prompting diet induces Pitha Kutram. This type of Pitha 
produces more heat and this heat goes to head resulting in sneezing, running nose, heaviness 
of head and neck and also induces formation of water vapors in the lung and causing 
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narrowing of air passage, which leads to the onset of the disease. This indicated as, the 
changes in the diet and deeds which elevate Vatha and Kaba produce the clinical symptoms 
of Swasa Kasam. 
In Uyir Nilaigal, Anagatham (chest) which is the residence of Udhanan (melnokku 
kal) and Pranan (Uyir kal) is deranged.When Pranan, the primary vayu is affected it lead to 
difficulty in breathing and involvement of Udhanan leads to cough and sneezing. 
Involvement of Kirukaran leads to running nose, cough, sneezing.  
Involvement of Devathathan leads to tiredness. Involvement of Samanan causes 
inability to control the other Vayus and causes loss of appetite.Involvement of Sadhaga 
pitham leads to sluggishness. In Kaba, the derangement of Avalambagam leads to cough, 
wheezing.  
In the seven Udal Thathus, Saaram, Senneer are affected which leads to lethargy and 
depression. In severe cases Oon and Kozhuppu are also affected leads to symptoms of 
emaciation and body pain.  
Piniyari Muraimai (Diagnosis) 
The way of diagnosis is very important by which a physician can deal the disease, by 
which he can rule out the cause of the disease which is the main thing to be treated.  
Thiruvalluvar Said,  
§¿¡ö ¿¡Ê §¿¡ö Ó¾ø¿¡ÊÂÐ ¾½¢ìÌõ 
Å¡ö¿¡Ê Å¡öôÀî ¦ºÂø.  
-¾¢ÕìÌÈû 
Piniyari muraigal (Method of Diagnosis) is based upon four main principles, 
1) Poriyal Arithal(Inspection)  3) Vinaathal (interrogation) 
2) Pulanal Arithal (Palpation)  4) Enn vagai thervugal  
Physicians „pori‟ and „pulan‟ are used as tools for examining the „pori pulan‟ of the patient. 
The above principles correspond to the methodology of 1.Inspection 2.Palpation 3. 
Interrogation in modern medicine in arriving a clinical diagnosis of the disease.    
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1. Poriyal Arithal 
    Porigal are the five organs of perception. They are Skin, Tongue, Eyes, Nose, and Ears. 
Poriyal arithal is examining the Pori of the patient by the Pori of the physician. In Swasa 
kasam, it is as follows, 
     Mei (Skin)                  :      Normal 
Vai (Tongue)  :      Excessive Salivation 
Kann (Eye)  :      Diminished vision  
Mookku (Nose) :      Running nose or nasal block 
Sevi (Ear)    :      Normal 
2. Pulanal Arithal  
Pulangal are the five objects of senses. In Swasa kasam, it is as follows, 
Ooru (Tactile sensation)  :   Warmth 
           Oosai (Hearing)             :   Normal 
 Ozhi (Visual)                         :   Normal 
 Suvai (Taste Sense)             :   Normal 
Naatram (Smell sense)        :   Altered or absent due to Running nose and       
    inflammation of nasal mucosa. 
3.  Vinadhal 
The influence factors such as Name, Age, Family history, occupation, Socio-
economic status, History of allergies related to food, seasons, deeds, etc. 
Ivagai Nilangal (Geographical Distribution) 
Study of Ivagai Nilangal is very important since geographical distribution plays a vital 
role in altering Mukkutram and produce disease which is peculiar to that area.   
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(i) Kurinchi (Mountains range and its surroundings) 
”   ¦¸¡   
               -   
                  
             ³Â§Á ¾íÌ ÁÈ¢”. 
 -   . 
In Kurunchi Nilam, people are affected by fever that results in blood dyscariasis, 
disease of spleen and liver, and prevalence of kaba disease is more in Kurunchi nilam.  
 
(ii)  Mullai (Pastoral area of the forests and its surroundings) 
“      
   -  
¦Á¡     §¿¡  
¦Á¡   ” 
                                  -   . 
In Mullai Nilam, the pastoral land of the forest is the birth place of many pitha 
diseases and diseases like abdominal colic and other vatha diseases also occur. 
 
(iii) Marudham (The fertile river bed and its surroundings) 
“ÁÕ¾¿¢Äõ ¿ýÉ£÷ ÅÇ¦Á¡ý¨Èì ¦¸¡ñ§¼ 
¦À¡   §¿¡  §À¡ - ¾  
   
§Ä   ”  
                                  -   . 
Marudham the agricultural land is fertile with very good water which will drive out 
the diseases of all the three humors. The nourishing food with all the tastes never allows such 
diseases to occur. 
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(iv) Neithal (The coastal region and its surroundings) 
         “     
       - ¾ø 
              Ìõ 
             ”      -   .  
Though Neithal Nilam has the dominant taste of Uvarppu (salt), it is the place of Pitha 
Vayu. The people who dwell here are susceptible to odema due to Kaba, Silapatha Rogam 
(Filariasis), Kudalanda Viruthi (Hernia). 
 
(v) Paalai (Arid-Deserts and its surroundings) 
          “   §À¡    
             –  
              
            ” 
                                          -   . 
The Palai Nilam is the birth place of all the disease caused by the derangement of 
Vatha, Pitha and Kapham. From Ivagai Nilangal we understood that kapha disease is 
predominant in kurinchi Thinai. 
 
4. Enn vagai thervugal: (Eight diagnostic Tools) 
It is the unique diagnostic tool in Siddha system of Medicine. The following lines 
reveal this as follows.  
“   ¦Á¡  
   ” 
-§¿¡ö ¿¡¼ø §¿¡ö Ó¾É¡¼ø 
“  ¦¾¡    ” 
                                   - §¿¡ö ¿¡¼ø §¿¡ö Ó¾É¡¼ø  
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The diagnostic value of EN VAGAI THERVUGAL is specific to Siddha system of 
medicine and presumes the vitiated dhoshas in the patients. 
Enn Vagai thervugal are, 
a. Naa (Tongue)    e. Malam (Motion)   
b. Niram (Colour of the skin)  f. Moothiram (urine) 
c. Mozhi (Speech)    g. Sparisam (Palpation)  
d. Vizhi (Eye)    h. Naadi (Pulse) 
1. Naa 
It is observed for its color, presence of ulcer, coating, etc. 
2. Niram 
It‟s observed for its Color of the skin, conjunctive. In Swasakasam, Niram is affected 
when the patient suffer from allergic skin lesions and anaemia etc. 
c. Mozhi 
It‟s observed for its character of speech, sound. In Swasa kasam mode of speech may 
be emotional or difficulty in speech, low pitched voice, wheezing sound is heard. 
d. Vizhi 
It‟s observed for its colour, vision power, lacrimal secretion. In Swasa kasam, the 
eyes may have itching and burning sensation  
e. Malam 
Its observed for its Consistency hard or semisolid or diarrohea, undigested food, fluid 
resembling the water used to clean meat, color, frothy, dysentery, bloody, pus, mucous, 
smell, frequency of defecation, constipation, reduced or increased stool content, lower 
abdominal pain during defecation are noted. 
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f. Siruneer  
Its observed for its Colour – yellow, black, white copper colored, mixed color, color 
of fumes, Smell – smell of fire, honey, sweet odours, fragrance of flowers, fruity odour of 
deer flesh, frothy or not, frequency and quantity are noted. 
g. Sparisam  
By Sparisam, the present of temperature and tenderness can be observed. 
h. Naadi  
Naadi is the very important tool for diagnosis and prognosis of the disease. 
Genesis of Naadi 
“     
   ¦¾¡  
 §Ä¡     
 §Ä¡   ” 
-   
Naadi is responsible for existence of life and can be felt one inch proximal to the wrist 
on radial side by means of palpitations with the tips of index, middle and ring fingers 
corresponding vatham, pitham, kapham respectively.The three humors vatham, pitham and 
kabam exisits in the ratio 1: ½: ¼ normally. Derangement in these ratios leads to various 
disease entities. 
 
Naadi Nadai in Swasa kasam 
Iya azhal  
   “    
          
                §¸¡   
                     §ர¡ ” 
                     - ச¾¸ . 
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Pitha Naadi  
              “     
                          
                    §¿¡  
                           
                   ” 
                                                         - ச¾¸ .   
Vatha Kapha Naadi 
              “     
                     
   §¾¡  
                     §ர¡  
                
                     
                
                   §¿¡  ”. 
                                              - ச¾¸ . 
Iya Naadi 
                                                                                        
“     
                          
                 §¾¡   
                      §Ã¡    §¾¡  
                   
                         ” 
                                                         - ச¾¸ . 
Iya Vayu 
  “¦¾¡    ¦¾¡  
                     
                   
                     ”    - ச¾¸  
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Hence the Naadi nadai in swasa kasam is Iya azhal, Pitham, Vatha Kapham, Iyam and 
Iya Vayu. 
Nei Kuri  
Neikuri is a prognostic tool in Siddha system of Medicine. For this examination first 
urine is collected in the early morning in a clear wide mouthed glass dish or China clay 
container and is subjected to analysis of “Neerkkuri and Neikkuri” within one and a half an 
hour. Prior to the day of urine examination the patient is instructed to take a balanced diet and 
quantities of food must be proportionate to his routine intake.  
“   §ர¡  
    
   
    
¦¾¡    
   “ 
                                         -   . 
After collecting the urine in a wide cleaned glass bowel a drop of gingelly oil is 
dropped into it which is kept under sunlight in a calm place. The derangement of the three 
dhoshas can be diagnosed by the mode of spread of gingelly oil on the urine surface. 
“  ¿£ñÊÉ·§¸ ” 
  ““ §ப¡    ” 
“ ¦¾¡   ¦Á¡  ” 
            -§¿¡ö ¿¡¼ø §¿¡ö Ó¾É¡¼ø.         
If oil spreading like a snake indicates derangement Vatham. If oil spreading like a 
ring indicates derangement Pitham. If oil spreading like a pearl indicates derangement 
Kapham 
   “    
       
   §¾¡  ¦¾¡  §¾¡ ”       
      -§¿¡ö ¿¡¼ø §¿¡ö Ó¾É¡¼ø 
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           When oil spreads like snake and ring, ring and snake, snake and pearl, ring and pearl 
indicates Dhondha Dhosham. (Dhondham – Combination of two) 
7. MUKKUTRA NILAIGAL 
VATHAM 
Pranan 
Pranan start from moolatharam and comes through the nostril and responsible for 
respiration in the ratio of 8:12. In Swasa kasam, this vayu is affected leading to difficulty in 
breathing. 
Abanan 
 It starts from swathittanam and descents down. It responsible for excretion of urine 
and faeces. In some patients of Swasa kasam, Abanan is affected resulting in Constipation. 
Viyanan 
It arises from the shoulder and goes through all the 72,000 nerves and responsible for 
movement of the body, appreciates the sense of touch, help to take the essence of the food to 
the strategic points the body and guards the body. 
Udhanan 
 It starts from umbilical region (Udharakkini) and its main function is generation of 
speech and distributes the saaram equally to all tissues. In Swasa kasam, this vayu is affected 
resulting in low pitched voice due to difficulty of breathing. 
Samanan 
Samanan starts from the umblicial cord and spread out upto the lower limbs and 
responsible for the balance of other four vadha and digestion. In Swasa kasam, this vayu is 
affected since it cannot control the other vayus. 
Nagan 
It is responsible for higher intellectual function, hearing, thinking etc. it causes 
opening and closing of eye lids. 
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Koorman 
It starts from mind and causes winking of the eyelids, yawning and closure of mouth. 
It gives strength and helps to visualize things and causes lacrimal secretion. 
Kirugaran 
It lies in tongue and causes salivary and nasal secretion, sneeze reflex, cough reflex 
and increase the appetite. It makes to concentrate on one thing. In Swasa kasam, this vayu is 
affected and causing running nose, sneezing, excessive cough and loss of appetite. 
Devathathan  
Laziness, occular movement and human passions are attributed to this vayu. In Swasa 
kasam, this vayu is deranged causing emotional stress and insomnia. 
Dhananjeyan  
It functions from the nose and it is responsible for the bloating of the body after death 
and also for the foul smell. After 3
rd
 day of death it escapes through the head. 
PITHAM 
Anal pitham 
It lies between the stomach and the intestine. It causes digestion and dries up moist 
ingestion substances. In Swasa kasam, most of the patients complain loss of appetite and 
indigestion. 
Ranjagam 
This fire lies in the stomach, where it helps in the absorption of food materials and 
finally it promotes the absorbed nutrients and gives red colour to the chyme and produces 
blood into the circulation. 
Sadhagam 
           It resides in the heart and executes the day to day activities according to the 
consciousness of the person. In Swasa kasam most of the patients complain restlessness, 
breathlessness. 
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Aalosagam 
It resides in both eyes and is responsible for clear vision. 
Prasagam  
It resides in skin and gives complexion and brightness to skin. In Swasa kasam, some 
patients may have allergic skin lesions. 
KAPHAM  
Avalambagam 
It lies in lungs and helps in respiration .it controls the functioning of other four types 
of kapham and equilibrium as well as the heart. In Swasa kasam patients, due to 
disarrangement of Avalambagam, will occur and causes tightness of chest, cough, wheezing 
and difficulty in breathing.  
Kilethagam 
It resides in the stomach and moistures the food materials making them soft and 
thereby helps in digestion process. In this disease, some patients have indigestion. 
Pothagam 
Resides in the tongue and helps to realize the taste of the consuming food. 
Tharpagam 
       Sustaining in the head and gives refrigerant effect to cool the eyes and other sense 
organs. In some patients of Swasa kasam, Tharpagam is affected resulting in Burning 
sensation. 
Sandhigam 
It resides in the joint and helps in the free and easy movements of joints. 
UDAL KATTUGAL 
Saaram (Chyle): 
It strengthens the body and mind. It is deranged in Swasa kasam due to loss of 
appetite causing tiredness in the body and mind. 
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Senneer (Blood): 
It is responsible for knowledge, strength, boldness and complexion in a person. In 
Swasa kasam it is affected resulting in general weakness of the body. 
Oon (Muscles): 
It gives the shape to the body according to the physical activity and nourishment of 
bone growth. 
Enbu (Bone): 
It forms the frame to the body and supports it to stand erect. It protects soft organs of 
the body and it also responsible for postures and movement of the body. 
Kozhuppu (Adipose tissue): 
It gives lubrication to the joint and other parts of the body to function smoothly.  
Moolai (Bone marrow): 
It resides the medulla of the bone and gives strength and softness to it. 
Sukkilam / Suronitham (sperm or ovum): 
It is responsible for reproduction. 
LINE OF TREATMENT: 
  In Siddha system of medicine Siddhar‟s follow different line of treatment for different 
disease. The deranged humour, primarily kabam and vatham is normalized by giving emetic 
or purgative. The line of treatment of Swasakasam consists of the following. 
1. Kalichal Maruthuvam    –  To bring the dhoshas in equilibirium. 
2. Internal Medicine                –  Mainly anti-spasmodic, expectorant to relieve the spasm       
of  respiratory system and to expel the sputum. 
3. Diet               –  To maintain tri-dhoshas and energy in equilibrium. 
4. Prevention methods  –  To strengthen the muscles of respiration (Pranayamam). 
 5. Yoga therapy   –  To maintain dhasa vayukkal and to improve mental and   
                                                          physical health. 
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Kalichal Maruthuvam (Purgation) 
As per siddha literature, before starting the treatment for SWASAKASAM, purgation 
will be given with medicine Mantha ennai 8ml OD with warm water at early morning in 
empty stomach for one day.   
Administration of internal medicine 
For the treatment of the disease swasa kasam, Mantharakasa lehiyum 5.4gm twice a 
day was given after meals. 
Dietary advice  
Swasakasam patient can have food as follows: 
 Steamed food like Idly, Idiyappam, Puttu 
 Mussumusukai adai, Kalyana murungai adai,Thoothuvalai adai 
 Turmeric / Pepper mixed milk 
 Ginger / Dry ginger mixed coffee 
 Crab soup, Vegetable soup, Pepper rasam, Mutton leg soup 
 Drumstic, Yam, Brinjal, Manathakkali(Greens), Sundaivatral 
 Take well boiled water to drink 
Swasa kasam patients should restrict the following also. 
 Avoid Cooldrinks, Chocolate, Cake 
 Oily substances 
 Curd, Ghee, Butter, Cheese 
 Dry fish, Chicken, Beaf 
 Sweets, Sour food, Tuberous food 
 Tined food, Preservative food, Refrigerated foods 
 Allergen foods 
 Citrus foods 
 Vegetables like Cucumber, Snake guard etc., 
General advise 
 Avoid smoking, Tobacco , Alcohol, 
 Avoid Cold weather 
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  Avoid Pollutated area, Dust 
  Avoid Stress, Emotion 
  Do pranayamam 
  Have your night food before 7‟o clock 
  Avoid overeating in night 
  Have a bath in hot water 
 
PRANAYAMAM (Breathing Exercise) & YOGA THERAPY 
Yoga has become a very popular curing vehicle for most of the ailment that plague 
humans today. Asthma too can control and cured completely with the help of yoga. The 
breathing exercises are often combined with yoga postures such as suryabheda and 
padahasthasana which further helps the body regain the natural inner harmony it requires for 
completely healthy functioning. These are the easy postures such as the salutation of the sun, 
simple shoulder lifts that complement the breathing exercises. 
À¢Ã½¡Â¡Áò¾¢ý ¾òÐÅõ  
 
                        ²Ú¾ø âÃ¸õ ®¦ÃðÎ Å¡Áò¾¡ø 
                        ¬Ú¾ø ÌõÀ¸õ «ÚÀòÐ ¿¡Ä¾¢ø 
                        °Ú¾ø ÓôÀò ¾¢Ãñ¼¾¢ø §Ãº¸õ 
Á¡Ú¾ø ´ýÈ¢ý ¸ñÅï º¸Á¡§Á. 
-¾¢ÕÁó¾¢Ãõ 
 
      Among the many health benefits of exercise is natural asthma relief. That‟s why yoga 
is catching on among people with asthma. Yoga is all around stress-relieving technique with 
gentle stretches and a slower pace than other workouts. Even better, recent research revealed 
specific benefits from yoga for asthma relief. So, practicing asanas is more helpful in 
asthmatic patients as supportive therapies. The following asanas are helpful in Bronchial 
asthma. 
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ASANAS FOR BRONCHIAL STHMA 
1. Nadi shodhan pranayamam (Alternate nostril breathing technique) 
2. Kapal bhati pranayamam (Skull shining breathing technique) 
3. Ardha matsyendrasanam (Sitting half spinal twist) 
4. Pavanamuktasanam (Wind relieving pose) 
5. Setu bandhasanam (Bridge pose) 
6. Bhujangasanam (Cobra pose) 
7. Adho mukha svanasanam (Downward-facing dog pose) 
8. Badhakonasanam (Butterfly pose) 
9. Poorvottasanam (Upward plank position) 
10. Shavasanam (Corpse pose) 
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ASANAS 
                 Pranayamam     Ardha matsyendrasanam  
 
 
 
                     Bhujangasanam        Poorvottasanam  
  
 
 
 
 
 
 
    Badhakonasanam      Shavasanam 
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DIFFERENTIAL DIAGNOSIS 
NOIKANIPPU VIVATHAM  
Swasa Pitham  
 In Swasa Pitham, there is increased breathing (tachypnoea), flatulence, pain all over 
the body, excessive salivation, loss of consciousness, pain in the chest followed by cough, 
loss of appetite etc., In Swasa kasam there is no loss of consciousness and pain in the chest 
followed by cough. 
Mandhara Kasam  
In Mandhara kasam there is running nose, sneezing, chest tightness, breath sound is like 
hissing of snake, excessive sweating present all over the body, cough with expectoration,  
hoarseness of voice, breathing difficulty etc. In Swasa kasam there is no sweating present all 
over the body 
Kandakiragam  
       In kandakiragam, there is difficulty in speech, pain in the chest and occipital region, pain 
all over the body, sweating in face, oral breathing, pain in the ribs, breathlessness and loss of 
appetite. In swasa kasam, there is no pain in the occipital region. 
Swasa Silethumam  
In Swasa Silethumam, there is accumulation of phlegm in the chest, cough, nasal block, 
difficulty in breathing, fever with rigor, syncope, tightness of chest, dryness of mouth, 
running nose, excessive thirst etc. In Swasa kasam, there is no fever with rigor, excessive 
thirst etc. 
Silethuma Vatha Suronitham  
In Silethuma Vatha Suronitham symtomps like chillness of body, abdominal 
distention with tenderness, decreased salivation, body pain, headache, loss of taste, 
expectoration, dreaming, dyspnoea, fainting, rapid pulse etc. In Swasakasam, there is no 
abdominal distention and decreased salivation. 
 
 
 
27 
 
 
ANATOMY OF RESPIRATORY SYSTEM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
MODERN ASPECTS 
 
  
28 
 
MODERN ASPECTS 
ANATOMY & PHYSIOLOGY OF RESPIRATORY SYSTEM 
The respiratory system is a complex biological system comprised of several organs 
that facilitate the inhalation and exhalation of oxygen and carbon dioxide in living 
organisms.In fact, the respiratory system is composed of the following biological structures:  
1. Nose and nasal cavity 
2. Mouth 
3. Pharynx 
4. Larynx 
5. Trachea 
6. Bronchi and bronchioles 
7. Lungs  
8. The muscles of respiration. 
A properly functioning respiratory system is a vital part of our good health. 
Respiratory infections can be acute and sometimes life threatening.  
Anatomical components 
Nose and Nasal cavity 
 The nose and nasal cavity constitute the main external opening of the respiratory 
system. They represent the entryway to the respiratory tract- a passage through the body 
which air uses for travel in order to reach the lungs. The nose is made out of bone, muscle, 
cartilage and skin, while the nasal cavity is more or less, hollow space.  
 The cavity is lined with mucus membranes and little hairs that can filter the air before 
it goes into the respiratory tract. They can trap all harmful particles such as a dust, mold and 
pollen and prevent them from reaching any of the internal components. 
Oral cavity  
The oral cavity, more commonly referred to as the mouth, is the only other external 
component that is part of the respiratory system. Not only does the mouth not possess the 
ability to warm and moisturize the air coming in but it also lacks the hairs and mucus 
membranes to filter out unwanted contaminants. On the plus side, the pathway leading from 
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the mouth is shorter and the diameter is wider, which means that more air can enter the body 
at the same speed. 
Pharynx 
 The pharynx resembles a funnel made out of muscles that acts as an intermediary 
between the nasal cavity and the larynx and esophagus. It is divided into three separate 
sections: (i) Nasopharynx (ii) Oropharynx (iii) Laryngopharynx. 
Larynx 
The larynx is the next component, but represents only a small section of the 
respiratory tract that connects the laryngopharynx to the trachea. It is commonly referred to 
as the voice box, and it is located near the anterior section of the neck, just below the hyoid 
bone.  
Trachea  
The trachea is a longer section of the respiratory tract, shaped like a tube and 
approximately 5 inches in length. The trachea, more commonly referred to as the windpipe, 
connects the larynx to the bronchi and also has the role of filtering the air prior to it entering 
the lungs. 
Bronchi 
The lower end of the trachea splits the respiratory tract into two branches that are 
named the primary bronchi. These first run into each of the lungs before further branching off 
into smaller bronchi. These secondary bronchi continue carrying the air to the lobes of the 
lobes of the lungs, and then further split into tertiary bronchi.  
The tertiary bronchi then split into even smaller sections that are spread out 
throughout the lungs called bronchioles. Each one of these bronchioles continues to split into 
even smaller parts called terminal bronchioles. The walls of the bronchi and bronchioles are 
also lined with muscle tissue, which can control the flow of air going into the lungs. 
Lungs 
 The lungs are two organs located inside the thorax on the left and right sides. They are 
surrounded by a membrane that provides them with enough space to expand when they fill up 
with air. The left lung is smaller and has only two lobes while the right lung has three lobes. 
30 
 
Inside the lungs resemble a sponge made of millions of small sacs that are named 
alveoli. These alveoli are found at the ends of terminal bronchioles and are surrounded by 
capillaries through which blood passes.  
Pleura and Pleural Cavity 
The inside of the thoracic cavities and the lung surface are covered with serous 
membranes, respectively the parietal pleura and the visceral pleura, which are in direct 
continuity at the hilum. The lungs are maintained in close opposition to the thoracic wall by a 
negative pressure between visceral and parietal pleurae. A thin film of extracellular fluid 
between the pleurae enables the lungs to move smoothly along the walls of the cavity during 
breathing. 
Muscles of respiration 
 The last component of the respiratory system is a muscle structure known as the 
muscles of respiration. These muscles surround the lungs and allow the inhalation and 
exhalation of air. The main muscle in this system is known as the diaphragm, a thin sheet of 
muscle that constitutes the bottom of the thorax.  
It pulls in air into the lungs by contracting several inches with each breath. In addition 
to the diaphragm, multiple intercostals muscles are located between the ribs and they also 
help compress and expand the lungs. 
Blood supply 
On the right side there is one bronchial artery which arises either from the third 
posterior intercostals artery or from the third posterior intercostal artery or from the upper left 
bronchial artery. On the left side there are two bronchial arteries both of which arise from the 
descending thoracic aorta, the upper opposite fifth thoracic vertebra and the lower just below 
the left bronchus. 
The venous blood from the first or two divisions of the bronchi is carried by bronchial 
veins. Usually there are two bronchial veins on each side. The right bronchial veins drain into 
the azygos vein. The left bronchial veins drain either into the left superior intercostals vein or 
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into the hemiazygos vein. The greater part of the venous blood from the lungs is drained by 
the pulmonary veins. 
Lymphatic drainage 
Superficial vessels drain the peripheral lung tissue lying beneath the pulmonary 
pleura. The vessels pass round the borders of the lung and margins of the fissures to reach 
the hilum. Deep lymphatics drain the bronchial tree, the pulmonary vessels and the 
connective tissue septa. They run towards the hilum where they drain into the 
bronchopulmonary nodes. 
Nerve supply 
     Parasymphathetic nerves are derived from the vagus. These fibers are (i) Motor to the 
bronchial muscles and on stimulation cause bronchospasm. (ii) Secretomotor to the mucous 
glands of the bronchial tree and (iii) Sensory. The sensory fibers are responsible for the 
cough reflex. 
 Sympathetic nerves are derived from second to fifth spinal segments. These are 
inhibitory to the smooth muscle and glands of the bronchial tree. That is how sympathetic 
drugs, like adrenalin, cause bronchodilatation and relieve symptom of bronchial asthma. 
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RESPIRATION 
During normal quiet breathing, inspiration is the active process and expiration is the 
passive process. During inspiration, thoracic cage enlarges and lungs expand. During 
expiration, the thoracic cage decrease in size and attain the preinspiratory position. 
Cycles of Respiration 
This occurs 12-15 times per minute and consists of three phases. 
 Inspiration 
 Expiration 
 Pause 
Inspiration 
The capacity of the thoracic cavity is increased by simultaneous contraction of the 
inter costal muscles and the diaphragm. The parietal pleura move with the walls of thorax and 
the diaphragm. This reduces the pressure in the pleural cavity to the level considerably lower 
than the atmospheric pressure. The visual pleura follow the parietal pleura. During the 
process, the lungs are stretched; the pressure within the alveoli and the air passage reduced 
drawing air into the lungs in an attempt to equalize the atmospheric and alveolar air pressure. 
The process of inspiration is active as it requires expenditure of energy for muscle 
contraction. The negative pressure created in the thoracic cavity aids venous return to the 
heart and is known as respiratory pump.  
Expiration 
Relaxation of inter costal muscles and the diaphragm results in the downward and 
inward movement of the rib cage and the elastic recoil of the lungs. As this occurs, the 
pressure of the gases inside the thorax exceeds the atmospheric pressure and therefore air is 
expelled from the respiratory tract. The lungs still contain some air and are prevented from 
complete collapse by the intact pleura. The process is passive as it does not require the 
expenditure of energy. After expiration there is a pause, before the next cycle begins.  
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Physiology Variables Affects Respiration  
Elasticity 
Loss of elasticity of the connective tissue in the lungs necessitates forced expiration 
and increased effort of inspiration.  
Compliance 
The ability of lungs and thorax to expand or the expansibility of lungs and thorax is 
called the compliance. It is defined as the change in volume per unit change in the pressure. 
Air flow resistance 
When this is increased e.g. in broncho constriction, more respiratory effort is required 
to inflate the lungs. 
 Pulmonary function tests: 
Pulmonary function tests are useful in assessing the functional status of the respiratory 
system both in physiological and pathological conditions. Pulmonary function tests are 
carried out mostly by using spirometer. The air in lung is classified into two divisions: 
I. Lung volume 
II. Lung capacities 
Lung volume  
 Lung volumes are the volumes of air breathed by an individual during altered pattern 
of respiration. The lung volumes are dynamic and are four types: 
I. Tidal volume 
II. Inspiratory reserve volume 
III. Expiratory reserve volume 
IV. Residual volume 
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Tidal Volume (TV) 
 The volume of air breathed in and out of lungs in a single normal quiet respiration is 
called tidal volume. Tidal volume signifies the normal depth of breathing. Normal value 
500ml 
Inspiratory Reserve Volume (IRV) 
An additional amount of air that can be inspired forcefully after the end of normal 
inspiration beyond tidal volume is called the inspiratory reserve volume.Normal volume 
3300ml. 
Expiratory Reserve Volume (ERV) 
 The additional amount of air that can be expired out forcefully, after normal 
expiration is called the expiratory reserve volume.Normal volume 1000ml.                          
Residual Volume 
Normally, lungs cannot be emptied completely even by forceful expiration. Some amount of 
air always remains in the lungs even after the forced expiration. The amount of air remaining in the 
lungs even after forced expiration is called residual volume. It is significant because of two reasons: 
(i) It helps to aerate the blood in between breathing and during expiration (ii) It maintains the 
contour of the lungs 
Lung capacities 
 Two or more lung volumes together are called lung capacities. Lung capacities are of four 
types: 
I. Inspiratory capacity 
II. Vital capacity 
III. Functional residual capacity 
IV. Total lung capacity 
Inspiratory capacity (IC) 
 It is the maximum volume of air that is inspired from end expiratory position. Inspiratory 
capacity includes tidal volume and inspiratory reserve volume.  
IC = TV + IRV=500+3300=3800ml 
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Vital capacity (VC) 
 It is the maximum amount of air that is expelled out forcefully after a maximal (deep) 
inspiration. Vital capacity includes inspiratory reserve volume, tidal volume and expiratory reserve 
volume. 
VC= IRV+TV+ERV=3300+500+1000=4800ml 
Functional residual capacity (FRV) 
 It is the volume of air remaining in the lungs after normal expiration. Functional residual 
capacity includes expiratory reserve volume and reserve volume. 
                 FRV= ERV+RV=1000=+1200=2200ml 
Total lung capacity (TLC) 
 Total lung capacity is the amount of air present in the lungs after a maximal inspiration. It 
includes all the volumes. 
                        TLC=IRV+TV+ERV+RV=3300+500+1000+1200=6000 
Alveolar Ventilation 
This is the volume of air that moves into and out of the alveoli per minute. It is the 
tidal volume minus the anatomical dead space, multiplied by the respiratory rate. 
Alveolar ventilation = (TV-anatomical dead space) respiratory rate 
= (500-150) ml x 15 per minute = 5.25liters / minute. 
Lungs function tests are carried out to determine respiratory function and are based on 
the parameters out lined above. 
External Respiration 
This is the exchange between alveoli and blood. Total area of gas exchange in the 
lungs is 70-80 square meters. CO2 diffuses from venous blood along the contraction gradient 
into the alveoli until equilibrium with alveolar air is reached. By the same process O2 diffuses 
from alveoli to the blood.  
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Internal Respiration 
This is the exchange of air between the tissue and blood. When there is difference in 
partial pressures, oxygen diffuses outward from the blood to extra cellular fluid then into the 
cell walls. The process involved is diffusion. 
Control of Respiration 
Control of respiration is normally involuntary. Voluntary control is exerted during 
activities such as speaking, singing but is over ridded if homeostasis of arterial PO2 and PCO2 
is threatened i.e. if this is high arterial PCO2 or low arterial PO2. 
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BRONCHIAL ASTHMA 
                    Bronchial asthma is a disease characterized by (i) airway obstruction (airway 
narrowing) that is reversible (but not completely so in some patients) either spontaneously or 
with treatment (ii) airway inflammation and (iii) airway hyper responsiveness to a variety of 
stimuli.  
                     Subsequently the Consensus Report describes asthma as a “Chronic 
inflammatory disorders of the airways in susceptible individuals, inflammatory symptoms are 
usually associated with widespread but variable airflow obstruction and an increase in airway 
response to a variety of stimuli. Obstruction is often reversible, either spontaneously or with 
treatment. 
Prevalence 
                     The prevalence of asthma is not exactly known. The disease has reached 
epidemic proportions affecting 334 million individuals in the world. The WHO estimates that 
there are 15-20 million asthmatics in India alone. The WHO estimates that asthma has 
increased by about 40-50 percent in the last decade. 
                      Asthma has a major economic impact over the family since; asthma treatment 
related expenditure might consume a large portion of a family‟s income in the developing 
countries like India. The hypothesis that environmental factors related to living conditions 
may have been responsible for varied prevalence and causation of asthma needs further study. 
Etiology  
Etiologically asthma is heterogeneous disease. There are two types of asthma  
 Early onset asthma (atopic, allergic, extrinsic) 
 Late onset asthma (Non-atopic, Idiosyncratic, Intrinsic) 
Atopic Asthma 
                     Atopic or extrinsic asthma defines the asthmatic symptoms manifesting in an 
atopic individual. The word atopic in reality denotes a genetic susceptibility to develop 
allergies hence why atopic asthma, is often associated with eczema or other hypersensitive 
related reactions. 
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    An individual who suffers from allergies can suffer from asthma attacks brought on 
by certain substances, called allergens, with the constriction and obstruction of the bronchi 
due to secretion of mucous causing breathing difficulties.  
                  This type of asthma is extremely common in children and the allergies are 
investigated using allergy tests called skin-prick tests, and often identified as dust mite, dust 
animal hair, or pollen allergies. Treatment for this type of asthma is the same for any typical 
form, with added measures of elimination of the allergens responsible. 
Non – Atopic Asthma  
   Non atopic asthma refers to inflammation and constriction of the airways that is not 
caused by exposure to allergens. There is no cure but identifying and avoiding the triggering 
factors will prevent symptoms developing. Symptoms may be managed by various asthma 
medications such as bronchodilators, antiinflammatories and asthma inhalers. 
 This type of asthma develops later in adult life with negative personal (or) family 
history of allergy, negative skin test and normal serum levels of IgE.  
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CHANGE IN BRONCHIAL TUBE DURING ASTHMA ATTACK 
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PATHOPHYSIOLOGY OF ASTHMA 
             The inhalation of an allergen in a sensitized atopic asthmatic patient results in a two 
phase bronchoconstrictor response. The inhaled allergen rapidly interacts with mucosal mast 
cells via IgE dependent mechanism, resulting in the release of mediators such as histamine 
and the cysteinyl leukotrienes with resulting brochoconstriction. 
            With increasing severity and chronicity of the disease, remodeling of the airway 
occurs leading to fibrosis of the airway wall, fixed narrowing of the airway and a reduced 
response to bronchodilator medication.Asthma has the following pathological characteristics: 
 Airway obstruction (or airway narrowing), that is reversible (at least partially), either 
spontaneously or with treatment. 
 Airway inflammation  
 Airway hyper responsiveness to a variety of stimuli 
Airway obstruction 
  Airway obstruction is responsible for the clinical manifestations of asthma such as 
wheezing, dyspnoea, and cough.  
  Airway obstruction, which is determined by the diameter of the airway lumen, can be 
influenced by a number of factors, including oedema of the bronchial wall, mucus 
production, airway smooth muscle contraction, and airway remodeling suggesting a rationale 
for early initiation of anti inflammatory therapy. 
Airway inflammation 
The airways of asthma patients are infiltrated by a number of different inflammatory 
cells, which then cause epithelial disruption and mucosal oedema. An initial trigger in asthma 
may cause the release of inflammatory mediators from bronchial mast cells, macrophages and 
epithelial cells. 
   In addition to the release of cytokines by mast cells, T-cells, fibroblasts, endothelial 
cells and epithelial cells activate neutrophils, eosinophils and macrophages, which produce 
chronic allergic inflammation characteristic of asthma. 
           This process produces epithelial injury, abnormalities in neural mechanisms, increase 
in airway smooth muscle responsiveness, and airflow obstruction. Epithelial injury can lead 
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to increased permeability and sensitivity to inhaled allergens, irritants, and inflammatory 
mediators.  
  In addition, transduction of fluids and reduced clearance of inflammatory substances 
and respiratory secretions occur with disruption of epithelium mucociliary mechanisms. The 
inflammatory process may chronically irritate the airway leading to chronic cough symptoms. 
Airway hyperresponsiveness 
Airway hyperresponsiveness is an exaggerated bronchoconstrictor response to many 
physical, chemical and pharmacological agents e.g., allergens, environmental irritants, viral 
respiratory infections, cold air or exercise.  
Whether airway hyperresponsiveness, an abnormality fundamental to the 
pathogenesis of asthma is present at birth in genetically predisposed individuals, or whether it 
is acquired, is under investigation. 
    The level of airway hyperresponsiveness usually correlates with the clinical severity 
of asthma and with medication requirement. Atopy, the genetic predisposition for the 
development of an IgE mediated response to common aero allergens, is the strongest 
identifiable predisposing factor for developing asthma. 
            The stimuli that interact with airway responsiveness and incite acute episodes of 
asthma can be grouped into ten major categories – allergic, pharmacological, environmental, 
infections, occupational, exercise, heart burn, food and drink, weather changes, smoking, 
sulfer dioxide and emotional stress. 
Allergens 
An allergy with asthma is a common problem. Eighty percent of people with asthma 
have allergies to airborne substances such as tree, grass, and weed pollens, mold, animal 
dander, dust mites, and cockroach particles. 
Allergic asthma is dependent on IgE response controlled by T and B lymphocytes and 
activated by the interaction of antigen with mast cells-bound IgE molecule. 
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Pharmacological stimuli 
  The drugs most commonly associated with the induction of acute episodes of asthma 
are aspirin, coloring agents – tartazine, b- adregenic antagonists, sulfating agent. 
Aspirin – sensitive syndrome affects adults through seen in childhood. The problem 
usually begins with perennial vasomotor rhinitis that is followed by a hyper plastic rhino 
sinusitis with nasal polyps, progressing to asthma. Indomethacin, fenoprofen, naprocen, 
zonepirae sodium, ibuprofen, mefanamic acid and phenylbutazone are particularly important. 
B-Adrenergic antagonist regularly obstructs the airway in asthmatics. In fact, the local 
use of b- blockers in the eye for the treatment of glaucoma has been associated with 
worsening asthma. 
Air pollutants 
Children with asthma who are exposed to maternal smoking have higher requirements 
for medication and more frequent emergency department visits. Other irritants such as wood 
smoke, household sprays, volatile organic compounds (e.g. polishes and cooking oils), and 
air pollutants may also exacerbate asthma. 
Respiratory infections 
It is well established that viral respiratory infections can excertable asthma, 
particularly in children with asthma under the age of 10. Respiratory syncytial virus, 
rhinovirus, and influenza virus have been implicated, with rhinovirus being implicated in the 
majority of the exacerbation of asthma in children.  
The role of infections as triggers also appears to be important but not common in 
adults. Respiratory virus may exacerbate asthma through different mechanism. One is that 
viral infections may cause epithelial damage and airway inflammation, both of which events 
may create asthma symptoms.  
In addition, virus has been shown to potentiate the allergic response to allergens by 
increasing the release of inflammatory mediators and the cascade of inflammatory events 
characteristic of asthma. 
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Occupational factors: 
Broncho constriction can result from working with or being exposed to metal salts, 
wood and vegetable dust, husk of grains, flour, gum acacia, pharmaceutical agents e.g. 
antibiotics, piperazine and cimetidine, industrial chemicals and plastics, biological enzymes, 
laundry detergents, animal & insect dusts, serum and secretions. There seems to be three 
underlying mechanisms: 
1. In some cases, the offending agent results in formation of significant IgE. 
2. Substances cause direct liberations of broncho constrictor substances. 
3. Substances cause direct or reflex stimulation of the airway of latent of frank asthmatics. 
 
Exercise:  
  Strenuous exercise can cause a narrowing of the airways in about 80% of people with 
asthma. These symptoms usually subside in the next 20 to 30 minutes of exercise, but up to 
50% of those with exercise-induced asthma may have another asthma attack six to 10 hours 
later. It is important to warm up slowly and adequately prior to rigorous exercise. This may 
prevent an attack. The mechanisms, by which exercise produce obstruction, may be related to 
a thermally produced hyperthermia and engorgement of the microvasculature of the bronchial 
wall and doesn‟t appear to involve smooth muscle contraction. 
Heartburn and Asthma 
Severe heartburn and asthma often go hand-in-hand. Recent studies show that up to 
89% of asthma patient also suffer from severe heartburn, known as gastroesophageal reflux 
disease (GERD). GERD generally occurs at night when the sufferer is lying down. The 
stomach acids reflux, or back up, into the esophagus; if the acid reaches into the throat or 
airways the irritation and inflammation can trigger an asthma attack. 
Certain clues that suggest reflux as the cause of asthma include the onset of asthma in 
adulthood, no family history of asthma, no history of allergies or bronchitis, difficult-to-
control asthma, or coughing while lying down. 
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Food additives  
It is widely believed that allergic reactions to foods are common asthma triggers but 
documented evidence for this is difficult to find in the literature. Some ingested substance, 
including salicylates, food preservatives, monosodium glutamate, and some food coloring 
agents, cause asthma symptoms in some patients. 
Preservatives in many beverages (including wine and beer) and in some foods contain 
metabisulphite, which may cause bronchospasm. 
Weather changes 
Adverse weather conditions such as freezing temperatures, high humidity, 
thunderstorms and episodes of acute pollution brought out by weather conditions have been 
associated with asthma exacerbations. 
Smoking:  
          Smokers appear to be at greater risk of developing asthma and have a higher 
prevalence of hyper-reactivity. Children of smokers also seem to have and increased risk of 
developing wheeze. Women who smoke during pregnancy increase the risk of wheezing in 
their babies.  
Sulfer dioxide 
The irritant can trigger dose dependent airflow limitation in patients with asthma, 
although it has no effect on the airway of normal subjects up to very high concentration. 
Airflow limitation may be incited by sulfer dioxide at concentrations as low as 1ppm, a level 
easily encountered in the work place or elsewhere in the environment  
Extreme Emotional Expression  
 Emotional stress may be trigger for asthma exacerbations primarily because extreme 
expressions of laughing, crying, anger, or fear can lead to hyperventilation and hypercapnoea 
that can cause airway narrowing. However it is important to note that asthma is not a 
psychosomatic disorder. 
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Clinical features 
 Bronchial asthma may be either episodic or chronic, and although there is a good deal 
of overlap between these two syndromes the distinction is clinically useful particularly in 
terms of prognosis and management. In general atopic individuals tend to develop episodic 
asthma, and non-atopic individuals chronic asthma. 
Episodic asthma 
 In this form of the disease the patient has no respiratory symptoms between episodes 
of asthma. Paroxysms of wheeze and dyspnoea may occur at any time and can be of sudden 
onset. Episodes of asthma can be triggered by allergens, exercise, viral infections such as 
common cold, or may be apparently spontaneous. Attacks may be mild or severe and may 
last for hours, days, or even weeks. 
Chronic asthma  
 Symptoms of chest tightness, wheeze, and breathlessness on exertion, together with 
spontaneous cough and wheeze during the night may be chronic unless controlled by 
appropriate therapy. Episodes of „severe acute asthma‟ can occur, and cough productive of 
mucoid sputum with recurrent episodes of frank respiratory infection is common in this type 
of asthma which in adults may be difficult to distinguish from chronic bronchitis. 
Nocturnal Asthma 
Nocturnal asthma is defined as an overnight fall of more than 20% in the FEV, or 
PEFR. It may be the sole manifestation of asthma. This is presumed to be due to  
a. Early morning fall in circulating adrenaline 
b. Overnight changes in vagal tone (increased vagal tone in early morning) 
c. Airway cooling at night 
d. Circadian changes in plasmas cortisol concentration (mid night to early morning 
fall in cortisol level. 
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DIFFERENTIAL DIAGNOSIS 
The differentiation of asthma from other disease associated with dyspnoea, wheezing 
is usually not difficult, particularly when the patient in seen during acute attacks. 
 Vocal cord dysfunction  
 Tracheal and bronchial lesions  
 Congestive heart failure  
 Pulmonary migraine  
S.NO FACTORS CARDIAC ASTHMA BRONCHIAL ASTHMA 
1 Past history 
Hypertension, aortic or 
coronary disease. 
Previous attacks of asthma or other 
allergic conditions in patients of other 
member of the family. 
2 Age Onset usually after 50y yrs Any age 
3 
Precipitating 
factors 
Precipitated by execration or 
acute myocardial infarction 
or hypertension. 
Precipitated by respiratory tract 
infections, cold weather, allergens such 
as pollen and house dust mites, stress, 
exercise and cigarette smoke. 
4 Symptoms 
Shortness of breath with or 
without wheezing ; Rapid or 
shallow breathing; An 
increase in blood pressure 
and heart rate 
A feeling of tightness in the chest; 
Difficulty in breathing or shortness of 
breath; Wheezing and Cough 
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S.NO PARAMETER BRONCHIAL ASTHMA COPD 
1. Age of onset 
Asthma is most often 
diagnosed in childhood or 
young adulthood. 
COPD is generally diagnosed 
later in life, often after age 40. 
2. 
Underlying 
cause 
Triggered by allergies or 
environmental factors, 
including cigarette smoke. 
COPD is due almost entirely to 
smoking cigarettes, exposure to 
certain substances such as 
chemical fumes and air pollution 
3. 
Timing and 
severity of 
symptoms 
People with asthma tend to 
have a dry cough and wheeze, 
symptoms which may become 
worse at night. 
People with COPD often start 
their day with a “productive 
cough” meaning they bring up 
phlegm. 
4. Sputum 
Eosinophilia, metachromatic 
cell, creola bodies. 
Neutrophilia. 
5. 
Related 
symptoms 
Often accompanied by other 
allergy symptoms, like rhinitis 
or eczema 
Nil 
6. 
 Related 
conditions 
People with asthma are very 
likely to have 
gastroesophageal reflux 
disease 
People with COPD are much 
more likely to have congestive 
heart failure 
7. 
Course of 
disease 
Asthma can be controlled 
COPD is considered to be a 
progressive loss of lung function. 
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DIAGNOSIS AND INVESTIGATION 
Lung function tests 
 The two most common lung function tests used to diagnose asthma are spirometry, 
exhaled nitric oxide and challenge tests. 
Spirometry 
Spirometry can be done before and after inhale a short- acting medication called 
broncho dilator, such as albuterol. The bronchodilator causes airways to expand, allowing for 
air to pass through freely. This test might also be done at future doctor visits to monitor 
progress and help to determine if and how to adjust your treatment plan. 
Exhaled Nitric Oxide 
Nitric oxide is a gas that is produced in the lungs and has been found to be an indicator of 
inflammation. Because asthma is an inflammatory process, this test has become helpful in the 
diagnosis and management of asthma.  
Challenge Test 
 The tests might be performed if your symptoms and screening spirometry do not 
clearly or convincingly establish a diagnosis of asthma. There are two types of challenge 
tests: Mathacholine and Mannitol. These agents when inhaled can cause the airways to spasm 
and narrow if asthma is present.  
Peak Expiratory Flow Meter: 
It is a popular instrument for assessing airflow obstruction there is a cheap, simpler 
version called the mini peak flow meter which is suitable for use at home by individual 
patients. Those machines measure the maximal rate of flow which is achieved during a forced 
expiration and most healthy people will achieve values of greater than 400 liters/min.  
Patients with airflow obstruction will have reduced flow rates, which values below 
200 liters/min being very significant and those below 100 liters/min extremely severe. 
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Flow Volume Curves 
The plotting of flow versus volume during both maximal expiratory and inspiratory 
maneuvers is of major help in differentiating central airflow obstruction (leading to strider)   
from diffuse airflow obstruction as seen in COPD and Asthma. 
Lung Volumes    
There are four lung volumes and four lung capacities. A lung capacity consists of two 
or more lung volumes. The lung volumes are Tidal volume (TV), Inspiratory reserve volume 
(IRV), Expiratory rreserve Volume (ERV) and Residual volume (RV). The four lung 
capacitoies are Total lung capacity (TLC), Inspiratory capacity (IC), Functional residual 
capacity (FRC) and Vital capacity (VC). The people with asthma may show changes in their 
lung volumes. 
Measurement of Diffusing Capacity 
           Diffusing capacity of the lungs measures how well gases such as oxygen move from 
the lungs into the blood. There are several ways to measure this, but the most common way is 
the ten second single breath-hold technique. Results of this test can tell your doctor about the 
amount of damage or abnormality that is present where the air and the blood meet. While this 
test does not specifically test for asthma, it may help your doctor to diagnose you correctly. 
Arterial Blood Gases (ABG)  
This is a blood test that may be ordered with your PFT‟s to give your doctor even 
more information about your health. ABGs can show how well your lungs are getting oxygen 
into your blood and carbon dioxide out of your blood. For this test, a sample of blood is 
drawn from your artery, from your wrist or elbow area. 
Skin Hypersensitivity Test 
A prick is made in the skin with a fine needle through a drop of an aqueous extract of 
the substance to be tested. A positive reaction is indicated by the development of a wheal and 
flare, which begins to appear within few minutes. Tests are usually performed with a group of 
common allergens knows to cause bronchial asthma.  
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Exercise Tests     
The six minute walk test is a good index of physical function and therapeutic response 
in patients with chronic lung disease such as COPD or Idiopathic pulmonary fibrosis. 
Physical Signs of the Chest 
On examination, 
 Percussion - Hyper resonant.  
 Breath sounds- High pitched polyphonic expiratory and inspiratory rhonchi are 
vesicular in character with prolonged expiration. 
Severe asthma persisting from childhood may cause a „pigeon chest‟ deformity 
Measurement of allergic status 
 An elevated sputum or peripheral blood eosinophil count may be observed and the 
serum total IgE is typically elevated in atopic asthma.  
Radiology Examination 
 Acute asthma is accompanied by hyperinflation, and lobar collapse may be seen if 
mucus has occuluded a large bronchus. Flitting infiltrates, on occasion accompanied by lobar 
collapse, suggest asthma complicated by allergic bronchopulmonary aspergillosis (ASPA). 
 Sputum Examination 
 This is useful for the demonstration of aspergillums fumigates. Eosinohhils are a 
prominent feature of the inflammatory exudates within the airway lumen lies a thick 
tenacious mucus which under the microscope is seen to contain strips of desquamated 
epithelial cells (Curschman‟s spirals) eosinophils, isolated metaplastic epithelial cells (Creola 
bodies) & crystalline materials consisting largely of major basic protein derived from 
eosinophilic granules. (Charcot – leydon crystals). 
Complications: 
Mortality is uncommon in asthma but a severe attack may result in respiratory failure 
and death. 
 Frequent respiratory infection 
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 Pulmonary collapse due to obstruction by viscid secretions 
 Pneumothorax,  
 Emphysema  
 Cough fracture (fracture of ribs due to violent coughing), 
 Long standing bronchial asthma, punctured with frequent expiratory infections may 
lead to emphysema and chronic corpulmonale. 
Prognosis: 
The prognosis of the individual attack is good, except in severe acute asthma, when 
there is occasionally a fatal outcome, especially if treatment is inadequate of delayed. 
Spontaneous remission is fairly common in episodic asthma, particularly in children, but rare 
in chronic asthma, which can lead to irreversible airflow obstruction. Seasonal fluctuation can 
occur in both types of asthma. Atopic subject with episodic asthma are usually worse in the 
summer, when they are more heavily exposed to antigens, while chronic asthmatics are 
usually worse in winter months, because of the increased frequency of viral infections. There 
is no cure for asthma, although symptoms sometimes improve over time. With proper self 
management and medical treatment, most people with asthma can a lead normal life. 
Prevention: 
Avoidance of allergens: 
 There are a few instances in which a single agent can be identified as the cause of 
attacks of asthma. These allergens include grass pollens, mites, animal dander, drugs, 
industrial chemicals such as isocyanates and certain articles of diet. The vast majority of 
asthmatic patients are hypersensitive to a wide range of allergens and attempts to avoid them 
all are impracticable. 
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MATERIALS AND METHODS 
 TITLE 
                    Clinical study on “SWASAKASAM” (Bronchial asthma) and the drug of choice 
is “MANTHARA KASA LEHIYUM” (Internal) 
OBJECTIVES 
 PRIMARY OBJECTIVE 
                   To study the Siddha formulation MANTHARA KASA LEHIYUM (INTERNAL) 
in the management of SWASAKASAM (Bronchial Asthma)  
SECONDARY OBJECTIVE 
1) To study other cofactors related to the disease like age, occupation, 
socioeconomic Status. 
2) To study the comorbid factors related to the disease such as gastro-esophageal 
reflux disease (GERD), rhinosinusitis, apnea and anxiety etc. 
STUDY DESIGN 
      Study type  :    An open clinical trial 
     Study place  :    OPD of Ayothidoss Pandithar Hospital, 
     National Institute of Siddha, 
     Tambaram sanatorium, Chennai -47. 
       Study period  :    12 months. 
                         Sample size  :    40 patients 
TREATMENT 
             Name of the drug        :   Manthara kasa lehiyum (Internal)
 
                        Dosage                         :   Thandrikkai alavu -5.4 gm  
       (Twice a day /after food) 
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                Route of drug administration :  Oral route 
               Duration                                    :   48 days  
                         Indication                                  :   Swasa kasam (BRONCHIAL ASTHMA),    
                                                                                Mantharakasam 
               Book Ref                                   :   Agathiyar vaithiya kaviyam-1500 
               Editor Name                             :   Munaiver.V.R.Madhavan 
            Edition                                      :   1st Edition 1994 
 SUBJECT SELECTION:  
           When patients reporting at OPD 1 Dept of Maruthuvam, Ayothidoss Pandithar 
Hospital, NIS with symptoms of inclusion criteria will be subjected to screening test and 
documentation will be done by using screening proforma. 
INCLUSION CRITERIA: 
 Age: 19- 60 years 
 Sex: Male/Female 
 Patient who having the symptoms of  Difficulty in breathing, Cough with or without 
expectoration, Dyspnoea , Tightness of chest, Wheeze- added sound (Rhonchi). 
 History of allergy and sneezing  
 Patient who are willing to take radiological investigation and provide blood for lab 
investigation. 
 Patient who are willing to estimate volume of air forcibly expired after a deep 
inspiration by using Mini –Peak Flow Meter and PEFR below normal range from 
250L /min to 150L/min for men; From 200L/min to 100L/min for women, for those 
patients are included 
  Normal range of PEFR: 
Male: Young adult: 400 – 650L/min: Above 40 yrs 300-500L/min 
Female: Young adult: 250-450L/min: Above 40 yrs 200-400L/min 
 Patient willing to participate in trial and signing in consent form. 
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EXCLUSION CRITERIA: 
 H/O Cardiac disease. 
 H/O Renal disease. 
 Tuberculosis. 
 H/O COPD. 
 Status asthmaticus. 
 Diabetes mellitus. 
 Hypertension. 
 Pregnancy. 
 Lactation. 
 Psychological factors. 
 Worm infestation. 
WITHDRAWAL CRITERIA: 
 Intolerance to the drug and Development of adverse reactions during the drug trial. 
 Poor Patient Compliance & Defaulters. 
 Patients turned unwilling to continue in the course cf clinical trial. 
 Patient will not take medication regularly. 
 Occurrence of any serious illness. 
TESTS AND ASSESMENTS:  
 Clinical Assessment 
 Siddha Assessment 
 Laboratory investigations 
 Routine Investigations 
 Special Investigation 
CLINICAL ASSESMENT: 
 Dry cough or protective  cough 
 Wheezing 
 Tightness of chest 
 Sneezing  
 Rhinorrhoea 
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 Hoarseness of voice 
 Sleep disturbance 
 Expiration is like a hiss of a serpent 
 Frequent  hemming 
 Sense of heat in both nostril 
 
SIDDHA ASSESSMENT: 
1. Thinai (Living Place): 
1. Kurinchi (Hill Areas) 
2. Mullai (Forest) 
3. Marutham (Fertile Land) 
4. Neithal (Costal Area) 
5. Paalai (Desert) 
2. Paruva Kaalam (season)  
1. Karkaalam 
2. Koothir kaalm 
3. Munpanikaalm 
4. Pinpani kaalam 
5. Ilavenil kaalam 
6. Mudhuvenil kaalam 
3. Poripulankal: 
1. Mei (Skin) 
2.Vaai (Tongue) 
3.Kan (Eye) 
4.Mooku (Nose) 
5.Sevi (Ear) 
56 
 
4. Kanmedriyam and Gnanenthiriyam: 
1. Vaai (Buccal cavity) 
2. Kaal (Lower limbs) 
3. Kai (Upper limbs) 
4. Eruvaai (Anorectal region) 
5. Karuvaai (Uro-genital region) 
5. Ezhuudalkattugal: 
1. Saram 
2. Senneer 
3. Uoon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam /suronitham 
6. Ennvagaithervu (Eight types of Examination): 
1. Naadi 
2. Sparisam 
3. Naa 
4. Niram 
5. Mozhi 
6. Vizhi 
7. Malam 
8. Moothiram 
Neerkuri- 
Nei kuri- 
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LABORATORY INVESTGATION - ROUTINE INVESTIGATION 
      BLOOD 
 Hb (gm/dl )                                                                                                                                                                                             
 Total WBC Count( Cells/cumm)            
 DC- Polymorphs (%)                              
 Lymphocytes (%)                    
 Eosinophils (%)                                       
 Monocytes (%)                                       
 Basophils (%)                   
 Total RBC count(Millioncells/cumm)    
 ESR(mm/hr)                                           
 Blood glucose( mg/dl):  ( Fasting)                                            
                                        (Post – prandial)        
 Blood urea(mg/dl)                                 
 Serum Creatinine (mg/dl)                         
 Serum cholesterol(mg/dl)                  
  HDL cholesterol(mg/dl)                     
  LDL cholesterol(mg/dl)               `                                            
 VLDL cholesterol(mg/dl)                     
 Serum triglycerides(mg/dl)                   
 Serum total bilirubin (mg/dl)                                               
 Serum Direct bilirubin (mg/dl)                  
 Serum Indirect bilirubin (mg/dl)               
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 Serum Alkaline phosphotases (u/l)       
 SGOT (u/l)                                            
 SGPT (u/l)                                             
 Serum Total Protein   ( g/dl)                 
 Serum Albumine( g/dl)                         
 Serum Globulin( g/dl)                          
 Serum Calcium (mg/dl)                          
 Serum Phosphorous (mg/dl)                     
 Serum Uric Acid (mg/dl                     
  IgE                                                     
 AEC                                                    
SPUTUM   - AFB               
URINE 
 Urine sugar (F)&(PP)                         
 Albumin                                              
 Deposits                                              
MOTION 
 Ova  
 Cyst 
 Occult blood 
SPECIFIC INVESTIGATIONS 
 X-ray chest (PA view) 
 ECG. 
 Peak Expiratory Flow Rate (PEFR) with the help of Peak expiratory flow meter. 
[L/min] 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT FORM 
 
ADVERSE REACTION 
ADVICED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES  
REFERRED TO 
PHARMACOVIGILANCE       
DEPARTMENT,    NIS 
ADVISED TO TAKE TREATMENT IN 
OPD/REFERRED TO NEARBY GH 
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METHODOLOGY 
STUDY ENROLLMENT 
 In this clinical trial Patient Reporting at the Maruthuvam, Ayothidoss pandithar 
Hospital, NIS, With Clinical symptoms of rhinitis for short period, difficulty in 
breathing due to chest tightness, cough, sweating present in the head, face become 
black, chillness of the extremities, dryness of mouth, eye look like exopthalmus state, 
body shivering, sleeplessness will be examined clinically for enrolling in the study 
based on the inclusion and exclusion criteria. 
  The patients enrolled in this study will be informed about the objective of the study, 
trial drug, possible outcomes in their own language and terms understandable to them. 
 After ascertaining the patient‟s willingness, informed consent will be obtained in the 
consent form. 
 All these patients will be given unique registration card which will contains 
information regarding patients‟ Registration number, Address, Phone number and 
Doctors phone number etc. It can help to report easily if any adverse reactions arise. 
 Complete clinical history, complaints and duration, examination findings-- all will be 
recorded in the prescribed case record form. Screening Form- I will be filled up; Form 
II will be used for recording the patients‟ history, clinical examination of signs and 
symptoms and laboratory investigations respectively. 
 Patients will be advised to take the trial drug with an appropriate dietary advice would 
be given according to the patients perfect understanding. 
     
CONDUCT OF THE STUDY   
 Patients who came under Incluction and Exclution Criteria will be recruited for the 
Study. 
 As per siddha literature, before starting the treatment for SWASAKASAM, purgation 
will be given with the OP medicine Mantha ennai 8ml OD with warm water at early 
morning in empty stomach for one day
.
 
 Then the trial drug “MANTHARA KASA LEHIYUM” is given at a dose of 5.4gm 
twice a day continuously for 48 days. For OP patients, they should visit the hospital 
once in 8days. At each visit clinical assessment will be done and prognosis will be 
noted.   
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 The laboratory investigation will be done before and after treatment and recorded in 
the prescribed format (Form No: III). For OPD patients, for further continuation of the 
treatment. 
 During the course of the treatment, patient is advised to take the diet as given in Form 
VIII. 
 If any of the trial patients who fail to collect the trial drug on the prescribed day but 
wants to continue in the trial, from the next day or two, he/ she will be allowed, but 
defaulters of more than one week will not be allowed to continue and be withdrawn 
from the study with fresh case being included.   
Follow-up  
      After the end of the treatment, the patient is advised to visit the OPD for another two 
months for follow-up. In the follow-up period the patient‟s improvement will be documented. 
Trial medicines will not be given in this period.  
DATA MANAGEMENT  
 After enrolling the patient in the study, a separate file for each patient will be opened 
and all forms will be filed in the file. Study No. and OPD/ IPD No. will be entered on 
the top of file for easy identification. Whenever the study patient visits OPD during 
the study period, the respective patient file will be taken and necessary recordings will 
be made at the CRF or other suitable forms. 
 The screening forms will be separately. 
 The Data recordings will be monitored for completion by Guide (HOD, Dept. of 
Maruthuvam), SRO (statistics) and the adverse event will be monitored by the 
members of the reactions Pharmacovigilance department of NIS. All forms will be 
further scrutinized in presence of investigator by Sr.Research Officer (statistics) for 
logical errors and incompleteness of data to avoid any bias. No modification in the 
results is permitted for unbiased reports. 
 
STATISTICAL ANALYSIS 
All the data will be entered into computer using MS Access software with macro for 
logical errors and manually cross checked for data entry error. Then the data will be exported 
to STATAL/SPSS Software for univariate/multivariate analysis. Student„t‟ test  and Paired „t‟ 
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test and Mantel-Haenszel chi-square test will be performed for determining the significance 
of a particular  effect variable. 
OUTCOME OF TREATMENT  
a. PRIMARY OUTCOME  
Primary outcome is mainly assessed by comparing the pre and post treatment Peak 
expiratory flow rate (L/min) 
 b. SECONDARY OUTCOME 
Secondary outcome is assessed by comparing the following parameters, before and 
after the treatment. 
                      1. Other clinical symptoms  
                      2. Eosinophils (%) and ESR 
ADVERSE EFFECT/ SERIOUS EFFECT MANAGEMENT 
 If the trial patient develops any adverse reaction, he/she will be referred to the 
pharmacovigilance department of NIS. The members of this department will assess the 
adverse event and recorded in the prescribed adverse reaction form. For any AE the 
investigator (PG Scholar) will be given the proper management at NIS, OPD with free of 
cost. 
ETHICAL ISSUES 
 To prevent any infection, while collecting blood sample from the   patient, only 
disposable syringes, disposable gloves, with proper sterilization of lab equipments 
will be used.  
 No other external or internal medicines will be used. There will be no infringement on 
the rights of patient for this particular indication. 
 The data collected from the patient will be kept confidentially. The patient will be 
informed about the diagnosis, treatment and follow-up. 
 After the consent of the patient (through consent form) they will be enrolled in the 
study. 
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 Informed consent will be obtained from the patient explaining in the understandable 
language to the patient. 
 Treatment would be provided free of cost. 
 In conditions of treatment failure, adverse reactions, patients will be given alternative 
treatment at the National Institute of Siddha with full care throughout the end. 
 The patients who are excluded [as per the exclusion criteria] will be given proper 
treatment, at NIS.  
ASSESSMENT FORMS: 
Form - I    Screening and Selection Proforma 
Form - II   Case record form 
Form - III   Laboratory investigation form 
Form – IV   Treatment Compliance form 
Form – V  Information sheet 
Form - VI    Consent form 
Form -VII   Withdrawal form/ Adverse drug reaction form/  
Pharmacovigilance form 
Form -VIII    Dietary Advice form. 
 
 
 
 
 
 
 
 
  
 
 
PREPARATION & 
PROPERTIES OF TRIAL 
DRUG 
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PREPARATION OF THE TRIAL MEDICINE 
MANTHARA KASA LEHIYUM (INTERNAL) 
INGREDENTS:    
Required raw drugs 
1. Kandankaththiri (Solanum surrattense, Burm .f)} 
2. Thuthuvelai (Solanum trilobatum.Linn) 
3. Adathodai leaves (Adathoda vasica.Linn)     
4. Araththai (Alpinia officinarum.Linn)                   
5. Chukku (Zingiber officinale, Rosc)                   
6. Milagu (Piper nigrum.Linn) 
7. Thippili (Piper longum.Linn),                                    
8. Nei (Ghee)                                                       
9. Then (Honey)                                                   
10. Powdered sugar        
 Source of drug 
The above said raw drugs were purchased from a well reputed country shop at 
Chennai. The raw drugs were authenticated by Botanist NIS, Pharmacognosist SCRI 
Arumbakkam, Chennai. The raw drugs were purified and the medicine was prepared as per 
SOP as in the Gunapadam Laboratory of NIS, Chennai.  
 
METHOD OF PURIFICATION: 
PURIFICATION OF RAW DRUGS:
 
1. Kandankaththiri  leaves(Solanum surrattense,Burm.f) 
                 Take the leaves and wiped with dry clean cloth and removed the putrefied parts 
and mid vein. 
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2. Thuthuvelai leaves (Solanum trilobatum.Linn) 
            Take the leaves and wiped with dry clean cloth and removed the putrefied parts 
and mid vein. 
 3. Adathodai leaves (Adathoda vasica.Linn) 
           Take the leaves and wiped with dry clean cloth and removed the putrefied parts 
and mid vein. 
 4. Chukku (Alpinia galangal.Linn) 
                 Soaked in lime stone water and allowed to dry. Then outer layer was removed. 
 5. Milagu (Zingiber officinale, Rosc) 
                Soaked in buttermilk for one hour fifteen mintues and then roasted. 
 6. Thippili (Piper nigrum.Linn) 
               Soaked in lemon juice 
7. Chitharathai (Alpinia officinarum) 
              The skin of the Chitharathai was removed, cut into pieces and dried.  
 
Preparation: 
STEP 1: 
       The purified raw drugs from 1 to 7 were made in to fine powder. 
STEP 2: 
       The powder was added to the sugar syrup (to the 180 gms of powdered sugar required 
quantity of water was added and boiled till it reaches syrup consistency) and mixed it well 
until it reaches lehiyum consistency. 
STEP 3: 
      Honey and ghee (each 180 gms) were added to the above mixture.  
66 
 
Drug Storage: 
      The prepared drug was stored in clean and dry new air tight container. 
    Dosage                      :    Thandrikkai alavu -5.4 gm (Twice a day /after food) 
    Duration                    :    48 days  
    Indication                  :   Swasa kasam (BRONCHIAL ASTHMA), Mantharakasam. 
    Book Rf                     :   Agathiyar vaithiya kaviyam-1500 
    Editoror Name           :   Munaiver.V.R.Madhavan 
    Edition                       :   1st edition 1994 
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PROPERTIES OF TRIAL DRUG 
 
The trial drug Mantharakasa lehiyum consists of 7 herbal ingredients. Most of 
the ingredients are having pungent taste [kaarpu suvai]. Least among them belongs to 
bitter and astringent taste [kaippu & thuvarppu suvai]. Siddha system of medicine is 
based on five elements. A Maruthuva Thanipadal quotes the formation of six tastes 
from five elements. 
Earth + Water      =   Sweet 
Earth + Fire     ` =   Sour 
Earth + Wind      =   Astringent 
Water + Fire       =   Salt 
Wind + Fire        =  Pungent 
Wind + Space =  Bitter 
 
As per Maruthuva thanipaadal the action and characters of kaarpu, kaippu & 
thuvarppu suvai as mentioned below: 
 
Action and character of Pungent taste 
       “  .......   
         §Å¡  ¦º¡ ” 
 (  ) 
Character of Pungent taste 
 “¦¾¡       
 ...........................ஐய  
     .” 
                                          (  ) 
 The pungent taste stimulates appetite. 
 It cures the diseases of throat 
 It destroys the vitiated kapha. 
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Character and action of bitter taste  
§ÅÚ ¸¡Ã½õ Å¢¨Çò¾ çñ ¦ÅÚô 
§À¡ðÎ Á¢ÂøÀ¡ §Âü¸ Å¢ÕõÀ¡î 
Í¨ÅÂ¡õ À¢ò¾¨ÁÂ Å¢¸÷ôÀí......... 
Å¡ö¿£åÈø «Æüº¢Ôõ ¾½¢ìÌõ 
¦Áö¿£÷ì ¸º¢¨ÅÔó ¾Ê¨ÂÔó ¾ÊÔõ 
°ñºÄõ ÁÄïºÄõ ¿¢½ºÄõ ±ýÀ¢Ûû ÅÈðÎõ. 
 (  ) 
 Astringent taste changes the hatred towards food. 
 It converts the vitiated kapha and pitha. 
 It reduces the hyper secretions of glands in the body 
Character of Astringent taste 
  "¸ðÎÅÐºüÚì ¸Ã¸Ãô À¡ìÌõÅÐ 
 ¾¢ð¼Á¡ö §¾¡üÀ¾Éï ¦ºöÅÐ- ÁðÊü 
 ¦¸¡ØôÒ¿£÷ ÁøÌí ¦¸¡ØôÒõ ÅÃð¼ø 
 ¦¾¡Æ¢Ä¡ó ÐÅ÷ôÒ Í¨ÅìÌ" 
    (  ) 
 Astringent taste controls the hyper secretion of glands in the body. 
Character of Astringent taste 
"¦À¡øÄ ¨ÅÂõ Á¡üÚõ ÌÇ¢÷ó¾ÐÅ÷ôÀ¢ý §Å¨Ä 
 ¨¸ôÀ¢ý ÀñÒõ ¦ºö¨¸Ôõ" 
 (  ) 
 It changes the vitiated kapha. 
Considering the actions and characters of kaarppu, kaippu and thuvarppu suvai, 
the drug is formulated in such a way that the adverse effect of excessive kaarppu is 
counteracted by kaippu and thuvarppu suvai. Also, kaippu and thuvarppu suvai corrects 
the deranged dheeshakini in the body and produces good appetite. Both kaippu and 
thuvarppu suvai has the ability to reduce excessive secretion of the sputum and expel 
out by expectorant action. Hence kaarppu suvai, by its inherent property antagonizes 
kapha by having fire as its component. 
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Generally in kapha disease patient‟s complaints reduced appetite or anorexia. In 
Swasa kasam patients their condition gets worse if they suffer from dyspnoea 
particularly after food due to improper digestion. Siddhars had given us plethora of 
drugs, mostly combinations of herbs as compound drugs. The drug Mantharakasa 
lehiyum one among those formulations. Most of the ingredients of this drug have the 
property of expectorant, carminative, stomachic, stimulant, which suits for the kapha 
disease patients. 
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INGRIDIENTS OF THE TRIAL MEDICINE 
1) Adathodai 
Botanical name :  Adhatoda vasica Nees 
Family  : Acanthaceae 
Vernacular names: 
Sans   :   Vasaka 
                        English :  Malabar-nut 
                        Tamil  :   Adathodai 
Mal   :  Ata-lotakam 
Taste    : Bitter 
Potency : Hot 
Division : Pungent 
Parts used : Leaves, flower, Bark, Root 
Actions :  Antispasmodic, Expectorant, Germicide, Diuretic 
Gunam 
  ¬¼¡§¾¡ ¨¼Â¢ý Ì½ò¨¾ «¨¼×¼ Û¨Ãì¸ì §¸Ùõ 
À¡¼¡¾ ¿¡×õ À¡Îõ ÀÃ¢óÐ§Á §¾¡¼õ §À¡Ìõ 
Å¡¼¡¾ À¢ò¾ï §ºòÁ §Ã¡¸í¸û Å¢Ä¸¢ô §À¡Ìõ 
¿¡¼¡Ð Å¢Â¡¾¢ ¾¡Ûõ ¿øÅ¢Æ¢ì ÌÆÄ¢É¡ §Ç. (².Î) 
 
Chemical constituents 
        The major chemical constituent of Adhatoda vasica is bioactive pyrroloquinazoline 
alkaloid, vasicine about 1.3%. Includes other alkaloids viz, vasicol, vasicinone, adhatonine, 
vasicinol, vasicinolone. 
 
Uses 
        The bronchodilatory and expectorant properties of the leaves are attributed to vasicine. 
The drug possesses abortifacient activity and significant antimicrobial activity against 
gingival inflammation and pyorrhea. 
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2) Kandankaththiri 
            Botanical Name    :  Solanum surattense Burm.f 
Family        :  Solanaceae 
Vernacular names: 
San  : Kanta-karika 
English : Yellow berried night shade 
Tamil  : Kandankaththiri 
Mal  : Vellottuvalutina 
Taste              :  Pungent 
Potency :  Hot 
Division :  Pungent 
Parts Used  :  Leaves, Flower, Unripe Fruit, Fruit, Seeds, Root 
Actions     :  Expectorant, Diuretic, Carminative 
Gunam     
¸¡ச ÍÅ¡சí ¸¾¢ò¾„ய Áó¾ÁÉø 
Å£ÍÍÃï ºýÉ¢ Å¢¨Ç§¾¡¼õ- ¬ÍÚí¸¡ø 
þò¾¨ÃÔ ½¢ü¸¡, ±Ã¢¸¡Ãï §º÷ì¸ñ¼í 
¸ò¾¢Ã¢Ôñ ¼¡Á¡¸¢ü ¸¡ñ.         
                            -  . 
Chemical constituents 
 The major chemical constituent of Solanum surattense is steroidal alkaloid 
solasodine about 0.2% and also have steroidal alkaloids viz solamargine, beta 
solamargine, steroids viz cycloartenol, norcarpesterol, cholesterol and their derivatives. 
 
Uses  
 Preliminary clinical trials of the drug have shown significant improvement in 
some respiratory diseases like bronchial asthma and the beneficial effects could be 
through depletion of histamine level.  
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3) Thuthuvalai 
             Botanical Name    :    Solanum trilobatum, Linn. 
   Family           :   Solanaceae  
Vernacular names 
Sans  : Alarka 
English : Climbing Brinjal 
Tamil  : Thuthuvalai 
Mal  : Mullakaththari 
 
Taste              :  Mild Bitter, Pungent 
Potency :  Hot 
Division :  Pungent 
Parts Used  :  Leaves, Flower, Unriped Fruit. 
Actions     :  Stimulant, Expectorant, Tonic. 
Gunam     
àÐ Àò¾¢Ã¢ äñÍ¨Å Â¡ìÌõâ 
¾¡Ð ¨Åò¾¨Æô À¢ò¾¢Îõ ¸¡ÂÐ 
Å¡¾ À¢ò¾¸ Àò¨¾Ô Á¡üÚ§Å÷ 
µÐõ ÅøÄ¢Àý §¿¡Ô¦Á¡ Æ¢ìÌ§Á.     
.                                   -  . 
Chemical constituents 
The major chemical constituents of Solanum trilobatum are alkaloids, sterols, 
saponins, phenolics, flavanoides and glycosides. Alkaloides such as soladunalinidine 
and tomatidine were isolated from leaf and stem. 
 
Uses      
 It cures all the Kapha diseases. The aqueous and alcoholic extracts of solanaum 
trilobatum exhibited mast cell degranulation inhibition activity. It has antibacterial anti 
inflammatory, antioxidant, antifungal, antimicrobial actions. 
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4) Chitharathai 
Botanical Name :  Alpinia officinarum.Linn  
         Family  :  Zingiberaceae 
Vernacular names 
Sans   :  Rasna 
English                 :  Galangal the lesser, Java galangal. 
Tamil  :  Chitharathai 
                            Mal                         :  Aratha.  
Taste           :  Pungent 
Potency :  Hot 
Division          :  Pungent
Parts Used     :  Root
Actions :  Expectorant,Febrifuge,Stomachic . 
Gunam     
Á¡÷¨À Â¼÷À¢½¢Í Å¡º¸¡ ºõãÄõ 
§º¡¨À¾ð¼î Ý÷Å¡¾ §º¡½¢¾§¿¡ö-¾£Àî 
ÍÃò¨¾ ÂÎôÒ÷Àø àÕÚ¸ñ §¿Ã¢ý 
«Ãò¨¾ ¦ÂÎÐ¸Ç ¾¡õ.   
                             -  . 
 
Chemical constituents 
The major chemical constituents of Alpinia officinarum are galangol, galangin 
and essential oil. 
 
Uses    
The root of this plant is used to cure vatha,kapha diseases, vomiting, eczema, 
cough,  it is used to equalise all the three dhoases.  
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5) Chukku 
Botanical Name         :       Zingiber officinale, Rose. 
Family  :       Zingiberaceae 
Vernacular names 
Sans    : Nagaram 
English      : Dried Ginger 
Tamil   : Chukku 
Mal   : Chukku 
Taste  : Pungent  
Potency : Hot 
Division : Pungent 
Parts used : Rhizome 
Actions : Stimulant, Stomachic, Carminative 
 
Gunam  
Ý¨ÄÁó¾õ ¦¿ï¦ºÃ¢ôÒ §¾¡¼§Áô ÀõÁÆ¨Ä 
ãÄõ þ¨ÃôÀ¢ÕÁø ãìÌ¿£÷-Å¡Ä¸À 
§¾¡¼Á¾¢ º¡Ãó ¦¾¡¼÷Å¡¾ ÌýÁ¿£÷ò 
§¾¡¼õ¬ Áõ§À¡ìÌï ÍìÌ.   
 -   . 
 
Chemical constituents 
The major chemical constituents of Zingiber officinale are oleoresin comprising of 
nonvolatile pungent principles {gingerols-mainly [6]-gingerol} nonpungent substances {fats 
and waxes} and Volatile oil {1.5-2.2%} containing sesquiterpene hydrocarbons viz., alpha 
zingiberene, beta sesquiphellandrene and ar-curcumene as major constituents. 
 
Uses 
The constituents of ginger are thought to play a role in the anti-inflammatory activity 
exhibited by the drug. Ginger also possesses hypolipidemic, antidiabetic, cardiotonic and 
antiatherosclerotic properties. 
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6) Milagu 
Botanical Name   :    Piper nigrum, Linn 
Family               : Piperaceae 
Vernacular names 
Sans     : Maricha 
Hindi    : Kali - mirch 
English    : Black pepper 
Tamil    : Milagu 
Mal    : Kurumulaku 
Taste  : Bitter, Pungent 
Potency : Hot 
Division : Pungent 
Parts used : Seed, Stem 
Actions : Carminative, Antidote, Stimulant 
 
Gunam 
    
   –  
    
 . 
                                        -   . 
 
Chemical constituents 
The major chemical constituents of Piper nigrum are chavicine, piperine, 
piperidine, piperetine and essential oil. 
 
Uses  
It is used to treat asthma, chronic indigestion, colon toxins, obesity, colic, 
intermittent fever, cold extremities, sinusitis, gastric ailments diarrhea and also have 
antibacterial, antifungal, larvicidal activities. 
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7) Thippili 
Botanical name       :    Piper longum, Linn. 
Family       : Piperaceae 
Vernacular names 
Sans       : Pippali 
English        : Long pepperr 
Tamil      : Thippili 
Mal      : Thippili 
Taste  :  Astrigent 
Potency :  Hot 
Division :  Sweet 
Parts used : Seeds, Unriped fruit 
Actions            : Stimulant, Carminative 
Gunam  
®¨Ç Â¢ÕÁ Ä¢¨ÃôÒô ÀºôÀ¢½¢¸û 
Á¡Ç ¦Å¡Æ¢Â¡Áø Å¡ðÎ§Á- Â¡ÙÓ¨È 
À¡í¸¡ ÂÈ¢óÐ¦ºöÅ£÷ ÀñÊ¾ò¨¾ô ÀñÊ¾§Ã 
§Åí¨¸Å¡öô À¡ý¸¨½ ¦Áö.    
                                         -§¾Ãý ¦ÅñÀ¡  
 
Chemical constituents 
The major chemical constituents of Piper longum are Piperine and volatile oil 
and also have Piperlonguminine, Piplartine a waxy alkaloid N-isobutyldecatrans 2-
trans-4-dinamide, piperidine alkaloids- pipernonaline piperundecalidine, sesamine, 
resin. 
 
Uses 
The fruits have anti allergic and anti asthmatic activities. 
 
 
 
78 
 
THE INGREDIENTS OF MANTHARAKASA LEHIYUM       
        
                         Adathodai         Kandankathiri                                                        
                                                                                
           
 
                         
 
 
 
                        Thuthuvelai            Chukku 
  
 
                           Milagu           Thippili 
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   Chitharathai        Honey 
 
 
 
 
 
White sugar         Ghee                                                                       
 
 
 
 
 
 
 
 
  
 
 
BIOCHEMICAL ANALYSIS 
OF TRIAL DRUG 
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BIOCHEMICAL ANALYSIS OF MANTHARAKASA LEHIYUM 
 
S.NO EXPERIMENT OBSERVATION INFERENCE 
 1.Test For Acid Radicals   
1. 
 
Test For Sulphate :  
       2ml of the above prepared 
extract is taken in a test tube to this 
added 2ml of 4% ammonium oxalate 
solution. 
 
No cloudy     
appearance present 
 
Absence of Sulphate 
2. Test For Chloride: 
      2ml of the above prepared 
extract is added with 2ml of dil- 
HNO3 till the effervescence ceases. 
Then 2 ml of silver nitrate solution is 
added. 
 
Cloudy appearance 
present 
 
Presence of Chloride 
3 Test For Phosphate: 
      2ml of the extract is treated with 
2ml of ammonium molybdate 
solution and 2ml of con.HNO3 
 
 Yellow colour     
appearance 
 
Presence of 
Phosphate     
4. Test For Carbonate:  
    2ml of the extract is treated with 
2ml magnesium sulphate solution 
 
No cloudy appearance 
 
Absence of  
Carbonate 
5. Test For Fluoride & Oxalate: 
    2ml of extract is added with 2ml 
of dil. Acetic acid and 2ml calcium 
chloride solution and heated. 
No cloudy appearance 
present. 
      
Absence  of     
fluoride and  oxalate 
6. Test For Nitrate: 
   1gm of the substance is heated 
with copper turning and 
concentrated H2So4 and viewed the 
test tube vertically down 
 
No  Brown   gas   is 
evolved 
    
Absence   of   Nitrate 
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7. Test For Sulphide:  
      1gm of the substance is treated 
with 2ml of con. HCL 
No Rotten Egg 
Smelling gas  evolved 
Absence of   
Sulphide 
8. Test For Nitrite: 
    3 drops of the extract is placed on a 
filter paper, on that - 2 drops of acetic 
acid and 2 drops of Benzidine 
solution is placed. 
No   Characteristic    
changes 
Absence  of  Nitrite 
9. Test For Borate: 
     2 Pinches of the substance is made 
into paste by using sulphuric acid and 
alcohol (95%) and introduced into the 
blue flame. 
Bluish  green  colour  
flame  not  appeared 
Absence   of   Borate 
 II. Test For Basic Radicals   
1. Test For Lead: 
      2ml of the extract is added with 
2ml of potassium iodine solution. 
No yellow precipitate 
is obtained. 
Absence  of   Lead 
2. Test For Copper: 
     2ml of extract is added with 
excess of ammonia solution. 
No blue color    
precipitate formed. 
 
Absence   of   Copper 
 
3. Test For Aluminium: 
    To the 2ml of extract sodium 
hydroxide is added in drops to 
excess. 
No characteristic 
changes.  
Absence   of 
Aluminium 
4. Test For Iron: 
    To the 2ml of extract add 2ml of 
ammonium thiocyanate solution. 
Mild red colour appear 
 
 
Presence of Iron 
 
 
5. Test For Zinc:  
        To 2ml of the extract sodium 
hydroxide solution is added in drops 
to excess  
 
White  precipitate   is   
not formed 
 
Absence of  Zinc 
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6. Test For Calcium:  
        2ml of the extract is added with 
2ml of 4% ammonium oxalate 
solution  
 
Cloudy appearance 
and white precipitate 
is not obtained 
Absence of  Calcium 
7. Test For Magnesium:  
     To 2ml of extract sodium 
hydroxide solution is added in drops 
to excess. 
White precipitate is  
not obtained 
Absence    of 
Magnesium 
8. Test For Ammonium: 
      To 2ml of extract few ml of 
Nessler's reagent and excess of 
sodium hydroxide solution are added. 
No Brown colour 
appeared 
 
Absence     of 
Ammonium 
9. Test For Potassium:  
   A pinch of substance is treated with 
2ml of sodium nitrite solution and 
then treated with 2ml of cobalt nitrate 
in 30% glacial acetic acid. 
 
No Yellowish 
precipitate is 
obtained. 
 
Absence of  
Potassium 
10. Test For Sodium: 
    2 pinches of the substance is made 
into paste by using HCl and 
introduced into the blue flame of 
Bunsen burner. 
  
Yellow   colour    
flame appeared 
   
Presence  of   
Sodium 
11. Test For Mercury:  
      2ml of the extract is treated with 
2ml of sodium hydroxide solution.  
 
No yellow precipitate 
is obtained 
    
Absence of  Mercury 
12. Test For Arsenic:  
      2ml of the extract is treated with 
2ml of sodium hydroxide solution. 
 
No brownish red 
precipitate is 
obtained 
 
Absence  of   Arsenic 
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S.NO EXPERIMENT OBSERVATION INFERENCE 
 III.Miscellaneous   
1.  Test For Starch:  
    2ml of extract is treated with weak 
iodine solution  
 
Blue   colour 
developed 
 
Presence of   Starch 
2.  Test For Reducing Sugar:  
    5ml of Benedict's qualitative 
solution is taken in a test tube and 
allowed to boil for 2 minutes and 
added 8 to 10 drops of the extract 
and again boil it for 2 minutes. The 
colour changes are noted. 
 
Brick   red  colour 
developed 
 
Presence of  
Reducing sugar 
3.  Test For The Alkaloids: 
a)  2ml of the extract is treated with 
2ml of potassium lodide solution. 
b)  2ml of the extract is treated with 
2ml of picric acid. 
c)  2ml of the extract is treated with 
2ml of phosphotungstic acid. 
 
 
  
Yellow   colour 
developed 
 
 
 
Presence of   
Alkaloid 
4.  Test For Tannic Acid:  
    2ml of extract is treated with 2ml 
of ferric chloride solution  
 
Block precipitate   is 
obtained 
 
Presence of  Tannic 
acid 
5.  Test For Unsaturated Compound:   
     To the 2ml of extract 2ml of 
Potassium permanganate solution is 
added.  
 
Potassium 
permanganate is  
decolourised 
 
Presence   of     
unsaturated 
compound  
6.  Test For Amino Acid: 
    2 drops of the extract is placed on 
a filter paper and dried well.. 
 
No Violet   colour 
developed 
 
Absence  of  Amino 
acids 
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S.NO EXPERIMENT OBSERVATION INFERENCE 
 III.Miscellaneous   
7. Test For Type Of Compound: 
    2ml of the extract is treated with 2 
ml of ferric chloride solution.  
 No Brown  colour 
developed 
 
 
No red colour 
developed  
 
 
 
No violet colour 
developed  
 
No Blue colour 
developed. 
Absence of  Oxy  
quinole, epinephrine  
and  Pyro catechol 
 
Anti pyrine, 
Alipathic amino 
acids and meconic 
acid are absent. 
 
Salicylate and 
resorcinol are absent. 
 
Morphine, Phenol 
cresol and 
hydroquinone are 
absent 
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RESULTS OF BIOCHEMICAL ANALYSIS 
S.no Analytical test Inference 
1. Sulphate Absence of Sulphate 
2. Chloride Presence of Chloride 
3. Phosphate Presence of  Phosphate     
4. Carbonate Absence of  Carbonate 
5. Fluoride & Oxalate Absence of  fluoride and oxalate 
6. Nitrate Absence of Nitrate 
7. Sulphide Absence of Sulphide 
8. Nitrite Absence of  Nitrite 
9. Borate Absence of Borate 
10. Lead Absence of  Lead 
11. Copper Absence of Copper 
12. Aluminium Absence of Aluminium 
13. Iron Presence of  Iron 
14. Zinc Absence of  Zinc 
15. Calcium Absence of  Calcium 
16. Magnesium Absence of Magnesium 
17. Ammonium Absence of Ammonium 
18. Pottasium Absence of  Potassium 
19. Sodium Presence of  Sodium 
20. Mercury Absence of  Mercury 
21. Arsenic Absence of  Arsenic 
22. Starch Presence of  Starch 
23. Reducing sugar Presence of  Reducing sugar 
24. Alkaloids Presence of  Alkaloid 
25. Tannic acid Presence of  Tannic acid 
26. Unsaturated compound Presence of Unsaturated compound  
27. Amino acid Absence  of  Amino acids 
28. Oxyquinole, Epinephrine, 
Pyrocatechol 
Absence of Oxy quinole, epinephrine and Pyro 
catechol. 
 
  
 
 
PHYSICOCHEMICAL 
ANALYSIS 
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PHYSICOCHEMICAL ANALYSIS OF MANTHARAKASA LEHIYUM 
S.NO PARAMATERS VALUES 
1. Loss on drying at 105
0
 C 17.58% 
2. Total ash 3.233% 
3. Water soluble ash 1.996% 
4. Acid soluble ash 0.054% 
5. Water soluble extractives 47.482% 
6. Alcohol soluble extractives 57.550% 
7. Fat content 4.350% 
8. Total solid content 82.42% 
9. pH 6.7 
10. Reducing sugar 7.83% 
11. Total sugar 47.81% 
 
HPTLC REPORT OF MANTHARAKASA LEHIYUM 
Sample Name/ID – Manthara Kasa Lehiyam 
Stationary Phase - Silica Gel 60 F254 
Mobile Phase - Toluene: Ethyl Acetate: Formic Acid (5: 2.5: 0.5 v/v/v) 
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  = 254 nm    = 366 nm    = 575 nm (Derivatized) 
Color Rf  value(s) Color Rf  value(s) Color Rf value(s) 
Green 0.14 Blue 0.15 Grey 0.06 
Green 0.18 Light Pink 0.29 Green 0.17 
Green 0.26 Pink 0.35 Blue 0.21 
Green 0.30 Light Pink 0.38 Light Grey 0.34 
Green 0.35 Green 0.42 Light Grey 0.38 
Green 0.38 Green 0.50 Grey 0.42 
Green 0.42 Pink 0.52 Grey 0.46 
Green 0.50   Grey 0.51 
    Dark Grey 0.65 
    Grey 0.72 
  
 
HPTLC Chromatogram of Mantharakasalehiyum at 254 nmUV:  
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Peak Table of Mantharakasalehiyum at 254 nmUV:  
 
 
3D Chromatogram of Mantharakasalehiyum at 254 nmUV: 
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HPTLC Chromatogram of Mantharakasalehiyum at 366 nmUV:  
 
 
Peak Table of Mantharakasalehiyum at 366 nmUV:  
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3D Chromatogram of Mantharakasalehiyum at 366 nmUV: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
OBSERVATION AND 
RESULTS 
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OBSERVATION AND RESULTS 
 
Results were observed with respect to the following criteria   
1. Sex Distribution  
2. Age Distribution   
3. Kaalam Distribution 
4. Occupation Distribution 
5. Duration of Illness 
6. Habits 
7. Diet 
8. Religion Distribution 
9. Socio-economic status 
10. Treatment history 
11. Triggering factors 
12. Marital History 
13. Family history  
14. Thegi Distribution 
15. Thinai Distribution  
16. Paruva Kaalam Distribution  
17. Gunam Distribution 
             18. Clinical features 
             19. Gnanendhiriyam (Imporigal)  
             20. Kanmendhiriyam  
             21. Kosam  
             22. Mukkutram  a)Vadham   b)Pitham   c) Kabam  
             23. Ezhu Udal Kattugal  
             24. Ennvagai Thervugal  
             25.  Neikuri 
             26. Laboratory Analysis 
             27. Primary Outcome (PEFR) 
             28. Secondary Outcome - Clinical Features (AT) 
     For this study 40 cases were selected. 
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SEX DISTRIBUTION 
TABLE NO: 1 
 
GENDER 
 
 
NO OF CASES 
 
PERCENTAGE (%) 
 
MALE 
 
 
16 
 
40 
 
FEMALE 
 
 
24 
 
60 
 
TOTAL 
 
 
40 
 
100 
 
 
 
 
 
 
 
 
 
 
 
 
Inference:   Out of 40 cases, 16 cases (40%) were male, 24 cases (60%) were female. 
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AGE DISTRIBUTION 
    TABLE NO: 2 
 
S.NO 
 
 
AGE IN 
YEARS 
 
NO OF CASES 
 
PERCENTAGE (%) 
1 
 
19-20 5 12.5 
2 
 
21-30 15 37.5 
3 
 
31-40 13 32.5 
4 
 
41-50 6 15 
5 
 
51-60 1 2.5 
 
 
Total 40 100 
 
 
 
 
 
 
 
 
 
 
 
Inference: Out of cases, 5 cases (12.5%) were in the age group between 19-20, 15 cases 
(37.5%) were in the age group between 21-30, 13 cases (32.5%) were in the age group 
between 31-40, 6 cases (15%) were in the age group between 41-50 and 1 case (2.5%) was 
in the age group between 51-60. 
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DISTRIBUTION OF CASES BY KAALAM (LIFE SPAN) 
TABLE NO: 3 
 
KAALAM 
 
NO OF CASES 
 
PERCENTAGE (%) 
Vadha kaalam 
1-33 Years 
 
 
25 
 
62.5 
Pitha kaalam 
34-66Years 
 
 
15 
 
37.5 
Kaba kaalam 
67-100 years 
 
0 
 
0 
 
 
Total 
 
 
40 
 
100 
 
 
 
Inference: Out of 40 cases, 25 cases (62.5%) were found to be affected in their Vadha 
kaalam (Between 1-33 Years) and 15 Cases (37.5%) were found to be affected in their 
Pitha Kaalam (Between 34-66Years). 
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OCCUPATION DISTRIBUTION 
TABLE NO: 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation: Out of 40 cases, 16 cases (40%) were House wives, 7 cases (17.5%) were 
Students, 4 cases (10%) were Software engineers, 2 cases  (5%) were Painter, 2 cases (5%) 
were Clerk, 2 cases (5%) were Shopkeeper, 1 case (2.5%) was Milkman, 1 case (2.5%) 
was Textile worker, 1 case (2.5%) was Police, 1 case (2.5%) was Tailor, 1 case (2.5%) was 
Fitter, 1 case (2.5%) was Teacher and 1 case (2.5%) was Driver. 
S.NO OCCUPATION NO OF CASES 
 
PERCENTAGE (%) 
1 House Wives 16 40 
2 Students 7 17.5 
3 Software Engineers 4 10 
4 Milkman 1 2.5 
5 Textile Worker 1 2.5 
6 Police 1 2.5 
7 Tailor 1 2.5 
8 Painter 2 5 
9 Clerk 2 5 
10 Fitter 1 2.5 
11  Teacher 1 2.5 
12 Shopkeeper 2 5 
13 Driver 1 2.5 
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DISTRIBUTION OF CASES BY DURATION ILLNESS 
                                      TABLE NO: 5 
S.NO DURATION NO OF CASES PERCENTAGE (%) 
1 Below 3 month 0 0 
2 3-6 months 2 5 
3 6months-1 year 4 10 
4 1-2 years 7 17.5 
5 2-3years 7 17.5 
6 3-6 years 20 50 
 
 
 
 
 
 
 
Inference: Out of 40 cases, 2 cases (5%) were affected by the illness from 3-6 months, 4 
cases (10%) were affected by the illness from 6months-1year, 7 cases (17.5%) were affected 
by the illness from 1-2 years, 7 cases (17.5%) were affected by the illness from 2-3 years 
and 20 cases (50%) were affected by the illness from 3-6 years. 
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6. HABITS 
All the 40 cases are non smokers, non alcohol consumers and non chewer of betel nut. 
DIET HISTORY 
TABLE NO: 7 
 
S.NO 
 
DIET 
 
NO OF CASES 
 
PERCENTAGE (%) 
1 Vegetarian 
 
4 10 
2 Non vegetarian 
 
36 90 
 
 
 
 
 
 
 
 
 
Inference: Out of 40 cases, 36 cases (90%) were Non vegetarian, 4 cases (10%) were 
vegetarian. 
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DISTRIBUTION OF CASES BY RELIGION 
TABLE NO: 8 
 
S.NO 
 
RELIGION 
 
 
NO OF CASES 
 
PERCENTAGE 
 
1 
 
Hindus 
 
36 
 
 
90 
 
2 
 
Christians 
 
 
1 
 
2.5 
 
3 
 
Muslims 
 
 
3 
 
7.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inference: Out of 40 cases, 36 cases (90%) were Hindus, 1 case (2.5%) was Christian and 3 
cases (7.5%) were Muslims. 
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SOCIOECONOMIC STATUS DISTRIBUTION 
TABLE NO: 9 
 
S.NO SOCIO ECONOMIC 
STSTUS 
NO OF CASES PERCENTAGE (%) 
1 Upper 3 7.5 
2 Middle 35 87.5 
3 Lower 2 5 
 
 
 
 
 
 
 
 
 
 
 
 
Observation: The incidence of the disease was found to be higher 35 cases (87.5%) in 
middle class, 3 cases (7.5%) were found in upper class and 2 cases (5%) were found in 
lower class. 
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TREATMENT HISTORY 
TABLE NO: 10 
 
S.NO TREATMENT HISTORY NO OF CASES PERCENTAGE % 
1 Yes 27 67.5 
2 No 13 32.5 
 
 
 
 
Inference: Out of 40 cases, 27 cases (67.5%) had taken other modes of treatment in the past 
and 13 cases (32.5%) had not taken any modes of treatment. 
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DISTRIBUTION OF TRIGGERING FACTORS 
TABLE NO: 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. NO TRIGGERING FACTORS 
NO OF 
CASES 
PERCENTAGE (%) 
1 Dust 40 100 
2 Cold exposure  40 100 
3 Smoke exposure 11 27.5 
4 Occupation  9 22.5 
5 Emotion  7 17.5 
6 Food Additive  13 32.5 
7 Exercise  5 12.5 
8 Fumes of Paint & Petrol 4 10 
9 Chemicals  2 5 
10 Detergents 0 0 
11 Husks, Grass & Pollens  3 7.5 
12 Menstruation cycle 1 2.5 
13 Other 0 0 
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Inference: 
 In all the 40 cases (100%) Dust and cold were the triggering factors.  
 In 13 cases (32.5%) food additive was a triggering factor. 
 In 11 cases (27.5%) smoke was a triggering factor.  
 In 9 cases (22.5%) occupation was a triggering factor.  
 In 7 cases (17.5%) emotion was a triggering factor.  
 In 5 cases (12.5%) exercise was a triggering factor.  
 In 4 cases (10%) fumes of paint & petrol was a triggering factor.  
 In 3 cases (7.5%) husks, grass, pollens were a triggering factor  
 In 2 cases (5%) chemicals was a triggering factor.  
 In 1 case (2.5%) wheezing occurred on menstruation cycle. 
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MARITAL HISTORY 
TABLE NO: 12 
 
S.NO MARITAL HISTORY 
 
NO OF CASES PERCENTAGE % 
1. Married 26 60 
2. Unmarried 14 40 
 
 
 
 
Inference: Among 40 cases, 26 cases (60%) were married and 14 cases (40%) were 
unmarried. 
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  FAMILY HISORY 
                                         TABLE.NO: 13 
 
S.NO 
 
FAMILY HISTORY 
 
NO OF CASES 
 
PERCENTAGE (%) 
1 Yes 8 20 
2 No 32 80 
 
 
 
 
 
 
 
 
Inference: Among 40 cases, 32 cases (80%) reported negative family history of similar 
illness and 8 cases (20%) reported positive family history of similar illness. 
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THEGI DISTRIBUTION 
TABLE NO: 14 
 
S.NO TYPES OF THEGI NO OF CASES PERCENTAGE % 
1. Vatha thegi 16 40 
2. Pitha thegi 9 22.5 
3. Kaba thegi 15 37.5 
  
  
 
 
 
 
 
 
 
 
 
Inference: Out of 40 cases, 16 cases (40%) were Vadha thegi, 9 cases (22.5%) were Pitha 
thegi and 15 Cases (37.5%) were Kaba thegi. 
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DISTRIBUTION OF CASES BY THINAI (LAND) 
TABLE NO: 15 
 
 
S.NO 
 
THINAI (LAND) 
 
NO OF CASES 
 
PERCENTAGE (%) 
 
1 
 
Kurinji (Hill areas) 
 
0 
 
0 
 
2 
 
Mullai (Forest) 
 
0 
 
0 
 
3 
 
Marutham (Fertile land ) 
 
7 
 
17.5 
 
4 
 
Neithal (Costal area) 
 
33 
 
82.5 
 
5 
 
Palai (Desert) 
 
0 
 
0 
 
 
 
 
 
 
 
 
 
                             
 
Inference: Out of 40 cases, 33 cases (82.5%) belonged to the Neithal (costal area& its 
surroundings) and 7 cases (17.5%) belonged to the Marutham (Fertile land and its 
surroundings). 
 
 
 
107 
 
DISTRIBUTION OF CASES BY PARUVAKAALAM 
TABLE NO: 16 
 
 
S.NO 
 
PARUVAKAALAM 
 
NO OF CASES 
 
PERCENTAGE (%) 
 
1 
 
Kar (Aug 16-Oct 15) 
 
0 
 
0 
 
2 
 
Koothir (Oct 16-Dec 15) 
 
0 
 
0 
 
3 
 
Munpani (Dec 16-Feb15) 
 
4 
 
10 
 
4 
 
Pinpani (Feb 16-Apr 15) 
 
36 
 
90 
 
5 
 
Ilavenil (Apr 16-Jun 15) 
 
0 
 
0 
 
6 
 
Mudhuvenil (Jun16-Aug 15) 
 
0 
 
0 
 
      
 
Observation: Among the 40 cases, in 4 cases (10%) the incidence of the disease seems to be 
in Munpanikalam. In 36 cases (90%) the incidence of the disease seems to be in 
Pinpanikalam. 
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GUNAM DISTRIOBUTION 
TABLE NO: 17 
 
S.NO TYPES OF GUNAM NO OF CASES PERCENTAGE % 
1. Sathuvam 2 5 
2. Rasatham 38 95 
3. Thamasam 0 0 
  
 
 
 
 
 
 
 
 
 
Inference: Out of cases, 2cases (5%) were found to posses Sathuva gunam and 38 cases 
(95%) were found to posses Rasatha gunam. 
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CLINICAL FEATURES 
                                         TABLE NO: 18 
 
S.NO CLINICAL FEATURES 
NO OF 
CASES 
PERCENTAGE (%) 
1 Difficulty in breathing 40 100 
2 Tightness of chest 40 100 
3 Wheeze-Added sound 
(Rhonchi) 
40 100 
4 Dry(or) Productive cough 40 100 
5 Sneezing 40 100 
6 Hoarseness of voice 34 85 
7 Sleep disturbances 12 30 
8 Nocturnal wheezing 12 30 
9 Associated symptoms 15 37.5 
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Inference:      
 Among 40 cases, in all the 40 cases (100%) had Difficulty in breathing, tightness of 
chest, wheeze-added sound (Rhonchi), Dry (or) Productive cough and sneezing. 
 34 cases (85%) had hoarseness of voice. 
 12 cases (30%) had sleep disturbances. 
 12 cases (30%) had nocturnal wheezing. 
 15 cases (37.5%) had some other associated symptoms. 
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   GNANAENDHIRIYAM (IMPORIGAL) 
                                             TABLE NO: 19 
 
S.NO IMPORIGAL NO OF CASES 
PERCENTAGE 
(%) 
1 Mei 0 0 
2 Vai 0 0 
3 Kan 0 0 
4 Mooku 15 37.5 
5 Sevi 0 0 
 
 
 
 
 
 
 
 
 
                         Inference: Out of 40 cases, Mooku was affected in 15 cases (37.5%). 
 
 
. 
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KANMENDHIRIYAM 
TABLE.NO: 20 
 
S.NO KANMENDHIRIYUM NO OF CASES 
PERCENTAGE 
(%) 
1 Kai 1 2.5 
2 Kal 3 7.5 
3 Vai 0 0 
4 Eruvai 3 7.5 
5 Karuvai 0 0 
 
 
 
 
 
 
 
 
 
 
 
Inference: Out of 40 cases, Kai was affected in 1 case (2.5%), Kal was affected in 3 cases 
(7.5%) and Eruvai was affected in 3 cases (7.5%). 
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KOSAM 
TABLE NO: 21 
 
S.NO KOSAM NO OF THE CASES PERCENTAGES 
(%) 
1 Annamayakosam 9 22.5 
2 Piranamayakosam 40 100 
3 Manomayakosam 0 0 
4 Vingyanamayakosam 5 12.5 
5 Anandhamayakosam 0 0 
 
 
 
 
 
 
 
 
 
Inference:  Among 40 cases, Pranamayakosam was affected in all 40 cases (100%), 
Annamayakosam was affected in 9 cases (22.5%) and Vingyanamayakosam was affected 
in 5cases (12.5%). In Swasa kasam Pranamayakosam was mainly affected. 
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22. MUKKUTRAM      A. VATHAM    B. PITHAM    C. KABAM 
22A.   VATHAM 
TABLE NO: 22A 
 
S.NO TYPES OF VATHAM NO OF CASES PERCENTAGE (%) 
1. Piranan 40 100 
2. Abanan 3 7.5 
3. Viyanan 4 10 
4. Udhanan 40 100 
5. Samanan 40 100 
6. Nagan 0 0 
7. Koorman 0 0 
8. Kirugaran 40 100 
9. Devathathan 40 100 
10. Dhanajeyan 0 0 
 
 
 
 
 
 
 
 
 
Inference:  Among 40 cases, Pranan, Udhanan, Samanan, Kirugaran and Devathathan 
were affected in all cases (100%), Viyanan was affected in 4 cases (10%) and Abanan was 
affected in 3 cases (7.5%). 
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22 B. PITHAM 
TABLE NO: 22B 
 
S.NO TYPES OF PITHAM NO OF CASES PERCENTAGE (%) 
1. Analpitham 0 0 
2. Ranjagapitham 6 15 
3. Sathagapitham 40 100 
4. Aalosagapitham 0 0 
5. Prasagapitham 0 0 
 
 
 
Inference: Among 40 cases, Sathagapitham was affected in all the 40 cases (100%) and 
Ranjagapitham was affected in 6cases (15%). 
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22 C. KABAM 
TABLE NO: 22C 
 
S.NO TYPES OF KABAM NO OF CASES PERCENTAGE (%) 
1. Avalambagam 40 100 
2. Kilaethagam 9 22.5 
3. Pothagam 0 0 
4. Tharpagam 0 0 
5. Santhigam 4 10 
 
 
 
 
 
 
 
 
 
 
 
Inference: Among 40 cases, Avalambagam was affected in all the 40 (100%) cases, 
Kilethagam was affected in the 9 cases (22.5%) and Sandhigam was affected in the 4 cases 
(10%). In Swasa kasam Avalambagam was mainly affected.                                          
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23. EZHU UDAL KATTUKAL 
TABLE NO: 23 
 
S.NO EZHU UDAL 
KATTUGAL 
NO OF CASES PERCENTAGE (%) 
1. Saaram 40 100 
2. Senneer 6 15 
3. Oon 0 0 
4. Enbu  4 10 
5. Kozhuppu 0 0 
6. Moolai 0 0 
7. Sukilam/ Suronitham 0 0 
 
 
 
 
 
 
 
 
 
 
 
Inference: Among 40 cases, Saaram was affected all the 40cases (100%), Senneer was 
affected in 6 cases (15%) and Enbu was affected in 4 Cases (10%). 
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24.  ENN VAGAI THERVUGAL 
TABLE NO: 24A 
 
S.NO EN VAGAI 
THERVUGAL 
NO OF CASES PERCENTAGE (%) 
1. Naa 0 0 
2. Niram 0 0 
3. Mozhi 40 100 
4. Vizhi 0 0 
6. Malam 3 7.5 
7. Moothiram 0 0 
 
 
 
 
 
 
 
 
 
 
Inference: Among 40 cases, Mozhi was affected in all the 40 cases (100%), Malam was 
affected in the 3 cases (7.5%). In Swasa kasam Mozhi was affected in all the patients. 
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ENN VAGAI THERVUGAL 
TABLE NO: 24B 
 
S.NO EN VAGAI THERVUGAL NO OF CASES PERCENTAGE (%) 
 Naadi   
1. Vadhapitham 20 50 
2. Pithavadham 13 32.5 
3. Kabapitham 7 17.5 
 
 
 
 
 
 
 
 
 
Inference: In Naadi Vathapitha naadi presened in the 20 cases (50%), Pitha vatham 
showed in the 13 cases (32.5%) and Kabapitham presened in the 7 cases (17.5%). In Naadi 
Vathapitha naadi presented higher frequency than the others. 
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25.  NEIKURI 
TABLE NO: 25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inference: Among 40 cases, 15 cases (37.5%) had Vatha neer, 7 cases (17.5%) had Pitha 
neer and 18 cases (45%) had Kaba neer. In majority of cases kaba neer was present. 
 
 
 
 
 
 
 
S.NO NEIKURI NO OF CASES PERCENTAGE (%) 
1 Vatha Neer 15 37.5 
2 Pitha Neer 7 17.5 
3 Kaba Neer 18 45 
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26. LABORATORY INVESTIGATIONS 
PEAK EXPIRATORY FLOW RATE 
S.No 
O.P / I.P 
NO 
Age/ Sex 
PEFR(Lit/min) Before 
Treatment 
PEFR (Lit/min) After 
Treatment 
1 G92139 50/F 130 380 
2 H17667 19/F 170 320 
3 H7442 25/M 180 470 
4 H12068 33/M 200 350 
5 G32326 29/F 170 380 
6 H26474 20/F 180 390 
7 G85930 33/F 190 420 
8 H17992 35/F 120 320 
9 H23387 33/F 160 390 
10 H26831 49/M 230 490 
11 H19563 26/F 130 280 
12 G73166 34/F 120 410 
13 H24367 41/F 160 260 
14 G89922 46/F 180 410 
15 H26132 36/F 140 390 
16 H2011 21/M 230 500 
17 H14663 36/F 180 320 
18 H26997 25/F 180 310 
19 H12761 33/M 200 500 
20 G86365 50/F 180 240 
21 G71874 23/M 230 400 
22 H27778 30/F 190 390 
23 H25912 26/F 120 220 
24 H11701 29/F 180 320 
25 H13931 28/F 140 270 
26 H11445 39/F 180 410 
27 G73056 37/M 220 490 
28 H26927 22/F 130 350 
29 H29920 46/F 180 370 
30 H15114 30/M 180 470 
31 H28456 19/F 150 340 
32 H574 19/M 220 490 
33 F74960 28/M 160 410 
34 H18109 57/M 210 340 
35 H25074 32/M 190 440 
36 H33269 20/M 180 480 
37 H25538 35/F 130 290 
38 H1185 35/M 200 430 
39 E98016 23/M 180 420 
40 H34343 21/M 180 380 
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EOSINOPHILS COUNT BEFORE AND AFTER TREATMENT 
S.No O.P / I.P No Age/ Sex Eosinophil% 
Before Treatment 
Eosinophil% 
After Treatment 
1 G92139 50/F 4 3 
2 H17667 19/F 6 5 
3 H7442 25/M 8 6 
4 H12068 33/M 6 6 
5 G32326 29/F 9 6 
6 H26474 20/F 6 4 
7 G85930 33/F 5 4 
8 H17992 35/F 6 2 
9 H23387 33/F 7 5 
10 H26831 49/M 8 2 
11 H19563 26/F 5 4 
12 G73166 34/F 6 4 
13 H24367 41/F 4 5 
14 G89922 46/F 4 3 
15 H26132 36/F 6 5 
16 H2011 21/M 7 5 
17 H14663 36/F 5 4 
18 H26997 25/F 7 5 
19 H12761 33/M 9 5 
20 G86365 50/F 18 16 
21 G71874 23/M 8 6 
22 H27778 30/F 5 5 
23 H25912 26/F 14 7 
24 H11701 29/F 5 5 
25 H13931 28/F 7 3 
26 H11445 39/F 7 7 
27 G73056 37/M 6 3 
28 H26927 22/F 6 5 
29 H29920 46/F 8 4 
30 H15114 30/M 7 4 
31 H28456 19/F 5 3 
32 H574 19/M 10 5 
33 F74960 28/M 3 3 
34 H18109 57/M 7 8 
35 H25074 32/M 7 6 
36 H33269 20/M 6 6 
37 H25538 35/F 7 5 
38 H1185 35/M 8 4 
39 E98016 23/M 6 4 
40 H34343 21/M 6 6 
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ESR RATE BEFORE AND AFTER TREATMENT 
S.No O.P / I.P No Age/ Sex ESR (mm/hr)  
Before treatment 
ESR (mm/hr)  
After treatment 
1 G92139 50/F 20 86 8 20 
2 H17667 19/F 16 32 2 4 
3 H7442 25/M 4 8 4 8 
4 H12068 33/M 2 4 4 8 
5 G32326 29/F 8 20 6 12 
6 H26474 20/F 8 16 8 16 
7 G85930 33/F 8 16 8 16 
8 H17992 35/F 2 6 2 4 
9 H23387 33/F 4 12 2 4 
10 H26831 49/M 12 26 6 12 
11 H19563 26/F 12 14 6 14 
12 G73166 34/F 10 26 8 16 
13 H24367 41/F 16 32 14 20 
14 G89922 46/F 12 40 8 16 
15 H26132 36/F 20 44 12 18 
16 H2011 21/M 12 16 4 8 
17 H14663 36/F 32 62 4 10 
18 H26997 25/F 4 12 2 10 
19 H12761 33/M 6 12 4 8 
20 G86365 50/F 30 40 24 36 
21 G71874 23/M 20 44 14 20 
22 H27778 30/F 16 32 4 10 
23 H25912 26/F 14 30 12 24 
24 H11701 29/F 14 18 8 16 
25 H13931 28/F 30 62 14 20 
26 H11445 39/F 10 14 4 8 
27 G73056 37/M 4 10 2 8 
28 H26927 22/F 20 42 12 20 
29 H29920 46/F 18 36 12 14 
30 H15114 30/M 6 12 4 8 
31 H28456 19/F 18 26 4 8 
32 H574 19/M 5 10 4 12 
33 F74960 28/M 6 12 4 8 
34 H18109 57/M 2 6 4 8 
35 H25074 32/M 4 8 2 6 
36 H33269 20/M 2 4 2 4 
37 H25538 35/F 4 10 2 4 
38 H1185 35/M 4 12 2 4 
39 E98016 23/M 2 4 2 4 
40 H34343 21/M 20 36 14 16 
 
 
 
124 
 
ABSOLUTE EOSINOPHIL COUNT BEFORE AND AFTER TREATMENT 
S.No O.P / I.P 
NO 
Age/ Sex AEC (cells/cumm) Before 
treatment 
AEC (cells/cumm) After 
Treatment 
1 G92139 50/F 211 188 
2 H17667 19/F 188 180 
3 H7442 25/M 355 320 
4 H12068 33/M 290 311 
5 G32326 29/F 320 188 
6 H26474 20/F 299 170 
7 G85930 33/F 270 266 
8 H17992 35/F 270 180 
9 H23387 33/F 280 169 
10 H26831 49/M 340 270 
11 H19563 26/F 140 122 
12 G73166 34/F 210 111 
13 H24367 41/F 144 160 
14 G89922 46/F 300 240 
15 H26132 36/F 240 122 
16 H2011 21/M 210 199 
17 H14663 36/F 244 188 
18 H26997 25/F                        240 166 
19 H12761 33/M 260 222 
20 G86365 50/F 720 640 
21 G71874 23/M 390 188 
22 H27778 30/F 122 222 
23 H25912 26/F 480 310 
24 H11701 29/F 240 210 
25 H13931 28/F 280 280 
26 H11445 39/F 280 260 
27 G73056 37/M 190 180 
28 H26927 22/F 240 170 
29 H29920 46/F 388 290 
30 H15114 30/M 240 160 
31 H28456 19/F 280 120 
32 H574 19/M 266 240 
33 F74960 28/M 340 280 
34 H18109 57/M 320 380 
35 H25074 32/M 240 222 
36 H33269 20/M 210 160 
37 H25538 35/F 360 344 
38 H1185 35/M 320 166 
39 E98016 23/M 330 232 
40 H34343 21/M 260 166 
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SERUM IgE LEVEL BEFORE AND AFTER TREATMENT 
S.No O.P / I.P 
NO 
Age/ Sex Serum IgE (IU/ml)  Before 
treatment 
Serum IgE (IU/ml)  After 
Treatment 
1 G92139 50/F 591 260 
2 H17667 19/F 978 550 
3 H7442 25/M 2695 111 
4 H12068 33/M 2500 1400 
5 G32326 29/F 142 120 
6 H26474 20/F 1381 710 
7 G85930 33/F 518 511 
8 H17992 35/F 1499 800 
9 H23387 33/F 2900 2316 
10 H26831 49/M 3000 3000 
11 H19563 26/F 1141 794 
12 G73166 34/F 535 478 
13 H24367 41/F 996 890 
14 G89922 46/F 54 50 
15 H26132 36/F 647 430 
16 H2011 21/M 928 610 
17 H14663 36/F 1074 769 
18 H26997 25/F 134 120 
19 H12761 33/M 790 540 
20 G86365 50/F 1562 778 
21 G71874 23/M 278 250 
22 H27778 30/F 162 110 
23 H25912 26/F 3000 3000 
24 H11701 29/F 931 571 
25 H13931 28/F 695 640 
26 H11445 39/F 176 130 
27 G73056 37/M 494 350 
28 H26927 22/F 480 329 
29 H29920 46/F 120 110 
30 H15114 30/M 526 515 
31 H28456 19/F 1318 720 
32 H574 19/M 995 679 
33 F74960 28/M 360 420 
34 H18109 57/M 617 530 
35 H25074 32/M 819 436 
36 H33269 20/M 543 310 
37 H25538 35/F 129 234 
38 H1185 35/M 184 311 
39 E98016 23/M 2500 1240 
40 H34343 21/M 1833 510 
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PRIMARY OUTCOME 
TABLE NO: 27 
 
OUTCOME BY PEFR  
 
S.NO RESULT NO OF CASES PERCENTAGE (%) 
1. Good 25 62.5 
2. Moderate 11 27.5 
3. Poor 4 10 
 
 
 
 
 
 
 
 
 
 
Inference: After treatment, Out of 40 cases, 25 cases (62.5%) showed good improvement by 
PEFR and completely relieved from wheezing, 11 cases (27.5%) showed moderately 
improvement, 4 cases (10%) showed mild improvement. 
Good          – PEFR value for Men above 400; for women above 250 
Moderate   – PEFR value for men between 400- 450; for women between 250-300 
Poor           – PEFR value for men below 400; for women below 250 
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SECONDARY OUTCOME 
CLINICAL FEATURES (AS PER SUBJECTIVE PARAMETER) 
TABLE NO: 28 
 
SNO CLINICAL FEATURES NO OF CASES PERCENTAGE (%) 
1. Wheezing 0 0 
2. Dry (or) Productive cough 7 17.5 
3. Breathlessness 0 0 
4. Tightness of chest 0 0 
5. Sneezing 9 22.5 
6. Hoarseness of voice 1 2.5 
7. Sleep disturbances 0 0 
            
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Inference: After treatment, Out of 40 cases, 82.5% cases relieved from cough, 77.5% cases 
were relieved from sneezing, and 97.5% cases were relieved from Hoarseness of voice.Other 
symptoms were gradually reduced well. 
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GRADATION OF RESULTS 
 
SNO RESULTS AFTER TREATMENT 
NO OF CASES PERCENTAGE (%) 
1. Good 30 75 
2. Fair 7 17.5 
3. Poor 3 7.5 
 
 
 
 
 
 
 
 
 
 
 
Inference: Out of 40 cases, Good results were found in 75% of cases. Fair results were found 
in 17.5% of cases. Poor results were found in 7.5% of cases. 
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STATISTICAL ANALYSIS 
All collected data were entered into MS Excel software using different columns as 
variables and rows as patients. SPSS software was used to perform statistical analysis. Basic 
descriptive statistics include frequency distributions and cross-tabulations were performed. 
The quantity variables were expressed as Mean ± Standard Deviation and qualitative data as 
percentage. A probability value of <0.05 was considered to indicate as statistical significance. 
Paired „t‟ test was performed for determining the significance between before and after 
treatment.  
Paired „t‟ test for Peak Expiratory Flow Rate  
Group Mean Std t value  P Value 
Before 174.50 31.29 -21.10 
 
P<0.0001 
After 381 74.96 
 
PEFR before treatment is 174.50 and after treatment is 381.00 which is statistically 
significant (p<0.0001). 
Paired „t‟ test for ESR ½ Hr  
Group Mean Std t value  P Value 
Before 11.42 8.23 5.2869 
 
P<0.0001 
After 6.55 4.91 
 
ESR 1/2 hr before treatment is 11.42 and after treatment is 6.55 which is statistically 
significant (p<0.0001). 
Paired „t‟ test for ESR 1 Hr  
Group Mean Std t value  P Value 
Before 23.80 18.36 4.89 
 
P<0.0001 
After 12.05 6.86 
 
ESR 1 hr before treatment is 23.80 and after treatment is 12.05 which is statistically 
significant (p<0.0001). 
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Paired „t‟ test for Esoinophil count 
Group Mean Std t value  P Value 
Before 6.85 2.62 3.86 
 
P<0.0001 
After 4.85 2.28 
 
          Eosinophil count before treatment is 6.85 and after treatment is 4.85 which is 
statistically significant (p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
LAB INVESTIGATION 
PARAMETERS 
  
LAB INVESTIGATIONS/BEFORE TREATMENT 
S. 
NO 
OP/IP 
NO 
Name Age/ 
Sex 
Hb TC DC T.RBC ESR Sugar Urea  
Creatinine 
Cholesterol 
      P L E  1/2hr 1hr F PP R   Total HDL LDL VLDL TGL 
1 G92139 Mrs.Chandra 50/F 10.7 10100 68 28 4 4 20 86 111 127 - 16 0.8 150 48 89 28 142 
2 H17667 Ms.Keerthika 19/F 11.7 10000 62 32 6 5.1 16 32 83 101 - 17 0.7 145 48 80 14 68 
3 H7442 Mr.Kumaravel 25/M 14.3 8200 59 33 8 5.2 4 8 96 82 - 14 0.8 120 41 68 11 56 
4 H12068 Mr.Sakthimurugan 33/M 15.7 9000 58 36 6 5.7 2 4 85 82 - 12 1.1 189 56 117 20 101 
5 G32326 Mrs.Kadharma 29/F 12 8400 45 46 9 4.7 8 20 83 90 - 12 0.8 169 58 94 23 116 
6 H26474 Ms.Radhika 20/F 10.2 11900 57 37 6 4.2 8 16 87 90 - 16 0.8 164 51 90 14 72 
7 G85930 Mr.Palanivel 33/F 13.3 7000 54 41 5 5.5 8 16 87 104 - 19 1.1 200 52 112 27 134 
8 H17992 Mrs.Radha 35/F 14.5 9700 55 39 6 14.5 2 6 108 138 - 19 0.9 191 48 106 25 124 
9 H23387 Mrs.Sheelarani 33/F 12.4 7200 51 42 7 4.3 4 12 88 81 - 13 0.8 192 52 107 21 104 
10 H26831 Mr.Boopalan 49/M 15.6 9900 68 24 8 5.3 12 26 100 144 - 23 1.1 152 56 81 17 89 
11 H19563 Mrs.Dilshat 26/F 12.5 5600 50 45 5 4.4 12 14 106 131 - 21 0.9 116 45 59 18 91 
12 G73166 Mrs.Geethalakshmi 34/F 10.3 7000 54 40 6 4 10 26 108 124 - 18 0.8 180 51 103 18 90 
13 H24367 Mrs.Jayalakshmi 41/F 12.1 6100 56 40 4 4.2 16 32 104 91 - 16 1 219 69 121 17 84 
14 G89922 Mrs.Sumathi 46/F 13.3 5500 58 38 4 5 12 40 97 103 - 14 0.9 172 59 97 32 159 
15 H26132 Mrs.Mobina 36/F 13.1 8200 55 39 6 4.6 20 44 95 97 - 28 0.8 187 70 104 13 64 
16 H2011 Mr.Vignesh 21/M 14.5 5800 46 47 7 5.3 12 16 86 81 - 11 0.9 143 51 78 18 88 
17 H14663 Mrs.Jeyanthi 36/F 12.5 8200 55 40 5 4.2 32 62 95 80 - 20 0.7 168 68 82 28 138 
18 H26997 Ms.Pugalarasi 25/F 11.7 6400 52 41 7 4.3 4 12 106 115 - 11 0.9 144 68 72 11 57 
19 H12761 Mr.Shunmugam 33/M 14.3 5800 55 36 9 5 6 12 92 82 - 17 1 196 54 95 17 141 
20 G86365 Mrs.Jayalakshmi 50/F 11.1 4800 48 32 18 3.3 30 40 84 94 - 32 0.4 215 63 127 38 159 
  
LAB INVESTIGATIONS/BEFORE TREATMENT 
S. 
NO 
OP/IP 
NO 
Name Age/ 
sex 
Hb TC DC T.RBC ESR Sugar Urea Creatinine Cholesterol 
      P L E  ½ 
hr 
1hr F PP R   Total HDL LDL VLDL TGL 
21 G71874 Mr.Balasubramaniyan 23/M 15.4 10500 70 22 8 5 20 44 102 90 - 13 0.1 178 54 97 20 102 
22 H27778 Mrs.Marimuthu 30/F 11.9 9400 60 35 5 4.9 16 32 100 120 - 27 0.9 220 63 110 29 146 
23 H25912 Ms.Senbagam 26/F 12.7 9000 67 29 14 4.4 14 30 91 105 - 22 0.8 180 60 101 7 36 
24 H11701 Mrs.Vidya 29/F 13.6 8800 67 28 5 4.8 14 18 109 90 - 17 0.9 186 53 106 20 160 
25 H13931 Mrs.Deepalakshmi 28/F 12.7 13800 58 35 7 4.7 30 62 106 133 - 16 0.9 223 63 130 27 135 
26 H11445 Mrs.Leony 39/F 11.7 9000 50 43 7 4.5 10 14 103 140 - 22 0.7 160 72 82 13 65 
27 G73056 Mr.Gunasekaran 37/M 14.5 6600 63 31 6 5.3 4 10 110 126 - 16 1.1 220 57 126 37 153 
28 H26927 Ms.Monikarani 22/F 12.2 9600 61 33 6 4.4 20 42 90 131 - 14 0.7 184 55 106 26 129 
29 H29920 Mrs.Navaneetham 46/F 12.7 11800 61 31 8 5.1 18 36 87 131 - 12 0.7 183 60 120 18 91 
30 H15114 Mr.Ramesh 30/M 12.9 7300 67 26 7 4.8 6 12 97 110 - 14 0.8 167 80 85 10 79 
31 H28456 Ms.Gopika 19/F 12.3 7200 63 32 5 4.5 18 26 93 103 - 13 0.7 183 79 93 13 70 
32 H574 Mr.Nagaraj 19/M 15.2 9200 62 28 10 5.3 5 10 101 116 - 13 1.0 136 44 76 10 48 
33 F74960 Mr.Seethapathy 28/M 15.0 10830 61 29 3 5.04 6 12 78 100 - 22 0.9 25 32 80 13 123 
34 H18109 Mr.Thiyagarajan 57/M 16.4 8100 73 20 7 5.8 2 6 96 117 - 22 1.0 154 51 93 12 62 
35 H25074 Mr.Navaraj 32/M 17.3 6200 59 34 7 6.1 4 8 79 78 - 25 1.0 199 80 104 21 105 
36 H33269 Mr.Adalarasu 20/M 15.2 7200 57 37 6 5.2 2 4 86 78 - 11 1.0 175 59 19 19 93 
37 H25538 Ms.Leena 35/F 14.5 9200 55 38 7 5.6 4 10 90 94 - 13 0.8 147 57 79 12 62 
38 H1185 Mr.Suresh 35/M 13.6 8700 63 29 8 5.9 4 12 93 151 - 23 0.9 173 50 95 23 0.9 
39 E98016 Mr.Vengai Diliban 23/M 5.7 6900 51 43 6 5.7 2 4 84 98 - 22 1.0 171 55 93 15 76 
40 H34343 Mrs.Yogalakshmi 21/F 13.1 6600 48 44 6 4.4 20 36 88 90 - 24 0.7 145 64 90 12 59 
 
LAB INVESTIGATIONS/AFTER TREATMENT 
S. 
No 
OP/IP 
NO 
Name Age/ 
Sex 
Hb TC DC T.RBC ESR Sugar Urea Creatinine Cholesterol 
      P L E  ½ 
hr 
1hr F PP R   Total HDL LDL VLDL TGL 
1 G92139 Mrs.Chandra 50/F 10.8 8900 60 38 2 4.1 8 20 92 84 - 17 0.9 159 51 63 32 100 
2 H17667 Ms.Keerthika 19/F 11.9 8200 65 30 3 5.1 2 4 88 95 - 19 0.7 135 48 53 12 59 
3 H7442 Mr.Kumaravel 25/M 15.0 8200 59 33 5 5.3 4 8 85 71 - 21 0.9 113 40 61 11 55 
4 H12068 Mr.Sakthimurugan 33/M 15.7 8800 57 37 6 5.7 4 8 82 133 - 22 1.1 166 41 97 32 160 
5 G32326 Mrs.Kadharma 29/F 12.4 6800 40 52 6 4.5 6 12 85 100 - 22 0.7 144 52 76 17 17 
6 H26474 Ms.Radhika 20/F 10.6 9100 62 34 6 4.3 8 16 83 96 - 11 0.8 116 36 60 14 73 
7 G85930 Mr.Palanivel 33/F 14.6 7300 54 40 4 5.3 8 16 81 83 - 29 0.1 188 53 100 26 131 
8 H17992 Mrs.Radha 35/F 14.5 9600 55 39 4 5.0 2 4 103 104 - 19 0.9 190 49 93 25 132 
9 H23387 Mrs.Sheelarani 33/F 12.5 7600 60 35 2 4.3 2 4 81 94 - 22 0.7 199 57 118 28 142 
10 H26831 Mr.Boopalan 49/M 16.1 6300 53 34 5 5.7 6 12 107 92 - 26 0.9 147 45 86 13 63 
11 H19563 Mrs.Dilshat 26/F 13.1 5200 50 46 2 4.7 6 14 95 106 - 23 0.7 116 46 53 18 91 
12 G73166 Mrs.Geethalakshmi 34/F 10.5 5900 50 46 4 4.2 8 16 96 133 - 19 0.9 173 42 102 21 80 
13 H24367 Mrs.Jayalakshmi 41/F 12.3 5500 55 40 4 4.4 14 20 93 128 - 16 0.6 180 62 110 16 90 
14 G89922 Mrs.Sumathi 46/F 13.5 6400 60 37 5 5.1 8 16 82 85 - 25 0.8 189 58 63 22 111 
15 H26132 Mrs.Mobina 36/F 13.5 6600 45 50 3 4.7 12 18 107 123 - 21 0.9 173 60 97 10 48 
16 H2011 Mr.Vignesh 21/M 15.4 5800 45 50 5 5.6 4 8 85 71 - 10 1.1 127 44 72 24 119 
17 H14663 Mrs.Jeyanthi 36/F 12.7 9800 63 33 5 4.2 4 10 79 111 - 19 0.8 163 63 80 38 128 
18 H26997 Ms.Pugalarasi 25/F 11.5 8400 68 27 4 4.2 2 10 83 107 - 11 0.7 124 59 62 11 88 
19 H12761 Mr.Shunmugam 33/M 15.3  5400 57 38 5 5.3 4 8 57 38 - 20 1.1 170 62 72 24 118 
20 G86365 Mrs.Jayalakshmi 50/F 11.3 4900 56 25 5 3.4 24 36 90 92 - 31 0.4 215 61 126 27 137 
  
LAB INVESTIGATIONS/AFTER TREATMENT 
S. 
No 
OP/IP 
NO 
Name Age/ 
Sex 
Hb TC DC T.RBC ESR Sugar Urea Creatinine Cholesterol 
      P L E  ½ 
hr 
1hr F PP R   Total HDL LDL VLDL TGL 
21 G71874 Mr.Balasubramaniyan 23/M 15.9 9500 60 30 16 5.4 14 20 91 86 - 13 0.8 181 47 106 18 91 
22 H27778 Mrs.Marimuthu 30/F 11.9 8500 51 44 6 4.9 4 10 91 104 - 16 0.8 209 50 90 40 130 
23 H25912 Ms.Senbagam 26/F 14.8 8300 67 26 5 4.6 12 24 83 90 - 26 0.8 156 50 87 13 62 
24 H11701 Mrs.Vidya 29/F 13.4 8800 68 27 7 4.6 8 16 94 89 - 28 0.9 174 46 100 31 153 
25 H13931 Mrs.Deepalakshmi 28/F 12.8 10200 67 30 5 4.8 14 20 86 138 - 15 0.8 220 63 122 22 136 
26 H11445 Mrs.Leony 39/F 11.8 8500 53 40 3 4.6 4 8 90 79 - 22 0.8 163 63 87 12 59 
27 G73056 Mr.Gunasekaran 37/M 14.7 8900 68 24 7 5.4 2 8 93 104 - 24 1.1 180 58 125 33 142 
28 H26927 Ms.Monikarani 22/F 12.0 8600 65 30 3 4.4 12 20 105 117 - 20 0.7 161 42 89 30 150 
29 H29920 Mrs.Navaneetham 46/F 12.7 9800 67 29 5 4.9 12 14 83 107 - 11 0.7 170 54 98 17 83 
30 H15114 Mr.Ramesh 30/M 13.6 6400 68 28 4 4.8 4 8 90 112 - 15 0.6 192 70 105 27 137 
31 H28456 Ms.Gopika 19/F 13.6 6400 68 28 4 4.8 4 8 93 114 - 13 0.6 180 60 104 24 80 
32 H574 Mr.Nagaraj 19/M 15.1 8600 53 42 3 5.3 4 12 86 100 - 15 0.9 126 36 36 25 43 
33 F74960 Mr.Seethapathy 28/M 15.2 10000 62 32 5 5.05 4 8 83 102 - 22 1.0 127 36 71 20 102 
34 H18109 Mr.Thiyagarajan 57/M 16.0 9700 75 17 3 5.6 4 8 105 120 - 19 1.1 150 46 85 23 115 
35 H25074 Mr.Navaraj 32/M 17.3 7500 56 38 8 6.0 2 6 95 79 - 21 1.2 181 76 94 14 70 
36 H33269 Mr.Adalarasu 20/M 14.3 5500 54 40 6 5.2 2 4 86 89 - 18 1.0 193 44 63 26 130 
37 H25538 Ms.Leena 35/F 14.5 9300 62 33 6 5.6 2 4 86 80 - 06 0.8 135 46 77 11 70 
38 H1185 Mr.Suresh 35/M 13.6 8900 66 30 5 5.9 2 4 95 134 - 25 1.0 146 40 94 43 113 
39 E98016 Mr.Vengai Diliban 23/M 16.2 7400 59 37 4 5.7 2 4 86 103 - 29 1.0 128 53 73 14 71 
40 H34343 Mrs.Yogalakshmi 21/F 12.9 5900 43 51 4 4.3 14 16 89 90 - 27 0.7 155 62 82 24 121 
  
LAB INVESTIGATIONS/BEFORE TREATMENT 
SNO OP NO Name Age/ 
Sex 
Bilirubin SGOT SGPT ALKPHOS Protein CAL PHOS Uric acid 
    T DB IDB    T Alb Glob    
1 G92139 Mrs.Chandra 50/F 0.3 0.2 0.1 11 10 85 7.2 4.0 3.2 8.8 3.7 3.7 
2 H17667 Ms.Keerthika 19/F 0.4 0.2 0.2 17 10 73 7 4.9 2.9 8.3 4.2 2.7 
3 H7442 Mr.Kumaravel 25/M 1.1 0.4 0.7 15 9 56 7.8 4.5 3.3 7.6 3.9 4.3 
4 H12068 Mr.Sakthimurugan 33/M 0.6 0.2 0.4 31 33 84 7.7 4.4 3.3 8.6 3.7 7.2 
5 G32326 Mrs.Kadharma 29/F 0.4 0.2 0.2 26 28 41 7.8 5.0 2.8 8.1 7.1 3.2 
6 H26474 Ms.Radhika 20/F 0.4 0.2 0.2 18 9 103 6.8 4.2 2.7 9.7 3.2 6.4 
7 G85930 Mr.Palanivel 33/F 0.5 0.2 0.3 34 34 93 8.4 4.9 3.5 9.1 4.2 6.5 
8 H17992 Mrs.Radha 35/F 0.7 0.3 0.4 15 20 68 7.2 4.2 3.0 8.7 3.7 6.4 
9 H23387 Mrs.Sheelarani 33/F 0.3 0.2 0.1 17 13 92 7.5 4.2 3.2 8.1 4.2 6.0 
10 H26831 Mr.Boopalan 49/M 0.9 0.3 0.6 20 42 102 7.6 4.6 3.0 8.5 4.5 6.9 
11 H19563 Mrs.Dilshat 26/F 0.5 0.3 0.2 14 23 93 7.5 4.6 2.9 6.9 4.4 3.1 
12 G73166 Mrs.Geethalakshmi 34/F 0.4 0.2 0.2 15 24 49 7.5 4.4 3.1 7.8 4.3 4.4 
13 H24367 Mrs.Jayalakshmi 41/F 0.6 0.3 0.3 15 09 86 7.5 4.3 3.2 8.6 3.7 3.7 
14 G89922 Mrs.Sumathi 46/F 0.4 0.2 0.2 21 21 50 7.1 4.3 2.8 8.5 4.5 4.9 
15 H26132 Mrs.Mobina 36/F 0.5 0.2 0.5 19 13 40 7.9 4.3 3.6 8.0 3.7 2.2 
16 H2011 Mr.Vignesh 21/M 0.8 0.3 0.8 21 15 102 7.7 4.4 3.3 8.5 6.1 4.7 
17 H14663 Mrs.Jeyanthi 36/F 0.5 0.3 0.2 16 15 52 6.7 3.9 3.2 8.6 3.2 3.2 
18 H26997 Ms.Pugalarasi 25/F 1.1 0.6 0.5 17 21 57 7.7 4.6 3.1 7.2 5.0 2.7 
19 H12761 Mr.Shunmugam 33/M 0.9 0.3 0.6 23 21 60 7.7 4.6 3.1 8.2 2.8 1.2 
20 G86365 Mrs.Jayalakshmi 50/F 0.4 0.1 0.3 30 15 57 7.8 4.2 3.5 8.3 3.5 6.1 
 
LAB INVESTIGATIONS/BEFORE TREATMENT 
SNO OP NO Name Age/ 
Sex 
Bilirubin SGOT SGPT ALKPHOS Protein CAL PHOS Uric acid 
    T DB IDB    T Alb Glob    
21 G71874 Mr.Balasubramaniyan 23/M 0.9 9.4 0.5 21 26 56 7.2 4.6 2.7 8.5 3.7 5.8 
22 H27778 Mrs.Marimuthu 30/F 0.4 0.2 0.2 19 21 64 8.3 4.6 3.7 8.3 7.4 4.7 
23 H25912 Ms.Senbagam 26/F 0.4 0.2 0.2 15 14 88 7.1 4.2 2.9 8.1 7.9 4.8 
24 H11701 Mrs.Vidya 29/F 0.6 0.2 0.4 16 15 94 7.1 4.5 2.6 8.3 4.3 3.7 
25 H13931 Mrs.Deepalakshmi 28/F 0.5 0.2 0.3 26 35 95 7.8 4.4 3.4 8.3 3.6 6.8 
26 H11445 Mrs.Leony 39/F 0.4 0.2 0.2 23 13 50 7.1 4.5 2.6 8.5 4.3 2.7 
27 G73056 Mr.Gunasekaran 37/M 0.9 0.3 0.6 19 42 58 7.8 4.8 3.0 9.7 4.4 6.0 
28 H26927 Ms.Monikarani 22/F 0.7 0.3 0.4 15 14 58 7.4 4.5 2.9 8.3 6.8 6.9 
29 H29920 Mrs.Navaneetham 46/F 0.5 0.2 0.3 16 21 88 7.5 4.1 2.7 8.2 3.7 4.4 
30 H15114 Mr.Ramesh 30/M 1.1 0.5 0.6 17 17 45 7.1 4.5 2.6 8.8 4.3 3.1 
31 H28456 Ms.Gopika 19/F 0.8 0.4 0.4 16 23 87 7.4 5.0 2.6 8.3 4.5 5.9 
32 H574 Mr.Nagaraj 19/M 0.7 0.3 0.4 13 20 87 7.3 4.9 2.5 8.3 4.2 6.2 
33 F74960 Mr.Seethapathy 28/M 1.1 0.3 0.8 22 21 70 7.1 4.5 2.6 8.2 2.1 8.6 
34 H18109 Mr.Thiyagarajan 57/M 0.7 0.3 0.4 21 17 46 7.3 4.2 3.1 8.8 2.8 5.9 
35 H25074 Mr.Navaraj 32/M 0.8 0.3 0.5 17 16 62 7.3 4.6 2.7 8.8 2.6 9.5 
36 H33269 Mr.Adalarasu 20/M 1.2 0.4 0.8 19 12 50 08 4.7 3.3 8.4 3.6 8.8 
37 H25538 Ms.Leena 35/F 0.6 0.2 0.4 17 14 102 7.9 4.3 3.6 7.9 3.7 3.7 
38 H1185 Mr.Suresh 35/M 0.6 0.2 0.4 24 27 113 7.7 4.4 3.3 8.6 3.6 5.5 
39 E98016 Mr.Vengai Diliban 23/M 1.2 0.4 0.8 24 16 77 7.2 4.6 2.6 9.3 3.6 5.2 
40 H34343 Mrs.Yogalakshmi 21/F 0.4 0.2 0.2 13 07 63 7.6 4.6 3.0 8.2 4.5 3.2 
 
LAB INVESTIGATIONS/AFTER TREATMENT 
SNO OP NO Name Age/ 
Sex 
Bilirubin SGOT SGPT ALKPHOS Protein CAL PHOS Uricacid 
    T DB IDB    T Alb Glob    
1 G92139 Mrs.Chandra 50/F 0.4 0.2 0.2 15 12 84 7.3 4.1 3.2 8.8 3.7 3.7 
2 H17667 Ms.Keerthika 19/F 0.4 0.2 0.2 16 08 75 7.4 4.6 2.8 8.7 4.2 2.8 
3 H7442 Mr.Kumaravel 25/M 1.2 0.5 0.7 17 6 66 7.9 4.6 3.3 8.4 66 4.4 
4 H12068 Mr.Sakthimurugan 33/M 0.8 0.4 0.4 31 33 84 6.9 4.5 2.4 8.6 4.3 5.8 
5 G32326 Mrs.Kadharma 29/F 0.3 0.2 0.1 19 15 30 7.3 4.4 2.9 8.4 6.9 3.9 
6 H26474 Ms.Radhika 20/F 0.4 0.2 0.2 21 8 96 6.8 4.1 2.7 9.9 3.3 6.4 
7 G85930 Mr.Palanivel 33/F 0.6 0.2 0.4 32 20 88 7.9 4.6 3.3 9.2 3.5 6.5 
8 H17992 Mrs.Radha 35/F 0.6 0.3 0.3 15 20 83 7.1 4.1 3.0 8.7 3.4 6.3 
9 H23387 Mrs.Sheelarani 33/F 0.5 0.2 0.3 17 06 72 6.9 4.6 2.3 8.2 5.2 4.6 
10 H26831 Mr.Boopalan 49/M 0.9 0.3 0.6 27 35 85 7.1 4.3 2.8 8.5 4.3 6.6 
11 H19563 Mrs.Dilshat 26/F 0.6 0.3 0.3 20 16 90 7.2 4.4 2.8 7.5 4.3 2.8 
12 G73166 Mrs.Geethalakshmi 34/F 0.4 0.2 0.2 16 12 37 6.9 3.9 3.0 8.2 3.5 4.4 
13 H24367 Mrs.Jayalakshmi 41/F 0.7 0.3 0,4 15 09 85 7.5 4.2 3.3 8.6 3.8 3.2 
14 G89922 Mrs.Sumathi 46/F 0.5 0.2 0.3 22 22 52 7.4 4.4 3.0 9.0 3.2 4.7 
15 H26132 Mrs.Mobina 36/F 0.7 0.3 0.4 18 13 42 7.9 4.4 3.5 8.8 3.6 2.6 
16 H2011 Mr.Vignesh 21/M 0.6 0.1 0.5 16 11 106 7.4 4.4 3.0 9.5 5.3 4.3 
17 H14663 Mrs.Jeyanthi 36/F 0.5 0.3 0.2 15 16 50 6.9 4.2 2.7 8.7 3.4 3.2 
18 H26997 Ms.Pugalarasi 25/F 1.0 0.4 0.6 22 10 48 6.8 4. 2.4 7.8 4.8 2.4 
19 H12761 Mr.Shunmugam 33/M 0.8 0.4 0.4 18 14 56 6.9 4.4 2.5 8.3 3.0 4.9 
20 G86365 Mrs.Jayalakshmi 50/F 0.4 0.1 0.3 36 17 43 7.8 4.8 3.4 9.2 4.2 5.3 
  
LAB INVESTIGATIONS/AFTER TREATMENT 
SNO OP NO Name Age/ 
Sex 
Bilirubin SGOT SGPT ALKPHOS Protein CAL PHOS Uricacid 
    T DB IDB    T Alb Glob    
21 G71874 Mr.Balasubramaniyan 23/M 0.9 0.6 0.3 20 33 56 7.3 4.6 2.7 8.8 3.8 5.6 
22 H27778 Mrs.Marimuthu 30/F 0.3 0.1 0.2 21 23 53 7.3 4.4 2.9 9.3 4.3 4.4 
23 H25912 Ms.Senbagam 26/F 0.5 0.2 0.3 15 9 88 6.6 4.1 2.5 8.4 6.1 4.0 
24 H11701 Mrs.Vidya 29/F 0.6 0.2 0.4 15 14 82 7.2 4.6 2.6 8.7 3.2 3.5 
25 H13931 Mrs.Deepalakshmi 28/F 0.5 0.2 0.3 17 18 108 7.7 4.4 3.3 8.6 3.4 6.2 
26 H11445 Mrs.Leony 39/F 0.5 0.2 0.3 22 13 40 6.5 4.2 2.3 8.7 4.2 2.7 
27 G73056 Mr.Gunasekaran 37/M 0.8 0.3 0.5 20 33 90 7.2 4.2 3.0 9.9 4.3 5.3 
28 H26927 Ms.Monikarani 22/F 0.8 0.3 0.5 13 14 48 6.9 4.5 2.4 8.3 4.3 4.4 
29 H29920 Mrs.Navaneetham 46/F 0.7 0.3 0.4 18 19 72 6.8 4.2 3.3 8.2 3.5 4.0 
30 H15114 Mr.Ramesh 30/M 0.9 0.3 0.6 15 17 41 7.1 4.7 2.4 9.7 4.2 2.8 
31 H28456 Ms.Gopika 19/F 0.7 0.3 0.4 17 15 36 7.0 4.7 2.3 9.3 4.3 4.2 
32 H574 Mr.Nagaraj 19/M 0.7 0.3 0.4 13 20 87 7.3 4.9 2.5 8.5 4.5 5.7 
33 F74960 Mr.Seethapathy 28/M 0.8 0.4 0.4 21 21 65 7.1 4.4 2.6 8.6 2.8 4.1 
34 H18109 Mr.Thiyagarajan 57/M 0.7 0.3 0.4 20 20 46 7.0 4.2 2.8 8.0 4.2 5.9 
35 H25074 Mr.Navaraj 32/M 0.9 0.3 0.6 19 18 57 7.0 4.6 2.4 8.9 4.3 5.3 
36 H33269 Mr.Adalarasu 20/M 1.1 0.4 0.7 18 14 48 7.3 4.7 2.6 9.4 3.5 8.6 
37 H25538 Ms.Leena 35/F 0.5 0.1 0.4 11 13 89 7.1 4.2 2.9 8.5 3.8 5.2 
38 H1185 Mr.Suresh 35/M 0.4 0.2 0.2 29 18 113 7.7 4.4 3.3 8.6 4.6 5.5 
39 E98016 Mr.Vengai Diliban 23/M 1.0 0.4 0.6 20 13 88 6.9 4.8 2.3 9.3 3.6 5.2 
40 H34343 Mrs.Yogalakshmi 21/F 0.3 0.1 0.2 14 06 49 7.0 4.7 2.3 8.4 4.5 2.8 
 
 
LAB INVESTIGATIONS/BEFORE TREATMENT 
SNO OP/IP 
NO 
Name Age/ 
sex 
AFB XRAY Urine Motion 
      Alb Sugar Deposits BS BP URO Ova Cyst 
1 G92139 Mrs.Chandra 50/F Negative Normal Nil Nil  2-3  Pus Nil Nil N Nil Nil 
2 H17667 Ms.Keerthika 19/F Negative Normal Nil Nil  2-3  Pus Nil Nil N Nil Nil 
3 H7442 Mr.Kumaravel 25/M Negative Normal Nil Nil  1-2  Pus Nil Nil N Nil Nil 
4 H12068 Mr.Sakthimurugan 33/M Negative Normal Nil Nil  2-3  Pus Nil Nil N Nil Nil 
5 G32326 Mrs.Kadharma 29/F Negative Normal Nil Nil  2-3  Pus Nil Nil N Nil Nil 
6 H26474 Ms.Radhika 20/F Negative Normal Nil Nil  1-2  Pus Nil Nil N Nil Nil 
7 G85930 Mr.Palanivel 33/F Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
8 H17992 Mrs.Radha 35/F Negative Normal Nil Nil  1-2 Pus Nil Nil N Nil Nil 
9 H23387 Mrs.Sheelarani 33/F Negative Normal Nil Nil  1-2 Pus Nil Nil N Nil Nil 
10 H26831 Mr.Boopalan 49/M Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
11 H19563 Mrs.Dilshat 26/F Negative Normal Nil Nil  2-3 Pus Nil Nil N Nil Nil 
12 G73166 Mrs.Geethalakshmi 34/F Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
13 H24367 Mrs.Jayalakshmi 41/F Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
14 G89922 Mrs.Sumathi 46/F Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
15 H26132 Mrs.Mobina 36/F Negative Normal Nil Nil  4-6 Pus Nil Nil N Nil Nil 
16 H2011 Mr.Vignesh 21/M Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
17 H14663 Mrs.Jeyanthi 36/F Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
18 H26997 Ms.Pugalarasi 25/F Negative Normal Nil Nil  2-4 Pus Nil Nil N Nil Nil 
19 H12761 Mr.Shunmugam 33/M Negative Normal Nil Nil  1-3 Pus Nil Nil N Nil Nil 
20 G86365 Mrs.Jayalakshmi 50/F Negative Normal Nil Nil  3-5 Pus Nil Nil N Nil Nil 
LAB INVESTIGATIONS/BEFORE TREATMENT 
SNO OP/IP 
NO 
Name Age/ 
sex 
AFB XRAY Urine Motion 
      Alb Sugar Deposits BS BP URO Ova Cyst 
21 G71874 Mr.Balasubramaniyan 23/M Negative Normal Nil Nil 1-4 Pus Nil Nil N Nil Nil 
22 H27778 Mrs.Marimuthu 30/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
23 H25912 Ms.Senbagam 26/F Negative Normal Nil Nil 4-6 Pus Nil Nil N Nil Nil 
24 H11701 Mrs.Vidya 29/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
25 H13931 Mrs.Deepalakshmi 28/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
26 H11445 Mrs.Leony 39/F Negative Normal Nil Nil 4-6 Pus Nil Nil N Nil Nil 
27 G73056 Mr.Gunasekaran 37/M Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
28 H26927 Ms.Monikarani 22/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
29 H29920 Mrs.Navaneetham 46/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
30 H15114 Mr.Ramesh 30/M Negative Normal Nil Nil 3-5 Pus Nil Nil N Nil Nil 
31 H28456 Ms.Gopika 19/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
32 H574 Mr.Nagaraj 19/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
33 F74960 Mr.Seethapathy 28/M Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
34 H18109 Mr.Thiyagarajan 57/M Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
35 H25074 Mr.Navaraj 32/M Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
36 H33269 Mr.Adalarasu 20/M Negative Normal Nil Nil 3-5 Pus Nil Nil N Nil Nil 
37 H25538 Ms.Leena 35/F Negative Normal Nil Nil 6-8 Pus Nil Nil N Nil Nil 
38 H1185 Mr.Suresh 35/M Negative Normal Nil Nil 3-5 Pus Nil Nil N Nil Nil 
39 E98016 Mr.Vengai Diliban 23/M Negative Normal Nil Nil 3-5 Pus Nil Nil N Nil Nil 
40 H34343 Mrs.Yogalakshmi 21/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
 
LAB INVESTIGATIONS/AFTER TREATMENT 
SNO OP/IP 
NO 
Name Age/ 
Sex 
AFB XRAY Urine Motion 
      Alb Sugar Deposits BS BP URO Ova Cyst 
1 G92139 Mrs.Chandra 50/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
2 H17667 Ms.Keerthika 19/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
3 H7442 Mr.Kumaravel 25/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
4 H12068 Mr.Sakthimurugan 33/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
5 G32326 Mrs.Kadharma 29/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
6 H26474 Ms.Radhika 20/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
7 G85930 Mr.Palanivel 33/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
8 H17992 Mrs.Radha 35/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
9 H23387 Mrs.Sheelarani 33/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
10 H26831 Mr.Boopalan 49/M Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
11 H19563 Mrs.Dilshat 26/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
12 G73166 Mrs.Geethalakshmi 34/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
13 H24367 Mrs.Jayalakshmi 41/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
14 G89922 Mrs.Sumathi 46/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
15 H26132 Mrs.Mobina 36/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
16 H2011 Mr.Vignesh 21/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
17 H14663 Mrs.Jeyanthi 36/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
18 H26997 Ms.Pugalarasi 25/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
19 H12761 Mr.Shunmugam 33/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
20 G86365 Mrs.Jayalakshmi 50/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
  
LAB INVESTIGATIONS/AFTER TREATMENT 
SNO OP/IP 
NO 
Name Age/ 
Sex 
AFB XRAY Urine Motion 
      Alb Sugar Deposits BS BP URO Ova Cyst 
21 G71874 Mr.Balasubramaniyan 23/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
22 H27778 Mrs.Marimuthu 30/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
23 H25912 Ms.Senbagam 26/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
24 H11701 Mrs.Vidya 29/F Negative Normal Nil Nil 2-4 Pus Nil Nil N Nil Nil 
25 H13931 Mrs.Deepalakshmi 28/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
26 H11445 Mrs.Leony 39/F Negative Normal Nil Nil 1-3 Pus Nil Nil N Nil Nil 
27 G73056 Mr.Gunasekaran 37/M Negative Normal Nil Nil 1- 2 Pus Nil Nil N Nil Nil 
28 H26927 Ms.Monikarani 22/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
29 H29920 Mrs.Navaneetham 46/F Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
30 H15114 Mr.Ramesh 30/M Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
31 H28456 Ms.Gopika 19/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
32 H574 Mr.Nagaraj 19/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
33 F74960 Mr.Seethapathy 28/M Negative Normal Nil Nil 2-3 Pus Nil Nil N Nil Nil 
34 H18109 Mr.Thiyagarajan 57/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
35 H25074 Mr.Navaraj 32/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
36 H33269 Mr.Adalarasu 20/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
37 H25538 Ms.Leena 35/F Negative Normal Nil Nil 1-3 Pus Nil Nil N Nil Nil 
38 H1185 Mr.Suresh 35/M Negative Normal Nil Nil 1-3 Pus Nil Nil N Nil Nil 
39 E98016 Mr.Vengai Diliban 23/M Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
40 H34343 Mrs.Yogalakshmi 21/F Negative Normal Nil Nil 1-2 Pus Nil Nil N Nil Nil 
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DISCUSSION 
Swasa kasam is a disease characterised by cough with or without expectoration, 
irritation of throat, breath sound like hissing of snake, redness of nose, flatulence and low 
pitched voice. The signs and symptoms of Swasa kasam as per saint Yugi can be correlated 
with Bronchial asthma in Modern science. 
 The aim of the study is to document the trial drug Mantharakasa lehiyum of the Siddha 
Herbal formulation in the treatment of Swasa kasam. 
 The study protocol has been approved by Institutional Ethical Committee. (IEC approval 
number: NIS/IEC/8-14/1 -26-08-2014) 
 The required raw drugs for preparation of Mantharakasa lehiyum are authenticated by the 
Botanist NIS. The drugs were purified and medicine was prepared in Gunapadam 
laboratory of National institute of siddha. 
 The biochemical (both Qualitative and Quantitative) analysis of the trial drug 
Mantharakasa lehiyum was done in the laboratories and the results were documented. The 
physico chemical analysis also done in SCRI, Arumbakkam, Chennai.  
 The present clinical study was done as per the approved protocol and the data were 
collected by using the Screening proforma from the 80 patients. 
 Out of 80 patients, 40 were enrolled to the clinical trial, satisfying the inclusion and 
exclusion criteria. 
 A day before starting the trial drugs treatment, to normalize the three thodams by 
purgation with Mantha ennai (OPD Medicine) was given at the dose of 8ml with warm 
water at early morning in empty stomach. 
 The patients were treated for a period of 48 days with Mantharakasa lehiyum (Internal 
medicine) at the dose of 5.4 gm, twice a day after meal. 
 Diet and medical advice were given to all cases. 
 Clinical assessment was done during each visit in OPD patients (8 days once) were noted 
in the prescribed proforma. After treatment all the patients attended OPD in followup 
period. 
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The observations discussed below: 
 Sex Distribution 
Out of 40 patients, the incidence of Swasa kasam was found to be higher in 
Females (24 cases, 60%) 
 Age Distribution 
A total of 40 patients of varying age group were included in this study, the 
maximum age distribution of Swasa kasam was in 21-30 age groups 15 cases (37.5%) 
due to sedentary life style. 
 Kaalam Distribution 
Out of 40 cases, 25 cases (62.5%) were found to be affected in their Vatha 
kaalam (Between 1 - 33 years) and 15 cases (37.5%) were found to be affected in 
their Pitha kaalam (Between 34 - 66 years). 
 Occupational Distribution 
Most of the affected cases were housewives 16 cases (40%), Students 7cases 
(17.5%), Software Engineers, Painters, Clerks, Shopkeepers 2cases (5%), and 
Milkman, Textile worker, Police, Tailor, Fitter, Teacher, Driver 1 case (2.5%). 
Moreover sedentary life style adds more to this problem. 
 Distribution of cases by Duration of illness 
Out of 40 cases, 20 cases (50%) were affected in the duration of 3-6 year, 7 
cases (17.5%) were affected by the illness from1-2 years & 2-3 years, 4cases (10%) 
were affected by the illness from 6 month- 1 year and 2 cases(5%) were affected by 
the illness from 3-6 months. 
 Distribution of Habits 
All the 40 cases are non smokers, non alcohol consumers and non chewer of 
betel nut. 
 Distribution of cases by Diet 
Among 40 cases, 36 cases (90%) had taken Non-Vegetarian; remaining   4 
cases (10%) were vegetarians. As per the literature, the dietary factors that cause the 
disease are taking non-vegetarian diet and taking improperly cooked food.  
 Distribution of  cases as per Religion   
Among 40 cases, 36 cases (90%) were Hindu, 1 case (2.5%) was Christians 
and 3 cases (7.5%) were Muslims. 
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 Distribution of  cases as per Socio-Economic status  
Out of 40 cases the higher level of disease distribution was observed in middle 
socio economical groups 35 cases (87.5 %) due to sedentary life style.  
 Distribution of cases as per Treatment history 
Out of 40 cases, 27 cases (67.5%) had taken other modes of treatment in the 
past and 13 cases (32.5%) had not taken any modes of treatment prior enrolling the 
study. 
 Distribution of cases as per Triggering factors  
Among 40 cases(100%), majority of them were allergic to dust and cold, food 
additive 13 cases (32.5%), smoke exposure 11 cases (27.5%) and occupation 9 cases 
(22.5%). As per the literature Dust, Smoke exposure, Cold exposure and Excessive 
food items, lifestyles are considered to be the main predisposing factor of Swasa 
kasam. 
 Distribution of cases as per Marital history 
 Among 40 cases, 26 cases (60%) reported were married and 14 cases (40%) 
were unmarried. 
 Distribution of cases by Family History  
Among 40 cases 32 cases (80%) reported negative family history and 8 cases 
(20%) reported positive family history of Swasa kasam. It is showed that most of the 
patients had negative family history. 
 Distribution of cases by Thegi 
 Out of 40 cases, 16 cases (40%) were Vadha thegi, 9 cases (22.5%) were Pitha 
thegi and 15 Cases (37.5%) were Kaba thegi. 
 Thinai Distribution 
Among 40 cases, 33 cases (82.5%) belonged to the Neithal (i.e.sea & its 
surroundings) and 7 cases (17.5%) belonged to the Marutham (i.e. plain & its 
surroundings). 
 Paruva Kaalam Distribution 
Among 40 cases, 4 cases (10%) were admitted in Munpanikaalam (Dec 16 - 
Feb 15) and 36 cases (90%) were admitted in Pinpanikaalam (Feb16 - Apr 15). 
 Distribution of cases as per Gunam 
Out of cases, 2cases (5%) were found to posses Sathuva gunam and 38 cases 
(95%) were found to posses Rasatha gunam. 
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 Distribution of cases as per Clinical Features 
Before treatment among 40 cases, all the 40 cases (100%) had wheezing, 
difficulty in breathing, sneezing, dry or production cough, tightness of chest, 34 cases 
(84%) had hoarseness of voice and 12 cases (30%) had Sleep disturbance and 
nocturnal wheezing. 
 Derangements noted In Gnanendhiriyam 
Among 40 cases, Mookku was affected in 15 cases (37.5%) due to running 
nose and nasal block.  
 Derangements noted In Kanmendhiriyam 
Out of 40 cases, Kai was affected in 1 case (2.5%), Kaal was affected in 3 
cases (7.5%) due to pain in upper and lower limbs. Eruvai was affected in 3 cases 
(7.5%) due to constipation. 
 Derangements noted In Kosam 
Out of 40 cases, Pranamaya kosam was affected in all the patients due to 
breathlessness, cough, wheeze and tightness of chest. Annamayakosam was affected 
in 9 cases (22.5%) due to indigestion and Vingyanamayakisam was affected in 5 cases 
(12.5%). 
 Derangements noted In Vatham 
Out of 40 cases, Pranan  was affected in 40 cases (100%) due to 
breathlessness, cough, wheeze , Abanan was affected in 3 cases (7.5%) due to 
constipation,Viyanan was affected in 4 cases (10%) due to pain in lower limbs, 
Udhanan and Samanan were affected in 40 cases (100%) due to low pitched voice, 
Kirukaran was affected in 40  cases (100%) due to excessive cough reflex, excessive 
sneezing reflex and Dhevathathan was affected in 40 cases (100%) due to tiredness.         
 Derangements noted In Pitham  
Sadhaga pitham was affected in all 40 cases (100%) and Ranjagapitham was 
affected in 6cases (15%). 
 Derangements noted In Kabam 
Avalambagam was affected in all the 40 cases (100%) due to the presence of 
tightness of chest, cough, wheezing and breathlessness. Kilethagam was affected in 9 
cases (22.5%) due to loss of appetite. Sandhigam was affected in 4 cases (10%) due to 
joints pain. 
 
135 
 
 
 Derangements  Noted In Ezhu udal kattugal 
Saram was affected in all cases (100%), Seneer was affected in 6cases (15%). 
Enbu was affected in 4 cases (10%) due to joint pain. 
 Derangements noted  In Ennnvagai thervugal 
Mozhi was affected in all 40 cases (100%) due to low pitched voice and 
difficulty in speech, Malam was affected in 3 cases (7.5%) due to constipation. 
 Distribution of cases by Naadi 
In Naadi, 20 cases (50%) had vadha pitha naadi, 13 cases (32.5%) had pitha 
vatha naadi and 7 cases (17.5%) had kaba pitha naadi.  
 Distribution of cases by Neikuri 
Among 40 patients, 15 cases (37.5%) had Vadha neer, 7 cases (17.5%) had 
Pitha neer and 18 cases (45%) had kapha neer.  
 Laboratory Investigations  
Routine investigations of blood and urine were done before and after treatment 
in every case. Sputum examination for AFB was found to be negative for all the 
patients. 
Before treatment blood investigations of patients showed Eosinophils count 
was increased, its ranged from 4- 18% cells and after treatment its ranged from 3-8%. 
ESR (Erythrocyte Sedimentation Rate), Serum IgE and AEC (Absolute esinophil 
count) were raised in before treatment and the after treatment it was moderately 
reduced. Out of 40 cases, in 14 cases (35%) Serum IgE level was reduced well, in 18 
cases (45%) serum IgE level was moderately reduced, in 8 cases (20%) serum IgE 
level was slightly redeced. 
  Other hematological parameters were normal in before treatment and after 
treatment.Biochemical parameters were found to be normal range in before and after 
treatment.  
 Radiological Examination 
Before treatment, chest X-ray PA view showed no abnormal findings observed 
in 100% of the 40 cases.  
 Special Investigation 
Among the 24 Female (60%) patients the peak expiratory flow rate ranged 
from 120 lit/min to 180 lit/min before treatment and after treatment it ranged from 
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220 lit/min to 410 lit/min. Among the 16 Male (40%) patients the peak expiratory 
flow rate ranged from 180 lit/min to 230 lit/min before treatment and after treatment it 
ranged from 340 lit/min to 500 lit/min. 
 Primary Outcome 
As per objective parameters (PEFR) 
After treatment, Out of 40 cases, 25 cases (62.5%) showed good improvement 
and completely relieved from wheezing, 11 cases (27.5%) showed moderately 
improvement, 4 cases (10%) showed mild improvement. 
 Secondary Outcome  
As per subjective parameters (Clinical symptoms) 
After treatment, Out of 40 cases, 82.5% cases relieved from cough, 77.5% 
cases were relieved from sneezing, and 97.5% cases were relieved from Hoarseness of 
voice. 
 Gradation of results 
Out of 40 cases, Clinical results were found to be good in 75% of cases, Fair 
results were found in 17.5% of cases and Poor results were found in 7.5% of cases. 
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SUMMARY 
 The aim of the study is to evaluate the therapeutic efficacy of trial drug Mantharakasa 
lehiyum (Internal medicine) in the management of Swasa kasam (Bronchial asthma).  
 The study protocol has been approved by Institutional ethical committee. (IEC 
approval number: NIS/IEC/8-14/1 -26-08-2014) 
 The raw drugs were authenticated by concerned department and the medicine was 
prepared in the Gunapadam laboratory of National Institute of Siddha. 
 Biochemical analysis (Qualitative analysis) was done in the Biochemistry lab of NIS 
and Physico chemical analysis and HPTLC were done at SCRI, Arumbakkam, 
Chennai.  
 For the clinical study, 40 cases were selected based on the inclusion and exclusion 
criteria and treated in OPD of Ayothidoss pandithar hospital of NIS, Chennai. 
 A day before starting the trial drug treatment, purgation was given to correct the 
elevated mukkutram. 
 The clinical trial was conducted in 40 patients of Swasa kasam with the trial drug 
Mantharakasa lehiyum (Internal medicine) at the dose of 5.4gm twice a day after 
food. During the study period, there were no adverse reactions. 
 The trial drug was found to play the major role to correct the deranged three humours, 
thereby correcting Pranan, Abanan, Udhanan, Kirugaran, Devathathan, Pitham such 
as Anal Pitham, Ranjagam and the vitiated kabam is restored to the normal. 
 Blood and urine Investigations were carried out before and after treatment and data 
were recorded in the proforma. 
 Radiological investigations (Chest X-ray PA view) and ECG were also done before 
treatment. 
 Clinical assessments Progress were done once in 8 days for OPD patients. 
 As per objective parameters (PEFR) Out of 40 cases, 25(62.5%) cases showed 
clinically good improvement, 11cases (27.5%) showed moderately improvement, 4 
cases (10%) showed mild improvement. 
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 Out of 40 cases, Clinical results were found to be good in 75% of cases, Fair results 
were found in 17.5% of cases and Poor results were found in 7.5% of cases. 
 This ensures the safety usuage of the drug as per the literature. 
 Biochemical study 
Qualitative analysis of Mantharakasa lehiyum reveals that the trial medicine 
contains the following: 
 Chloride 
 Phosphate 
 Iron 
 Sodium 
 Starch 
 Reducing sugar 
 Alkaloids 
 Tannic acid 
 Unsaturated compounds 
 Physicochemical analysis 
S.NO PARAMATERS VALUES 
1. Loss on drying at 105
0
 C 17.58% 
2. Total ash 3.233% 
3. Water soluble ash 1.996% 
4. Acid soluble ash 0.054% 
5. Water soluble extractives 47.482% 
6. Alcohol soluble extractives 57.550% 
7. Fat content 4.350% 
8. Total solid content 82.42% 
9. pH 6.7 
10. Reducing sugar 7.83% 
11. Total sugar 47.81% 
 
 HPTLC Report 
                      HPTLC fingerprint at 254nmUV showed highest peak in 7
th
 peak (0.32Rf, 
21.16%Area) which could serve as a marker and it is responsible for biological action. 
              HPTLC fingerprint at 366nmUV showed highest peak in 7
th
 peak (0.34Rf, 
30.43%Area) which could serve as a marker and it is responsible for biological action. 
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CONCLUSION 
 As per objective parameters (PEFR) Out of 40 cases, 25 cases (62.5%) showed clinically 
good improvement, 11cases (27.5%) showed moderately improvement, 4 cases (10%) 
showed mild improvement. 
 Out of 40 cases, Clinical results were found to be good in 75% of cases, Fair results were 
found in 17.5% of cases and Poor results were found in 7.5% of cases  
 The results of the clinical trial indicate that the trial drug is clinically effective in 
Bronchial asthma. No adverse effects were reported during the course of treatment.  
 The method of preparation is simple, cost is comparatively economical and the medicine 
is one of the complete herbal medicine. 
 No recurrence of episodes in the follow up of period of 60 days. 
 Phytochemical analysis should presence of Alkaloids which is responsible for its 
therapeutic action. 
 Physicochemical values are within the limits. 
 HPTLC fingerprint could serve as a marker. 
 The trial drug gives good results clinically, so the study may be undertaken with same 
medicine in a large number of cases and it may throw new lights for the treatment of 
Swasa kasam. 
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NATIONAL INSTITUTE OF SIDDHA,                                                                                                                           
AYOTHIDASS PANDITHAR HOSPITAL,                                                                                                            
DEPARTMENT OF MARUTHUVAM,                                                                                                                                        
AN OPEN CLINICAL STUDY ON  SWASA KASAM (BRONCHIAL ASTHMA)                                                            
AND THE DRUG OF CHOICE IS “MANTHARAKASA LEHIYUM” (INTERNAL) 
FORM I- SCREENING AND SELECTION PROFORMA 
1. O.P No ________________   2.IP.NO: _______________3. S. No___________ 
4. Name: _________________ 5. Age:  _____ 6. Gender: M/F 7. Occupation 
_____________  
8. Phone number _____________ 
9.Address___________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
________ 
10. INCLUSION CRITERIA                                                                    Yes       No                                                
 Age : 19- 60 Yrs 
 Sex – Both Male and Female 
 
 The symptoms of, cough, wheezing, Difficulty in breathing etc PEFR 
 below normal range (From 150 L/min to 250 L/min for men; from  
100 L/min to 200 L/min for women).                     
 H/O allergy  
 Patient willing to sign the informed consent stating that   he/she will  
Conscientiously stick to the treatment during 48 days but can opt out  
of the trial of his/her own conscious discretion. 
  Patients who are willing to subject themselves to take X Ray of Chest  
(PA view) ECG, PEFR, as well as to Undergo routine lab investigation. 
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1. EXCLUSION CRITERIA  
 
 Yes No  Yes    No 
1.   Cardiac disease   .7. Hyper tension   
2.   Renal disease    8. Pregnancy   
3. Tuberculosis.    9. Lactation.   
4. COPD.    10. Psychological factor. 
 
  
5. Status asthmaticus   11. Worm infestation. 
 
  
6. Diabetes mellitus      
             
10. PEFR (Peak Expiratory Flow Rate) [L/min] –  
 
11. ADMITTED TO TRAIL:           YES                   NO                   If Yes Serial NO:  ---- 
 
 
Date:                                                                               Signature of the Investigator: 
Station:                                                                           Signature of the Lecturer:  
                                                                                           Signature of the HOD: 
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NATIONAL INSTITUTE OF SIDDHA,                                                                                                                           
AYOTHIDASS PANDITHAR HOSPITAL,                                                                                                            
DEPARTMENT OF MARUTHUVAM,                                                                                                                                        
AN OPEN CLINICAL STUDY ON  SWASA KASAM (BRONCHIAL ASTHMA)                                                            
AND THE DRUG OF CHOICE IS “MANTHARAKASA LEHIYUM” (INTERNAL)                                                                
FORM II-CASE RECORD FORM 
1 O.P NO ______________    2. IP.NO: ___________3.  S. NO _________ 
4. NAME_________________.5.AGE ____ .6. GENDER:  Male/Female  
7. OCCUPATION __________________________ 
8.ADDRESS________________________________________________________________
___________________________________________________________________________
______ 
9. EDUCATIONAL STATUS:   A) Illiterate               B) Literate          
10. HEIGHT ______   cms                11.WEIGHT:   ------- kg 
 
12. COMPLIANTS AND DURATION: 
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
_________ 
 
 13. HABITS OF                        Yes      No 
 
    A) Smoking                                                               ………………………………………                    
                                                                  
    B) Alcoholism                                                           ………………………………………             
   
    C) Tobacco chewing                                                  .…………………………………….     
                                                                          
    D) Betel nut chewing                                                ………………………………………      
                                
14. DIETARY STYLE:  Vegetarian              Non  vegetarian 
 
15. SOCIOECONOMIC STATUS: Lower             Middle          Upper 
   
16. DRUG HISTORY: Had the patient been treated before with allopathic drug? Yes       No 
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17. WHEEZING TRIGGER FACTORS: 
 
Dust Yes/No Food additive Yes/No 
Smoke exposure  Yes/No Fumes of paints and 
petrol. 
Yes/No 
Cold exposure Yes/No Detergents Yes/No 
Exercise Yes/No Chemicals Yes/No 
Emotion Yes/No Husks, Grass, Pollans. Yes/No 
Occupation Yes/No Menstruation Yes/No 
Others  
 
18. MARITAL STATUS    1.Married      2.Unmarried  
   
No of children:                                Male                 Female 
 
19. FAMILY HISTORY:  Whether this problem runs in family?  1. Yes            2.No   
  
 If yes, mention the relationship of affected person(s) 
__________________________________ 
 
20. MENSTRUAL HISTORY:    Regular           Irregular              Menopause       
 
21. BOWEL HABITS & MICTURITION:  Normal            
 
            History of habitual constipation   1.Yes                 2.No                                                       
 
            History of frequent diarrhoea      1.Yes                 2.No                                                         
 
            History of frequent dysuria         1.Yes                 2.No                
 
22. PSYCOLOGICAL STATE:  Normal         Anxiety       Depression    
  
23. SIDDHA SYSTEM OF EXAMINATION: ENVAGAI THERVU: [EIGHT-FOLD 
EXAMINATION] 
I.NAADI: [PULSE PERCEPTION] 
 0
th
 day 8
th
 day              16
th
  day                24
th
day         32
nd 
day 40
th
 day 48
th
 day 
Vali        
Azhal        
Iyyam         
Vali Azhal        
Azhal vali        
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Iyya vali        
Vali Iyyam        
Azhal 
Iyyam 
       
Iyya Azhal        
 
II.NAA:[TONGUE] 
 0
th
 day 8
th
 day              16
th
  day                24
th
 day         32
nd
 day 40
th
 day 48
th
 day 
Colour Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Re
d 
pale/yellow 
Taste Sweet/Sour/ 
Pungent/ 
Bitter/ None 
Sweet/Sour/ 
Pungent/  
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/None 
Sweet/Sour/ 
Pungent/ 
Bitter/ None 
Sweet/Sour/ 
Pungent/ 
Bitter/ None 
Sweet/Sour
/ Pungent/ 
Bitter/ 
None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/    
Increased      
/ Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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III.NIRAM: [COMPLEXION]    
0
th
 day 8th day 16th day 24th day   32
nd
 day 40
th
 day  48
th
 day 
Dark/pale/  
Yellow 
tinted/whitish 
brown 
Dark/pale/ 
Yellow 
tinted/whitish 
brown 
Dark/pale/ 
Yellow 
tinted/whitish 
brown 
Dark/pale/ 
Yellow 
tinted/whitish 
brown 
Dark/pale/ 
Yellow 
tinted/whitish 
brown 
Dark/pale/ 
Yellow 
tinted/whitish 
brown 
Dark/pale/ 
Yellow 
tinted/whitish 
brown 
 
IV.MOZHI: [VOICE] 
0
th
 day 8th day 16th day 24th day  32
nd
 day 40
th
 day 48
th
 day 
Medium/High
/Low pitched 
Medium/High 
/Low pitched 
Medium/High 
/Low pitched 
Medium/High 
/Low pitched 
Medium/High/ 
Low pitched 
Medium/High 
/Low pitched 
Medium/High  
/ Low pitched 
 
V.VIZHI: [EYES] (Lower palpebral conjunctiva)     
0
th
 day 8th day 16th day 24th day  32
nd
 day 40
th
 day 48
th
 day 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
Normal/Red 
pale/yellow 
 
VI. MALAM: [BOWEL HABITS / STOOLS] 
 0
th
 day   8th day 16
th
 day 24th day  32
nd
 day 40
th
 day 48
th
 day 
Colour Dark/pale/ 
yellow/Re
d 
Dark/pale/ 
yellow/ Red 
Dark/pale/ 
Yellow/ 
Red 
Dark/pale/ 
yellow/ 
Red 
Dark/pale/ 
yellow/ Red 
Dark/pale/ 
yellow/Red 
Dark/pale/ 
yellow/ Red 
Consistency Solid/Sem
i solid/ 
Watery 
Solid/Semi 
solid/ 
Watery 
Solid/Semi 
solid/ 
Watery 
Solid/Semi 
solid/ 
Watery 
Solid/Semi 
solid/ 
Watery 
Solid/Semi
solid/ 
Watery 
Solid/Semi 
solid/ 
Watery 
Stool  bulk                          Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation   Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Diarrhea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/Ab
sent 
Present/ 
Absent 
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VII.MOOTHIRAM: [URINE EXAMINATION]     
Neerkkuri 0
th
 day   8th day  16th day  24
th
 day  32
nd
 day 40
th
 day 48
th
 day 
Niram 
[Colour]   
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/Red/ 
White/Straw 
coloured/ 
Crystal clear 
Yellow/ 
Red/ 
White/Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ 
White/ 
Straw 
coloured/ 
Crystal 
clear 
Yellow/ 
Red/ White/ 
Straw 
coloured/ 
Crystal 
clear 
Manam 
[Odour] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Nurai 
[Froth] 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/Reduced
/ Increased 
Nil/Reduced
/ Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Nil/ 
Reduced/ 
Increased 
Edai [Sp. 
gravity]                                
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/  
Reduced  
Normal/ 
Increased/ 
Reduced  
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Enjal 
[Deposits] 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Volume   
Normal/ 
Increasd/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
Normal/ 
Increased/ 
Reduced 
 
Neikkuri  0
th
 day 8th day 16th day 24th day  32
nd
 day 40
th
 day 48
th
  day 
Serpentine fashion at__ mins at__mins at__mins at__mins at__mins at__mins at__mins 
Annular/Ringed fashion at__mins at__ mins at__mins at__mins at__mins at__mins at__mins 
Pearl beaded fashion    at__ mins at__mins at__mins at__mins at__ mins at__mins at__ mins 
Mixed fashion at__mins at__mins at__mins at__ mins at__mins at__mins at__ mins 
Other fashion at__ mins at__mins  at__mins at__mins at__mins at__ mins at__mins 
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VIII. SPARISAM: [PALPATORY PERCEPTION] 
0
th
 day 8th day 16th day 24th day  32
nd
 day 40
th
 day 48
th
 day 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
Warmth/Hot/ 
cold/ Sweat 
 
THEGI: [TYPE OF BODY CONSTITUTION]    
Vatham predominant  Kabam predominant  
Pitham predominant  Thondha udal  
 
 NILAM: [LAND WHERE PATIENT LIVED MOST] 
 
 Kurinji                            Mullai               Marutham              Neithal                        Palai 
 
(Hilly terrain)            (Forest range)           (Plains)               (Coastal belt)              (Arid 
regions)  
  
 KAALAM:    Kaarkalam             Koothirkalam              Munpanikalam                          
 
             Pinpanikalam          Ilavenil                          Mudhuvenil 
 
 
GUNAM:       Thamasam               Sathuvam           Rasatham                                             
 
IYMPORIGAL: [SENSORY ORGANS] 
 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/  
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/  
Affected 
Normal/  
Affected 
Normal/ 
Affected 
Normal/    
Affected 
Mei [Skin]        
Vaai(Buccal 
cavity) 
       
Kan (Eyes)                
Mooku (Nose)               
Sevi [ear]               
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IYMPULANGAL: [MOTOR ORGANS] 
 0
th
 day 8
th
 day 16
th
 day 24
th
 day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Kai (Upperlimb)        
Kal (Lowerlimb)        
Vai[Buccal cavity]        
Eruvai 
[excretoryorgan] 
       
Karuvai 
[Reproductiveorgan] 
       
 
KOSAM:[SHEATHS] 
 0
th
 day 8th day 16th 
day 
24th day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Annamaya kosam        
PranamayaKosam        
Manonmayakosam        
Vinanamaya kosam        
Ananthamaya 
kosam 
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A) VATHAM:                                                                          
 0
th
 day 8th day 16
th
 day 24
th
 day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/  
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Praanan        
Abaanan         
Samaanan        
Udhaanan        
Viyaanan        
Naahan        
Koorman        
Kirukaran        
Devathathan        
Dhananjeyan        
 
B) PITHAM:               
 0
th
 day 8th day 16th 
day 
24th day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Analapithm        
 Prasakam        
Ranjakam        
Aalosakam        
Saathakam        
 
 
 
150 
 
C) KABAM:            
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Avalambagam        
Kilethagam        
Pothagam        
Tharpagam         
Santhigam        
 
SEVEN DHATHUS: [SEVEN SOMATIC COMPONENTS]                                         
 0
th
 day 8th day 16th day 24th day  32
nd
 day 40
th
 day 48
th
 day 
 Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Normal/ 
Affected 
Saaram [chyme]        
Senneer [Blood]         
Oon [Muscle]        
Kozhuppu [Fat]        
Enbu [Bones]        
Moolai [Bone 
marrow] 
       
Sukkilam/ 
Suronitham  
[Genital 
discharges] 
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SYSTEMIC EXAMINATION: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 48
th
 day 
Cardiovascular System         
Respiratory  System          
Gastrointestinal System        
Central Nervous System        
Endocrine System        
 
GENERAL EXAMINATION: 
 0
th
 day 8th day 16th day 24th day 32
nd
 day 40
th
 day 48
th
 day 
Height (cms)        
Weight (kg)        
Temperature(°F)           
Pulse rate (per min)        
Heart rate (per min)        
Respiratory rate (per 
min) 
       
Blood pressure 
(mm/Hg) 
       
Pallor        
Jaundice        
Cyanosis        
Lymphadenopathy        
Pedal edema        
Clubbing        
Jugular vein pulsation        
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SYSTEMIC EXAMINATION: RESPIRATORY SYSTEM 
 
I.INSPECTION: 
 0
th
 day 48
th
 day 
Trachea   
Drooping of shoulder   
Form of chest   
Apical impulse    
Intercostal Muscle Wasting 
 
  
Intercostal bulging   
Respiratory movement   
Measurements:              
  AP         -          Transverse     - 
  
  
II. PALPATION: 
 0
th
 day 48
th
 day 
Tracheal position ( trial‟s sign )  
 
  
Apical impulse 
 
  
Respiratory Movements   
Tactile vocal fremitus   
   
III. PERCUSSION: 
 0
th
 day 48
th
 day 
Normal /Dullness/ hyper-resonance   
 
IV. AUSCULTATION:             
 0
th
 day 48
th
 day 
Character of  Breath Sound   
Foreign Sounds   
Vocal Resonance   
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V. SPUTUM: 
 0
th
 day 8
th
 day 16
th
 day 24
th 
day 32
nd
 day 40
th
 day 48
th
 day 
Colour White/ 
Green/ 
Yellow/red 
White/  
Green / 
Yellow/red 
White/ Green/ 
Yellow/Red 
White/ Green 
/ Yellow/red 
White/ 
Green / 
Yellow/red 
White/ 
Green/ 
Yellow/red 
White/   
Green/ 
Yellow/red 
Amount Less/More Less/more Less/More Less/More Less/More Less/More Less/More 
Consistency Mucoid/ 
Purulent 
/Frothy 
Mucoid/ 
Purulent 
/Frothy 
Mucoid/ 
Purulent/ 
Frothy 
Mucoid/ 
Purulent/ 
Frothy 
Mucoid/ 
Purulent/ 
Frothy 
Mucoid/ 
Purulent/ 
Frothy 
Mucoid/ 
Purulent 
/Frothy 
Odour Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No Yes/No 
 
OTHER SYSTEMIC EXAMINATIONS:  
      
 0
th
 day 8
th
 day 16
th
 day 24
th 
day 32
nd
 day 40
th
 day 48
th
 day 
Cardio vascular system        
Alimentary system        
Central Nervous system        
Loco motor system        
Genito-Urinary system        
Endocrine system        
 
CLINICAL SYMPTOMS: 
 
 0
th
 day 8
th
 day 16
th
 day 24
th
 day 32
nd
 day 40
th
 day 48th day 
Difficulty in breathing        
Tightness of chest        
Wheeze - Added sound  
(Rhonchi) 
       
Dry (or) productive cough        
Sneezing        
Hoarseness of voice 
 
       
Sleep disturbance        
Nocturnal wheezing        
Associated symptoms        
 
 
Date: 
      
Station:     Signature of the Investigator: 
                                                                                  
                                                                                      Signature of the Lecturer:                                                                       
  
                                                                                   Signature of the HOD: 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI- 47 
AYOTHIDASS PANDITHAR HOSPITAL,  
DEPARTMENT OF MARUTHUVAM,  
AN OPEN CLINICAL STUDY ON  SWASA KASAM (BRONCHIAL ASTHMA) 
 AND THE DRUG OF CHOICE IS “MANTHARAKASA LEHIYUM” (INTERNAL) 
FORM III -   LABORATORY PARAMETERS-CHART 
1.  O.P NO ________ 2. IP.NO: ______ 3.  S. NO ________ 4. LAB.NO_________ 
 
4. NAME________________________ 5.AGE ____.   6. GENDER:  Male/Female 
 
 
 
BLOOD INVESTIGATION BEFORE 
TMT 
Date: 
AFTER TMT 
Date: 
NORMAL VALUES 
HBV (gms %)   Men- 12.0-17.0;   Women – 11.0-16 
T.RBC(milli/cu.mm)   Men-4.4-5.7;  Women-3.8-5.0 
 
ESR (mm) 
½ hr.   
Men-1-13 ; Women-1-20 
1 hr.   
T.WBC (cu.mm)   Men:4000-11000;  Women:4000-
11000 
 
DIFFERENTIAL COUNT 
(%) 
Polymorphs   40-75% 
Lymphocytes   20-40% 
Monocytes   2-10% 
Eosinophils   1-6% 
Basophils   0-1% 
Blood glucose (mg/dl) Fasting   70-110 mg/dl 
  PP   80-140 mg/dl 
 Random   80-120 mg/dl 
Lipid profile (mg/dl) Serum cholesterol   150-225 mg/dl 
 HDL   30-63 mg/dl 
 LDL   < 130  mg/dl 
 VLDL    < 40 mg/dl 
 TGL   <160 mg/dl 
 RFT (mg/dl) Blood Urea   16-50 mg/dl 
 Serum Creatinine   0.6-1.2 mg/dl 
 Uric acid   Men-3-9 mg/dl; Women-2.5-7.5 
mg/dl 
LFT (mg/dl) Total bilirubin   0.2-1.2 
 Direct bilirubin   0.1-0-4 
 Indirect bilirubin   0.2-0.7 
 SGOT (IU/L)   0-40 
 SGPT (IU/L)   0-35 
 Alkaline 
phosphatase(IU/L) 
  80-290 (IU/L) 
Serum total protein   6-8 
Serum Albumin   3.5-5.0 
Serum globulin   2.3-3.5 
Serum calcium   8.5-10.5 
Serum phosphorous   3.0-4.5 
Peak Expiratory Flow Rate (Lit / min)   Male : Adult 400-650: 
above 40yr 300-500 
Female : Adult 250-450: 
above 40yr 200-400 
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AFB: 
   
Radiological investigation- Chest X-ray PA View: 
 
ECG:                                                                                          Signature of the Investigator: 
   
Date:                                                                                          Signature of the Lecture: 
    
Station:                                                                                      Signature of the HOD: 
 
 
 
 
                                
 
 
 
Urine investigation 
Before TMT 
Date: 
After TMT  
Date: 
Neer Kuri   
Niram   
Manam   
Nurai   
Edai   
Enjai   
Neikuri   
Albumin   
Fasting sugar   
PP sugar   
Random Sugar   
Deposits   
Bile salt   
Bile pigments   
Urobilinogen   
MOTION TEST Before TMT 
Date:  
After TMT 
Date: 
Ova   
Cyst   
Occult blood   
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       §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ,  
«§ய¡ò¾¢¾¡…÷ பñÊ¾÷ ÁÕòÐÅÁ¨É,¦சý¨É-47, 
Àð¼§ÁüÀÊôÒ ÁÕòÐÅòÐ¨È. 
IV - ´ôÒ¾ø ÀÊÅõ 
 
   ¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð 
                 ¿¡ý þó¾ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌ  ÒÃ¢Ôõ 
Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
 §¾¾¢ :                                          ¨¸¦Â¡ôÀõ: 
 þ¼õ:                                               ¦ÀÂ÷     : 
 
                                          §¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø 
 
                ±ýÉ¢¼õ þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ 
ÁÕòÐÅ ÅÆ¢Ó¨Èô ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ ¸ñ¸¡½¢ì¸×õ, 
«¾¨É À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢ 
«Ç¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢ûì¸¢ì ÜÈôÀð¼Ð.       
               ¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ 
§ÅñÎÁ¡É¡Öõ þó¾ ¬öÅ¢Ä¢ÕóÐ ±ý¨É Å¢ÎÅ¢òÐ ¦¸¡ûÙõ ¯Ã¢¨Á¨Â 
¦¾Ã¢ó¾¢Õì¸¢ý§Èý. 
               ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ ¯Ã¢¨Á¨Âì ¦¸¡ñÎ ÍÅ¡º 
¸¡ºõ §¿¡öì¸¡É Áó¾¡Ã ¸¡º §Ä¸¢Âõ ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ 
ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø «Ç¢ì¸¢§Èý. 
 
  §¾¾¢:                                            ¨¸¦Â¡ôÀõ: 
  þ¼õ:                                            ¦ÀÂ÷     : 
 
 
  §¾¾¢:                               º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ: 
  þ¼õ:                                       ¦ÀÂ÷                : 
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI -47 
AYOTHIDASS PANDITHAR HOSPITAL 
DEPARTMENT OF MARUTHUVAM 
AN OPEN CLINICAL STUDY ON   SWASA KASAM (BRONCHIAL ASTHMA) AND 
DRUG OF CHOICE IS “MANTHARA KASA LEHIYUM” (INTERNAL). 
FORM IV – INFORMED CONSENT FORM 
Certificate by Investigator 
 
     I certify that I have disclosed all details about the study in the terms readily understood by 
the patient. 
 
Date:         Signature: 
                                                                            Name:      
              
Consent by Patient 
    I have been informed to my satisfaction, by the attending physician, the purpose of 
the clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
    I am aware of my right to opt out of the trial at any time during the course of the 
trial without having to give the reasons for doing so. 
      I, exercising my free power of choice, hereby give my consent to be included .As a 
subject in the clinical trial of Manthara kasa lehiyum for the management of Swasakasam 
(Bronchial Asthma)  
 
Date:                           Patient Signature: 
                                                              Patient Name:  
 
Date:               Signature of Witness:  
                                                                           Name:  
                                                                    Relationship:                                        
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ, ¦ºý¨É 47 
«§Â¡ò¾¢¾¡º÷ ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
ÍÅ¡º¸¡ºõ §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý (Áó¾¡Ã ¸¡º §Ä¸¢Âõ) ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì 
¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ. 
FORM IVA ¾¸Åø ÀÊÅõ 
Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷ :  Dr. À.ÓòÐ¦ºøÅ¢ 
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷            :  §¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
                               ¾¡õÀÃõ º¡Éð§¼¡Ã¢Âõ, ¦ºý¨É 47 
Dr. À.ÓòÐ¦ºøÅ¢ ¬¸¢Â ¿¡ý §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø Àð¼ §ÁüÀÊôÒ 
ÀÂ¢ýÚ ÅÕ¸¢§Èý. ÍÅ¡º¸¡ºõ ±ýÛõ §¿¡Â¡ÉÐ ãì¸¢ø ¦ÅÇ¢Â¡Ìõ ¸¡üÚ «Éø 
Å£ÍÅÐ §À¡Äò §¾¡ýÈ¢, ¦¾¡ñ¨¼ ¸ðÊ,ãîÍ,Á¡÷À¢ø §¸¡¨Æ¸ðÊ þÕÁ¦ÄØõ 
§¿¡ö.  þó§¿¡öìÌ §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø ÀÄ º¢ò¾ ÁÕóÐ¸û 
ÀÂýÀÎò¾ôÀðÎ ÅÕ¸¢ýÈÐ. º¢ò¾ ÁÕòÐÅ Àð¼ §ÁüÀÊôÀ¢ø, ¬öÅ¢ý ´Õ 
ÀÌ¾¢Â¡¸ Ò¾¢Â ÁÕóÐ¸¨Ç ÀÂýÀÎòÐõ §¿¡ì¸¢ø þó§¿¡öìÌ Áó¾¡Ã ¸¡º 
§Ä¸¢Âõ ÅÆí¸ ÀÃ¢óÐ¨Ã ¦ºö¸¢§È¡õ. þó¾ ÁÕó¾¢ý ¦ºöÓ¨È, «Ç×, «ÛÀ¡Éõ 
ÁüÚõ ÁÕòÐÅ ÀÂý¸û «¨ÉòÐõ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾ ÁÕòÐÅ áÄ¢ø 
ÜÈôÀðÎûÇÐ. ±ó¾Å¢¾ ¸ð¼½ÓÁ¢ýÈ¢ ¾¡í¸û þó¾ ÁÕó¾¢¨É 
¦ÀüÚì¦¸¡ûÇÄ¡õ. þó¾ ¬öÅ¢ø ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 48¿¡ð¸û ¬Ìõ. 
Å¡Ãõ ´ÕÓ¨È §¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨ÉìÌ §¿Ã¢ø ÅóÐ 8¿¡ð¸Ùì¸¡É 
ÁÕó¾¢¨É ¦ÀüÚì¦¸¡ûÇ §ÅñÎõ. þó¾ ¬ö× ºõÀó¾Á¡É ¬öÅ¸ 
ÀÃ¢§º¡¾¨É¸û ¸ð¼½Á¢ýÈ¢ ¦ºöÂôÀÎõ. 48 ¿¡ð¸û ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äõ 
ÓÊó¾ À¢ÈÌ §¿¡öì¸¡É ÌÈ¢Ì½í¸û ÁüÚõ ¬öÅ¸ ÀÃ¢§º¡¾¨É¸û þÅüÈ¢ý 
ÓÊ×¸Ç¢ý «ÊôÀ¨¼Â¢ø ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢Èý ¸ñ¼È¢ÂôÀÎõ.  
   þó¾ ¬ö× ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Ç ¾í¸Ç¢¼õ §¸ð¸ þÕì¸¢§Èý. 
¾í¸Ç¢¼Á¢ÕóÐ ¦ÀÈôÀÎõ ¸ÕòÐì¸û ÁüÚõ ÌÈ¢ôÒ¸û «¨ÉòÐõ ¿õÀ¢ì¨¸Â¡¸ 
À¾¢× ¦ºöÂôÀÎõ.þó¾ ¬öÅ¢ø ¾í¸¨Ç ¯ðÀÎò¾¢ì¦¸¡ûÅ¾¢ý ãÄõ ±ó¾ 
Å¨¸Â¢Öõ À¡¾¢ôÒìÌûÇ¡¸ Á¡ðË÷¸û ±É ¯Ú¾¢ «Ç¢ì¸¢§Èý. 
     ±ó¾Å¢¾ ÅüÒÚò¾ÖÁ¢ýÈ¢, þó¾ ¬öÅ¢ø Àí§¸ü¸×õ, þó¾ ¬ö× ºõÀó¾Á¡¸ 
§¸ð¸ôÀÎõ §¸ûÅ¢¸ÙìÌ À¾¢ø ÜÈ×õ ¾í¸ÙìÌ ÓØ Í¾ó¾¢Ãõ «Ç¢ì¸ôÀÎ¸¢ÈÐ. 
þó¾ ¬öÅ¢ø Àí§¸üÀ¾üÌ ±ó¾ ºýÁ¡ÉÓõ ÅÆí¸ôÀ¼Á¡ð¼¡Ð.  ¬É¡ø, ¬ö× 
ÓØÅÐõ ±ÉÐ §ÁüÀ¡÷¨ÅÂ¢Öõ, ¾í¸û ¯¼ø¿Äý ÌÈ¢ò¾ ¾É¢ ¸ÅÉò¾¢Öõ ¬ö× 
§Áü¦¸¡ûÇôÀÎõ.ÍÅ¡º¸¡ºõ §¿¡öì¸¡É Ò¾¢Â ÁÕó¾¢ý ÀÃ¢¸Ã¢ôÒò¾¢È¨É 
ºã¸ò¾¢üÌ ¯½÷òÐõ Å¨¸Â¢ø þó¾ ¬ö× §Áü¦¸¡ûÇôÀÎ¸¢ÈÐ. þó¾ ¬öÅ¢ø, 
ÁÕóÐ ¯ð¦¸¡ûÙõ ¸¡Äò¾¢ø º¢ÄÕìÌ Á¡ÚÀð¼ ÌÈ¢Ì½í¸û ¦¾¡¼÷óÐ 
þÕìÌõ Àðºò¾¢ø, Ó¾ý¨Á ¬Ã¡öîº¢Â¡ÇÃ¡É ±ýÉ¢¼õ ¦¾Ã¢Å¢ì¸ôÀðÎ, §¾º¢Â 
º¢ò¾ ÁÕòÐÅÁ¨ÉÂ¢ø «¾üì¸¡É ¾£÷× ÅÆí¸ôÀÎõ. þó¾ ¬öÅ¢¨Éò ¦¾¡¼Ã 
¾í¸ÙìÌ Å¢ÕôÀõ þø¨Ä¦ÂÉ¢ø, ±ô¦À¡ØÐ §ÅñÎÁ¡ÉÖõ ¬öÅ¢ý þ¨¼Â¢ø 
Å¢Ä¸¢ì¦¸¡ûÇ×õ, ÁÕòÐÅÁ¨ÉÂ¢ø ÅÆí¸ôÀÎõ þó§¿¡öì¸¡É ÅÆì¸Á¡É 
ÁÕóÐ¸¨Ç ¦ÀüÚì¦¸¡ûÇ×õ «È¢×Úò¾ôÀÎ¸¢È£÷¸û. 
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       þó¾ ¬öÅ¢ø §º¸Ã¢ì¸ôÀÎõ Å¢ÀÃí¸û «¨ÉòÐõ ¾í¸ÙìÌõ Ó¾ý¨Á 
¬Ã¡öîº¢Â¡ÇÃ¡É ±ÉìÌõ þ¨¼Â¢ø þÃ¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ. §¸ûÅ¢ À¾¢ø 
ÅÊÅò¾¢ø ¾í¸Ç¢¼õ §¸ûÅ¢¸û §¸ð¸ôÀÎõ. «¨ÉòÐô ÀÊÅí¸Ç¢Öõ ¾í¸Ç¢ý 
¦ÀÂ÷ ¾Å¢÷ì¸ôÀðÎ ¬öÅ¡ÇÃ¡ø ¾í¸Ùì¦¸É ¾É¢ì ÌÈ¢Â£Î ÅÆí¸ôÀÎõ. «ó¾ì 
ÌÈ¢Â£Î ¬öÅ¡ÇÕìÌ ÁðÎ§Á ¦¾Ã¢ó¾¾¡¸ þÕìÌõ. ¿£í¸û þó¾ ¬öÅ¢ø 
Àí§¸ü¸ Å¢ÕôÀôÀð¼¡ø, ¾¢ð¼ Å¨Ã× ÀÊ §¾÷× ¦ºöÂôÀÎÅ£÷¸û.         
¿£í¸û þó¾ ¬öÅ¢ø Àí§¸üÌõ Óý, þó¾ ¬öÅ¢¨Éô ÀüÈ¢Â §ÁÖõ Å¢ÀÃí¸û 
¦ÀÈ §ÅñÎ¦ÁÉ Å¢ÕôÀôÀð¼¡ø, þó¾ ¬öÅ¢ý Ó¾ý¨Á ¬Ã¡öîº¢Â¡Ç÷ ÁüÚõ 
§¾º¢Â º¢ò¾ ÁÕòÐÅÁ¨É, Àð¼ §ÁüÀÊôÒòÐ¨È Á¡½Å÷ Dr. À.ÓòÐ¦ºøÅ¢ 
¬¸¢Â ±ý¨É 8220329060 ±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ. §ÁÖõ, ¿£í¸û 
þó¾ ¬öÅ¢ø, ¯í¸ÇÐ Àí§¸üÒ ÁüÚõ ¯Ã¢¨Á ÀüÈ¢ ¦¾Ã¢óÐ ¦¸¡ûÇ §¾º¢Â 
º¢ò¾ ÁÕòÐÅÁ¨É, ¾¨ÄÅ÷/¦ºÂüìÌØ ¯ÚôÀ¢É÷ «Å÷¸¨ÇÔõ 91-44-22411611 
±ýÈ ±ñ½¢ø ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ.    
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NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
AYOTHIDASAR PANDITHAR HOSPITAL 
DEPARTMENT OF   MARUTHUVAM 
AN OPEN CLINICAL STUDY ON “SWASAKASAM” (BRONICAL ASTHMA) AND 
THE DRUG OF CHOICE IS “MANTHARAKASA LEHIYUM” (INTERNAL) 
FORM IV A – INFORMATION SHEET 
Name of the Principal Investigator:  Dr.P.MUTHUSELVI 
Name of the Institution                    : National Institute of Siddha 
                                                            Tambaram Sanatorium, Chennai- 47. 
           I am, Dr.P.Muthuselvi studying M.D(S) in National Institute of Siddha, 
Chennai.  Bronchial asthma is the common chronic inflammatory disease of the airway 
characterized by variable and recurring symptoms of wheezing, coughing, chest tightness and 
shortness of breath. This condition is being treated is NIS with many siddha formulations. As 
a part of M.D(S) research programme and developing new efficacious medicine, we propose 
to study the MANTHARA KASA LEHIYUM formulation for treating the condition. This 
formulation has been mentioned in siddha literature and empirical evidence with 
contemporary tools is required for documentation. You can receive medicines free of cost. 
The duration of treatment period is 48days. You have to visit NIS every week and collect 
drugs for 8 days. The diagnosis tests will be carried out free of cost.  We will assess the effect 
of treatment after completion of 48days of treatment using clinical and lab parameters. 
 In this regard, we need to ask you few questions. We will maintain confidentiality of 
your comments and data obtained from you. There will be no risk of disclosing your identity 
and no physical, psychological or professional risk is involved by taking part in this study. 
 Taking part in this study is voluntary. No compensation will be paid to you for taking 
part in this study. You can choose not to answer any specific question. There is no specific 
benefit for you if you take part in the study, but you will be under our clinical monitoring and 
specific attention will be given for your health. Taking part in the study may be of benefit to 
the community, as it may help us to develop medicine for swasakasam. In case of any adverse 
symptoms during the treatment   which is expected for few patients during the treatment, 
shall be reported to PIs and care will be taken in NIS for relief. You can withdraw from the 
study at the midst of treatment period, if you are not interested to continue and you will 
receive our usual treatment without condition. 
 The information we will collect in this study, will remain between you and the 
principal investigator. We will ask you a few questions through questionnaire. We will not 
write your name on different forms which sent to different investigating/analysis sections and 
we will use a code instead given by the principal investigator. Only the principal investigator 
will know the key to this code which will be kept in safe custody. If you agree to be a 
participant in this study, you will be screened as per the study protocol.  
         If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.P.Muthuselvi, M.D(S) scholar cum principal investigator of 
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this study, attached to the National Institute of Siddha, Chennai (Mobile phone 
no:8220329060) You can also contact the Chairman/Member-secretary of Ethics committee, 
National Institute of Siddha, Chennai – 600047, Tel no: 91-44-22411611, for rights and 
participation in the study. 
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       NATIONAL INSTITUTE OF SIDDHA, CHENNAI- 47                                                                                                                          
AYOTHIDASS PANDITHAR HOSPITAL,                                                                                                            
DEPARTMENT OF MARUTHUVAM,                                                                                                                                        
AN OPEN CLINICAL STUDY ON  SWASA KASAM (BRONCHIAL ASTHMA)                                                            
AND THE DRUG OF CHOICE IS “MANTHARAKASA LEHIYUM” (INTERNAL)  
FORM IV B – DRUG COMPLIANCE FORM 
 1. O.P NO ______________      .2. IP.NO: ___________3.  S. NO _________ 
4. NAME_________________.5.AGE ____ .6. GENDER:  Male/Female  
Name of the Drug:, MANTHARA KASA LEHIYUM (Internal),                                                    
On 0
th
 day
 –Date                  ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
On 8th day-Date:                 ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
On 16th day -Date:              ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
On 24
th
 day-Date:                ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
On 32
nd
 day-Date:               ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
On 40
th
 day-Date:                ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
On 48
th
 day-Date:                ;Drug issued:  (Nos)   /   Drug returned:    (Nos) 
 
          Day               Date           Morning            Evening 
Day 1    
Day 2    
Day 3    
Day 4    
Day 5    
Day 6    
Day 7    
Day 8    
Day 9    
Day 10    
Day 11    
Day 12    
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
Day 20    
Day 21    
Day 22    
Day 23    
Day 24    
Day 25    
Day 26    
Day 27    
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Day 28    
Day 29    
Day 30    
Day 31    
Day 32    
Day 33    
Day 34    
Day 35    
Day 36    
Day 37    
Day 38    
Day 39    
Day 40    
Day 41    
Day 42    
Day 43    
Day 44    
Day 45    
Day 46    
Day 47    
Day 48    
 
 
 
Date:  
               
Station: 
 
Signature of the Investigator: 
 
Signature of the Lecturer:                                                                    
 
Signature of the HOD: 
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§¾º¢Â º¢ò¾ ÁÕòÐÅ ¿¢ÚÅÉõ 
«§Â¡ò¾¢¾¡º ÀñÊ¾÷ ÁÕòÐÅÁ¨É 
ÍÅ¡º¸¡ºõ §¿¡öì¸¡É ¯½× Ó¨È¸Ùõ ¦ºö¨¸¸Ùõ 
§º÷ì¸ ¾Ìó¾¨Å : 
   1. ¬Å¢Â¢ø §Å¸¨Åò¾ Àñ¼í¸û þðÄ¢, þÊÂ¡ôÀõ, À¢ðÎ, ¬ôÀõ. 
   2. ÓÍÓÍì¨¸ «¨¼, ¸øÂ¡½ÓÕí¨¸ «¨¼, àÐÅ¨Ç «¨¼ 
   3. Áïºû / Á¢ÇÌàû ¸Äó¾ À¡ø 
   4. ÍìÌ / þïº¢ §º÷ó¾ ¸¡À¢ 
   5. ¿ñÎ Ýô, Á¢ÇÌ Ãºõ, ¬ðÎ¸¡ø Ýô,  
   6. ¸ò¾Ã¢À¢ïÍ, ÓÕí¨¸ì¸¡ö, ¸Õ¨½, Íñ¨¼ ÅüÈø, Á½ò¾ì¸¡Ç¢.  
   7. ¦¸¡¾¢ì¸ ¨Åò¾¡È¢Â ¿£¨Ã ÀÕ¸ §ÅñÎõ. 
§º÷ì¸ Ü¼¡¾¨Å :   
1. ÌÇ¢÷îº¢Â¡É ¯½× Å¨¸¸Ç¡É ÌÇ¢÷À¡Éí¸û, º¡ì¦Äð, §Àì¸Ã¢ ¯½×¸û, 
À¾ôÀÎò¾ôÀð¼ ¯½×¸û, ±ñ¦½ö À¾¡÷ò¾í¸û, ¸¢ÆíÌ Å¨¸¸û  
2. ¦¸¡¾¢ì¸ ¨Åò¾¡È¢Â ¿£¨Ã ÀÕ¸ §ÅñÎõ. 
3. ¾Â¢÷, §Á¡÷, ¦¿ö, À¡Ä¡¨¼, ¦Åñ¦½ö. 
4. ¸ÕÅ¡Î, Á¡ðÊ¨Èîº¢, §¸¡Æ¢ì¸È¢. 
5. þÉ¢ôÒ, ÒÇ¢ôÒ §º÷ó¾ ¯½×¸û 
6. ´ùÅ¡¾ ¯½×¸û, ¿£÷ ¸¡öÈ¢¸û, ¿£÷ ÀÆí¸û, À¨ÆÂ ¯½×¸û, ±Ç¢¾¢ø 
¦ºÃ¢ì¸¡¾ ¯½×¸û 
 
¦ºöÂ Ü¼¡¾¨Å : 
 
1. Ò¨¸À¢Êò¾ø, Ò¨¸Â¢¨Ä ¿£ì¸×õ 
2. ÌÇ¢÷ó¾ ¸¡üÈ¢ø, ÀÉ¢Â¢ø ®ÎÀÎ¾ø ¾Å¢÷ì¸×õ 
3. àÍ, Ìô¨À ¿¢¨Èó¾ þ¼ò¾¢ø þÕôÀ¨¾ ¾Å¢÷ì¸×õ 
4. ¸Å¨Ä§¸¡Àõ Ì¨Èì¸×õ 
5. À¢Ã½¡Â¡Áõ ¦ºö¾ø ¿øÄÐ 
6. þÃ× 7 Á½¢ìÌû º¡ôÀ¢¼ §ÅñÎõ 
7. þÃÅ¢ø ÅÂ¢Ú ÓØ¨ÁÂ¡¸ º¡ôÀ¢ÎÅ¨¾ ¾Å¢÷ì¸×õ
8. Ý¼¡É ¯½×¸¨Ç ¯ñ½×õ 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDASS PANDITHAR HOSPITAL 
DIET FOR SWASA KASAM (BRONCHIAL ASTHMA) 
1.Do‟s 
1. Steamed food like idly, Idiyappam, Puttu. 
2. Mussumusukai adai, Kalyana murungai adai, Thoothuvalai adai. 
3. Turmeric / Pepper mixed milk 
4.  Ginger / Dry ginger mixed coffee.  
5. Crab soup, Vegetable soup, Pepper rasam, Mutton leg soup. 
6. Drumstic, Yam, Brinjal, Manathakkali(Greens), Sundaivatral. 
7. Take well boiled water to drink.  
2. Don‟t 
1. Avoid cooldrinks, Chocolate, Cake 
2. Oily substance 
3. Curd, Ghee, Butter, Cheese 
4.  Dry fish, Chicken, Beaf, 
5.  Sweets, Sour food  
6.  Tuberous food 
7.  Tined  food, Preservative food, Refrigerated foods.  
8.  Allergen food 
9.  Vegetables like Cucumber, Snake guard etc.. 
10.  Citrus fruits 
3.General advise 
1. Avoid Smoking, Tobacco, Alcohol, 
2. Avoid Cold weather 
3. Avoid Pollutated area, Dust 
4. Avoid Stress, Emotion. 
5. Do pranayamam 
6. Have your night food before 7‟o clock, 
7. Avoid overeating in night. 
8. Have a bath in hot water 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
DEPARTMENT OF  MARUTHUVAM 
  
An open clinical trial to evaluate the Therapeutic Efficacy of Siddha Herbal formulation 
MANTHARA KASA LEHIYUM (Internal) in the management of SWASA KASAM 
(BRONCHIAL ASTHMA)                                                             
 
Name of Principal Investigator:     Reg. No : 
 
FORM - WITHDRAWAL FORM 
 
1. SERIAL NO OF THE CASE: …………………   
2. OP / IP NO: ......................................    
3. NAME: ………………………     
4.AGE: …………        
5.GENDER:...........                           
6. DATE OF TRIAL COMMENCEMENT: ………………... 
7. DATE OF WITHDRAWAL FROM TRIAL: …………….. 
8. REASONS FOR WITHDRAWAL: 
Long absence at reporting:               Yes/ No 
Irregular treatment:                           Yes/ No 
Shift of locality:                                     Yes/No 
Increase in severity of symptoms:     Yes/No 
Development of severe adverse drug reactions:   Yes/No 
Development of adverse event:                                              Yes/No 
 
Date:          
Station: 
Signature of the Investigator: 
Signature of the Lecturer:                                                         
Signature of the HOD: 
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NATIONAL INSTITUTE OF SIDDHA 
AYOTHIDOSS PANDITHAR HOSPITAL, CHENNAI – 600 047. 
 
 DEPARTMENT OF  MARUTHUVAM 
 
An open clinical trial to evaluate the Therapeutic Efficacy of Siddha Herbal formulation 
MANTHARA KASA LEHIYUM (Internal) in the management of SWASA KASAM 
(BRONCHIAL ASTHMA)                                                             
 
Name of Principal Investigator:     Reg. No:  
 
FORM –ADVERSE REACTION FORM 
 
SERIAL NO:                                                                                                           
OP/IP NO: 
NAME:                                                             AGE:                     GENDER: 
DATE OF TRIAL COMMENCEMENT: 
DATE OF THE ADVERSE REACTION OCCUR: 
DESCRIPTION OF ADVERSE REACTION: 
 
 
 
Date:                                                                              
Station:  
Signature of the Investigator: 
Signature of the Lecturer:                                                             
Signature of the HOD: 
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NATIONAL PHARMACOVIGILANCE PROGRAMME FOR SIDDHA DRUGS 
 
 
Please note:  i. All consumers / patients and reporters information will remain confidential. 
                        ii. It is requested to report all suspected reactions to the concerned, even if  it 
does not have complete data, as soon as possible. 
Peripheral Center code:     State:  
1. Patient / consumer identification (please complete or tick boxes below as appropriate) 
Name  Father name 
 
Patient / Record No. 
Ethnicity  Occupation 
Address  
Village / Town 
Post / Via 
District / State    
Date of Birth / Age: 
 
Sex: Male / Female  
Weight : 
Degam: 
 
2. Description of the suspected Adverse Reactions (please complete boxes below) 
Date and time  of 
initial observation 
 Season: 
Description of 
reaction   
 
 Geographical area: 
 
 
 
 
Reporting Form for Suspected Adverse Reactions to Siddha Drugs 
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3. List of all medicines / Formulations including drugs of other systems used by the 
patient during the reporting period: 
 
Medicine Daily 
dose 
Route of 
administration
& Vehicle – 
Adjuvant 
Date  Diagnosis for 
which medicine 
taken  
Starting Stopped 
Siddha      
Any other 
system of 
medicines 
     
 
4. Brief details of the Siddha Medicine which seems to be toxic: 
Details Drug – 1 Drug – 2 Drug - 3 
a) Name of the medicine    
b) Manufacturing unit and batch No. and date    
c) Expiry date    
d) Purchased and obtained from    
e) Composition of the formulation / Part of 
the drug used 
   
 
b) Dietary Restrictions if any 
c) Whether the drug is consumed under institutionally qualified medical supervision or used 
as self medication.  
d) Any other relevant information. 
5. Treatment provided for adverse reaction: 
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6. The result of the adverse reaction / side effect / untoward effects (please complete the 
boxes below) 
Recovered:           Not 
recovered: 
 Unknown: Fatal: If Fatal 
Date of death: 
Severe:   Yes   /   No. Reaction abated after drug stopped or dose reduced: 
Reaction reappeared after re introduction: 
 
Was the patient admitted to hospital? If 
yes, give name and address of hospital 
 
 
7. Any laboratory investigations done to evaluate other possibilities?  If yes specify:  
8. Whether the patient is suffering with any chronic disorders? 
Hepatic    Renal    Cardiac    Diabetes    Malnutrition    
 
Any Others  
9. H/O previous allergies / Drug reactions:  
 
10. Other illness (please describe): 
 
11. Identification of the reporter: 
Type (please tick):  Nurse / Doctor / Pharmacist / Health worker / Patient / Attendant / 
Manufacturer /Distributor / Supplier / Any others (please specify) 
Name: 
Address: 
Telephone / E – mail if any : 
Signature of the reporter:       Date: 
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Please send the completed form to:  
                The Director 
                National Institute of Siddha, 
                                                           (Pharmacovigilance Regional Centre For Siddha 
Medicine), 
                                                           Tambaram Sanatorium, Chennai-600 047. 
                                                            (O) 044-22381314       Fax : 044 – 22381314 
            Website : www.nischennai.org  
            Email: nischennaisiddha@yahoo.co.in   
This filled-in ADR report may be sent within one month of observation /occurrence of 
ADR   
 
 
 
Date:                                                                              
Station:  
 
Station:                                                                      Signature of the Investigator: 
Date:                                                                         Signature of the Lecturer:                                                             
                            Signature of the HOD:   
  
 
 
 
 
Name & address of the RRC-ASU / 
PPC-ASU 
Who Can Report? =Any Health care professionals like Siddha Doctors / Nurses / Siddha Pharmacists / 
Patients etc.  
What to Report? =All reactions, Drug interactions,  
Confidentiality =The patient‟s identity will be held in strict confidence and protected to the fullest extent.  
                =Submission of report will be taken up for remedial measures only not for legal claim  
  
 
 
 
CERTIFICATES 
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